








Mackin, Sharon Tracey (2021) Vascular function in hyperglycaemic 
pregnancy: studies into potential mechanisms for adverse obstetric outcomes 






Copyright and moral rights for this work are retained by the author 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
When referring to this work, full bibliographic details including the author, 


















VASCULAR FUNCTION IN HYPERGLYCAEMIC 
PREGNANCY:STUDIES INTO POTENTIAL 
MECHANISMS FOR ADVERSE OBSTETRIC 
OUTCOMES IN DIABETES 
 
 
Dr Sharon Tracey Mackin 








Thesis submitted in fulfilment of the requirements for the 
degree of Doctor of Medicine (MD) at the Institute of 








Diabetes in pregnancy confers increased risk of adverse outcomes in pregnancy.  
Increased risks of fetal overgrowth with subsequent delivery complications and 
neonatal hypoglycaemia are consequence of fetal hyperinsulinaemia due to 
maternal hyperglycaemia. Other complications such as stillbirth and 
preeclampsia, both of which are increased in diabetic pregnancy are less well 
understood.  Understanding of pathophysiological mechanisms in stillbirth and 
preeclampsia remain limited, but both have links to vascular dysfunction.  
Specifically, many cases of stillbirth are associated with features of placental 
vasculopathy. Preeclampsia also originates from abnormal placental vascular 
development, resulting in release of pro-inflammatory and angiogenic factors 
from the placenta into maternal circulation and subsequent endothelial and 
organ dysfunction. Maternal endothelial dysfunction has also been shown to exist 
in women prior to the onset of preeclampsia.  In diabetes, the exact triggers for 
preeclampsia and stillbirth development are unclear.  Most of our understanding 
of these conditions comes from studies in the general obstetric population. With 
preeclampsia there is a proven linear relationship with higher maternal 
glycaemia and increased risk of developing the condition.  The hypothesis for 
this thesis was that diabetes in pregnancy is associated with maternal and 
placental vascular dysfunction as a potential mechanism for adverse outcome in 
pregnancy complicated by diabetes.  Furthermore, it was hypothesised that such 
vascular dysfunction is associated with higher maternal glycaemia. 
To investigate this hypothesis, I first sought to establish the prevalence of 
adverse outcomes in pregnancy complicated by diabetes by examining Scottish 
epidemiological data, and compare these to the rates  seen in the population 
without diabetes.  Between the years of 1998-2013, pregnancies complicated by 
type 1 or type 2 diabetes had 3-6-fold higher rates of adverse outcomes in 
pregnancy compared to women without diabetes.  Specifically, higher rates of 
large for gestational age birthweight infants (52%, 38% and 10% in type 1, type 2 
and no diabetes respectively), operative delivery (68% in type 1, 60% in type 2, 
26% in those without diabetes) and preterm delivery (35% type 1, 22% type 2 and 
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6% in those without diabetes).  Stillbirth rates were high at 19.5 and 24.8 per 
1,000 births in type 1 and type 2, which was significantly higher than the 4.9 per 
1,000 births in the population without diabetes.  Worryingly, trend data showed 
that stillbirth and perinatal mortality data were not improving with time.  
To better understand why we were failing to improve upon stillbirth statistics, I 
sought to identify the maternal and neonatal phenotype associated with 
stillbirth.  I explored associations of maternal and neonatal demographics and 
maternal glycaemic data with stillbirth outcome in the Scottish obstetric 
population with diabetes. Glycaemia had a significant association with stillbirth 
in both type 1 and type 2 diabetes.  In women with type 1 diabetes, higher 
HbA1c in later pregnancy had the strongest association (OR 1.06 [95% CI 
1.04,1.08]) whilst in type 2 diabetes, prepregnancy HbA1c was associated (OR 
1.03 [95%CI 1.00-1.04]).  Maternal BMI was also linked with risk in type 2 
diabetes (OR 1.07 [95% CI 1.01, 1.15]).  Taken together, this suggests metabolic 
factors, and specifically glycaemia play a key role in stillbirth pathophysiology.  
Other non-metabolic risk factors identified include extremes of birthweight 
centiles and advancing gestation towards term both of which are linked with 
placental vascular insufficiency and failure.  
I then performed mechanistic studies to determine differences in vascular 
function in pregnancies complicated by diabetes.  I designed and recruited to a 
prospective cohort study comparing maternal and placental vascular function in 
women with gestational diabetes and pregnant controls with and without risk 
factors for GDM.  For the maternal study, I was interested to see if maternal 
endothelial dysfunction was present in women with gestational diabetes (GDM), 
similar to that seen in women who later go on to develop preeclampsia.  I made 
serial measurements of flow-mediated dilatation (FMD) of the brachial artery (a 
widely accepted, non-invasive test of endothelial function) from 24 weeks across 
the third trimester of pregnancy.   FMD brachial artery was no different in 
women with GDM compared to both control groups at study entry (14.3+4.5% in 
GDM, 16.2+5.2% in risk factor group and 14.4+4.5% in control group).  FMD did 
not change significantly with advancing gestational age, and remained no 
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different between groups.  There was no association with biochemical measures 
of glycaemia or insulin resistance and FMD.  This suggests that maternal 
endothelial function is not significantly disrupted in otherwise uncomplicated 
GDM pregnancy. 
From the same cohort, I then went onto perform wire myography studies on 
chorionic plate arteries (CPAs) taken from the fetal side of placental circulation.  
I tested vasoreactivity to various agonists:  U46619 thromboxane mimetic for 
contraction, calcitonin gene-related peptide to test endothelium-dependent and 
endothelium-independent vasodilatation mechanisms and sodium nitroprusside 
(SNP) to test endothelium-independent vasodilatation.  In these studies, CPAs 
from GDM placentas showed reduced vasodilatory response to SNP with lower 
Emax (49.5+11.0% in GDM compared to 73.9+11.0% and 74.0+12.0% in risk factor 
and control).  There was no difference in response to the other agonists tested 
suggesting that cyclic GMP (cGMP) pathways are altered in GDM pregnancy.  
Furthermore, there was significant inverse correlation with fasting blood glucose 
(Pearson’s r -0.526, p=0.01) and significant effect of higher glucose on lower 
Emax to SNP (p=0.03).  In multivariate modelling, insulin resistance measures 
were not associated with SNP Emax.  
In summary, adverse obstetric outcomes are high in the population with diabetes 
and are significantly so compared to the population without diabetes.  Despite 
best efforts of clinical teams and mothers, serious outcomes such as stillbirth 
and perinatal mortality are not improving. Glycaemia is an important modifiable 
risk factor associated with fetal mortality.  Placental vascular vasodilatory 
response is reduced in GDM pregnancy.  Specifically, this appears specific to 
altered cGMP pathways and is negatively associated with higher fasting blood 
glucose. This could be a possible mechanism for placental vascular dysfunction 
and adverse outcome in diabetic pregnancy, particularly where glycaemia is 
uncontrolled.  Conversely, maternal endothelial function did not appear 
significantly altered by GDM suggesting that this is not a major mechanism to the 
higher rates of adverse outcome in such pregnancies. Further mechanistic work 
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is required to better understand effects of glucose on the fetal side of the 
placental circulation.    
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HELLP  Haemolysis, elevated liver enzymes and low platelets 
HOMA-IR Homeostatic model assessment of insulin resistance 
hPL  Human placental lactogen 
HUVEC Human umbilical vein endothelial cell 
IADPSG International Association of Diabetes and Pregnancy Study Group 
IGF  Insulin-like growth factor 
IQR  Interquartile Range 
IL-  Interleukin 
iNOS  Inducible nitric oxide synthase 
IOM   Institute of Medicine 
ISD   Information Services Division Scotland 
ISSHP  International Society for the Study of Hypertension in Pregnancy 
IUGR  Intrauterine growth restriction 
KCa  Calcium gated potassium channel 
kPa  kilopascals 
KDR  Kinase insert domain receptor 
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KPSS  Potassium containing physiological salt solution 
LGA  Large for gestational age 
LMWH  Low molecular weight heparin 
LNAME N(ω)-nitro-L-arginine methyl ester 
MAPK  Mitogen activated protein kinase 
MLCK  Myosin light chain kinase 
mmHg  Millimetres of mercury 
NDDG  National Diabetes Data Group 
NICE  National Institute for Health and Care Excellence 
NICU  Neonatal intensive care unit 
NO  Nitric oxide 
NOS  Nitic oxide synthase 
NPID  National Pregnancy in Diabetes 
NPV  Negative predictive value 
O2-  Superoxide 
OGTT  Oral glucose tolerance test 
ONOO-  Peroxynitrite 
PDE  Phosphodiesterase 
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PGDM  Pregestational diabetes mellitus 
PGI2  Prostacyclin 
pGH  Placental growth hormone 
PIH  Pregnancy induced hypertension 
PKG  Protein kinase G 
PPV  Positive predictive value 
PSS   Physiological salt solution 
RAAS  Renin angiotensin aldosterone system 
RAGE  Receptor for advanced glycation end products 
RCOG  Royal College of Obstetricians and Gynaecologists 
RCT  Randomised control trial 
RDS  Respiratory distress syndrome 
ROS  Reactive oxygen species 
SBP  Systolic BP 
SDRN  Scottish Diabetes Research Network 
sFlt-1  Soluble fms-like tyrosine kinase-1 
SGA  Small for gestational age  
SIMD  Scottish index of multiple deprivation 
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SMR02  Scottish Maternity Record 02 
SNP   Sodium nitroprusside 
SOD  Superoxide dismutase 
T1DM  Type 1 diabetes 
T2DM   Type 2 diabetes 
Th1  T-helper 1 
Th2  T-helper 2 
TIR  Time in range 
TNFα  Tumour necrosis factor α 
TXA2  Thromboxane A2 
VSMC  Vascular smooth muscle cell 
VEGF  Vascular endothelial growth factor 
VEGFR2 Vascular endothelial growth factor receptor 2 




1 Chapter 1: Introduction 
1.1 Diabetes and pregnancy 
Hyperglycaemia is the most prevalent metabolic disorder complicating 
pregnancy.  Diabetes during pregnancy can be categorised broadly into three 
groups: 1) Pre-gestational diabetes (PGDM) which includes women entering 
pregnancy with a diagnosis of chronic diabetes mellitus pre-dating pregnancy 2)  
diabetes in pregnancy (DIP) which includes women  who have severe 
hyperglycaemia first detected in pregnancy that meet the standard diagnostic 
criteria for diabetes, and 2) gestational diabetes (GDM) i.e. women who have 
evidence of glucose intolerance first detected in pregnancy. DIP was first 
introduced as a term in the World Health Organisation (WHO) 2013 guidelines in 
recognition that women who have more severe diabetes were more likely to 
experience adverse outcomes in pregnancy, were more likely to require 
aggressive pharmacotherapy, were often excluded from trials looking at GDM 
outcomes, and were at risk of diabetes complications (World Health Organisation 
2013).  
DIP and PGDM, can be further subclassified according to the type of diabetes.  
Type 1 diabetes (T1DM) which is an autoimmune condition resulting in 
pancreatic β-cell failure and an absolute insulopaenic state and type 2 diabetes 
(T2DM), which is associated with insulin resistance and resultant hyperglycaemia 
are the two most common types of diabetes within this category.  Depending on 
longevity of diabetes, patients with T2DM diabetes usually have 
hyperinsulinaemia to compensate for the insulin resistance (earlier stages of 
disease), but can progress to β-cell failure and absolute insulin deficiency in 
long-standing advanced T2DM. DIP and PGDM will also include rarer causes of 
pre-existing diabetes including secondary pancreatic diabetes and genetic forms 
of diabetes.  
The International Diabetes Federation estimated around 16% of all pregnancies 
worldwide are complicated by hyperglycaemia.  Of these, the vast majority of 
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have GDM (86%) whilst the remainder consist of PGDM (6%) and DIP (7%) (Cho et 
al., 2018).  However, in the case of GDM, diagnostic criteria vary internationally 
and have changed with time, meaning that wide variation in prevalence is 
reported across different studies.   Furthermore, regional variation in GDM 
occurs due to genetic risk associated with different ethnicities. A systematic 
review of UK-based studies showed regional prevalence of GDM ranging from  8-
24% (Farrar D, 2016). 
1.1.1 Normal glucose homeostasis in pregnancy 
In order to optimise fetal growth, maternal metabolic adaptations must occur to 
promote nutrient delivery from mother to fetus.  As such, a host of coordinated 
hormonal adaptations occur from early pregnancy.  In early pregnancy, maternal 
adaptation shows an initial increase in insulin secretory response and an increase 
in insulin sensitivity compared to the pre-pregnancy state.  This leads to 
increased lipogenesis and adipose stores as a fuel reserve for later pregnancy 
(Powe et al., 2019).  As pregnancy progresses, maternal insulin signalling is 
altered such that insulin sensitivity decreases whilst insulin secretion and β-cell 
mass increases (Powe et al., 2019, Angueira et al., 2015).  This insulin resistant 
state coupled with increased adiposity, acts to promote maternal free fatty acid 
production, hepatic gluconeogenesis and ultimately increased availability of 
glucose to the developing fetus. Post-prandial glucose levels are typically higher 
in later pregnancy than in the non-pregnant state, whereas fasting levels tend to 
be lower.    
The changes in insulin sensitivity seen in pregnancy are driven by some part in 
increasing levels of placental-derived hormones such as oestradiol, 
progesterone, placental growth hormone and lactogen, alongside altered 
corticosteroid metabolism.  There is a continual increase in expression of these 
pregnancy hormones from the conceptus and placenta from early pregnancy, 
peaking alongside insulin resistance in the third trimester. These hormones have 
a multitude of effects to help support pregnancy, and their role in placental 
development and glucose homeostasis are discussed individually in chapter 1.2.     
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In GDM, this homeostasis is dysregulated in favour of pathological insulin 
resistance and compensatory mechanisms to combat hyperglycaemia are 
insufficient (Baz et al., 2016).   Insulin secretion from pancreatic β-cells is 
significantly reduced in the order of 30-70% in GDM mothers compared with non-
GDM mothers, whereas insulin sensitivity is slightly reduced (Angueira et al., 
2015).  Obese mothers are more susceptible to development of GDM, with a 
predisposition to insulin resistance from high adiposity contributing further to 
insulin resistance in pregnancy (Li et al., 2014).   
1.1.2 Diagnostic criteria for DIP  
The diagnostic criteria used to diagnose DIP are the same as those glucose 
criteria used to define diabetes in the non-pregnant population, except it is first 
detected in pregnancy.  This is any of:  
• fasting plasma glucose (FPG) > 7.0 mmol/L 
• 2-hour post-75g oral glucose tolerance test (OGTT) > 11.1 mmol/L  
• random plasma glucose > 11.1 mmol/L in the presence of symptoms of 
hyperglycaemia or  
• HbA1c > 48 mmol/L 
These criteria are applicable across all stages of pregnancy (2013).  
1.1.3 Diagnostic criteria for GDM 
Diagnostic criteria for GDM are more contentious and cause debate amongst 
experts about which glycaemic criteria best estimate increased obstetric risk. 
This is partly because there is a continuous relationship with maternal glycaemia 
with no clear inflection point at which risk of adverse pregnancy outcome is 
increased (Metzger et al., 2008).  Furthermore, GDM screening is utilised 
differently across healthcare settings, with some populations undergoing 
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universal screening in pregnancy, and others screening only those with identified 
risk factors for GDM, such as obesity and family history of diabetes.   
1.1.3.1 Historical evolution of GDM diagnostic criteria 
Prior to 2010, international guidelines had higher glycaemic thresholds for 
diagnosing GDM than current guidelines, although glycaemic markers were still 
significantly lower than those used to diagnose overt diabetes (table 1.1).  The 
earliest GDM criteria using maternal whole blood glucose levels were published 
by O’Sullivan and Mahan in 1964, although concerns of morbidity and mortality 
associated with diabetes during pregnancy had been recognised before this.  
O’Sullivan and Mahan used statistical modelling to identify the second and third 
deviations of upper limit of normal of maternal glucose levels in later pregnancy 
post 100g-OGTT and produced criteria for GDM that included: FBG >5.0 mmol/L, 
1-hour post-OGTT >9.2 mmol/L, 2-hour post-OGTT >8.1mmol/L and 3 hours post-
OGTT >7.0mmol/L.  Diagnosis required at least two of these parameters to be 
met (O’sullivan and Mahan, 1964).  These criteria were originally designed to 
identify those women who had an increased risk of developing T2DM post-partum 
although there was concurrent recognition that obstetric risk was increased in 
these women.  In later years, these criteria were further refined as laboratory 
techniques became more advanced and allowed better detection of glucose in 
plasma compared with older technologies using whole blood (National Diabetes 
Data Group criteria (NDDG)), and furthermore when technology advanced that 
could distinguish glucose from other reducing substances (Carpenter and 
Coustan, 1982).  These refined criteria are still adopted today for GDM diagnosis 
in some nations including the United States of America, and are termed the 
Carpenter-Coustan criteria.  When compared with NDDG, Carpenter-Coustan 
criteria have been shown to diagnose higher numbers of women with GDM, but 
also were superior at detection of pregnancies at risk of adverse outcome.  In a 
large American cohort, Carpenter-Coustan criteria resulted in a 42% relative 
increase in women diagnosed with GDM versus NDDG criteria, but these women 
who would have went undetected by NDDG criteria had a 70% increased risk of 
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preeclampsia, 16% increased risk of operative delivery and a 25% increased risk 
of delivering a large birthweight infant (>4000 g) (Berggren et al., 2011). 
The diagnostic criteria recommended by different prominent learned societies 
across time are listed in table 1.1.  Not only was there debate about the 
glycaemic thresholds used for diagnosis, but differences in the glucose load used 
in OGTT were also disputed. For example, the WHO showed preference for the 
75g OGTT, as there was consensus internationally that this was the optimal dose 
for diagnosing diabetes in the non-pregnant individual.  American societies 
favoured the 100g OGTT from the original O’Sullivan and Mahan, due to lack of 
validation of the lower dose in pregnant populations when guidance was first 
developed (National Diabetes Data Group, 1979).  
In recognition of the need for an evidenced-based international consensus on 
GDM diagnosis and the prediction of adverse outcomes in GDM, the landmark 
Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study was conducted 
and published in 2008 (Metzger et al., 2008).  The results and impact of this 
study are discussed in the next section. From the HAPO data, new diagnostic 
criteria where developed by the International Association of Diabetes and 
Pregnancy Study Group (IADPSG) (table 1.1) (International Association of 
Diabetes and Pregnancy Study Groups Consensus, 2010).   
There remains variation in diagnostic criteria internationally. IADPSG criteria are 
currently used in Scotland, Australia and New Zealand, and Ireland amongst 
others, and are endorsed by the International Federation of Obstetricians and 
Gynaecologists (FIGO).   The Carpenter and Coustan criteria are favoured by the 
American College of Obstetricians and Gynaecologists (ACOG Practice Bulletin 
190, 2018). Other countries have their own variations of these based on clinical 
and economic analysis of outcomes and criteria in their populations.  For 
example, the National Institute for Clinical Excellence adopted the IADPSG 
criteria but altered them slightly after health economic analysis in 2015 
demonstrated improved cost effectiveness with FBG >5.6 mmol/L and 2-hour 
post-75g OGTT >7.8 mmol/L.  Obstetric outcomes included in the economic 
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model were shoulder dystocia, caesarean section, induction of labour, 
preeclampsia, neonatal jaundice and neonatal intensive care stay (Diabetes in 
Pregnancy (National Institute for Health and Care Excellence), 2015) .   
 
Table 1.1: Different glycaemic thresholds used for diagnosis of  GDM according to 
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1.1.3.2  Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) study 
The HAPO study was a large, multicentre observational study that explored the 
association of adverse maternal and neonatal outcomes with maternal 
glycaemia, and included women across the spectrum of glycaemia that was 
below the threshold for diagnosing DIP. In this study, women underwent a 75g 
OGTT between 24-32 weeks of gestation with fasting, 1-hour and 2-hour post-
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OGTT plasma glucose levels measured.  The primary outcome was to measure 
the association of maternal glycaemia with large for gestational age (LGA) infant 
(birthweight >90th centile), need for primary caesarean delivery, occurrence of 
neonatal hyperglycaemia and cord serum C-peptide level indicating neonatal 
hyperinsulinaemia.  However, it also explored a number of important secondary 
maternal and neonatal outcomes.  Table 1.2 shows the adjusted odds ratio for 
each incremental rise in maternal glycaemic parameters (Metzger et al., 2008).   
 
Table 1.2:  Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study results of 
adjusted odds ratio of adverse pregnancy outcomes per incremental increase in fasting, 1-
hour and 2-hour maternal plasma glucose levels post 75g GTT.   
 Odds ratio per 0.4 
mmol/L increase in 
fasting plasma 
glucose 
Odds ratio per 1.7 
mmol/L increase in 
1-hour 75g OGTT 
plasma glucose 
Odd ratio per 1.4 
mmol/L increase in 
2-hour 75g OGTT 
plasma glucose 
Birthweight > 90th 
centile 
1.38 [1.32-1.44] 1.46 [1.39-1.53] 1.38 [1.32-1.44] 
Caesarean section 1.10 [1.06-1.15] 1.10 [1.06-1.15] 1.08 [1.03-1.12] 
Clinical neonatal 
hypoglycaemia 
1.08 [0.98-1.19] 1.13 [1.03-1.26] 1.10 [1.00-1.12] 
Cord blood serum C-
peptide > 90th 
centile 
1.55 [1.47-1.66] 1.46 [1.38-1.54] 1.37 [1.30-1.44] 
Preterm delivery < 
37 weeks 
1.05 [0.99-1.11] 1.18 [1.12-1.25] 1.16 [1.10-1.23] 
Shoulder dystocia 1.18 [1.04-1.33] 1.23 [1.09-1.38] 1.22 [1.09-1.37] 
Neonatal intensive 
care admission 
0.99 [0.94-1.05] 1.07 [1.02-1.13] 1.09 [1.03-1.14] 
Neonatal jaundice 1.00 [0.95-1.05] 1.11 [1.05-1.17] 1.08 [1.02-1.13] 
Preeclampsia 1.21 [1.13-1.29] 1.28 [1.20-1.37] 1.28 [1.20-1.37] 
Table adapted from table 2, Hyperglycaemia and adverse pregnancy outcome (HAPO) study, 
NEJM 2008 (Metzger et al., 2008).  Results in bold red show those with statistically significantly 




The study showed a linear and continuous relationship with maternal glycaemia 
and adverse pregnancy outcomes.  Smaller increments in fasting plasma glucose 
levels were associated with similar odds ratios seen with higher increments in 
post-OGTT glucose levels. Importantly, there was no clear threshold at which 
risk was exponentially increased, and no clear level of glycaemia which could 
define pregnancies as binary “high” or “low” risk (Metzger et al., 2008). Smaller 
observational cohort studies had previously shown similar continuous 
relationships with increasing maternal glycaemia and adverse outcomes (Pettitt 
et al., 1980, Sermer et al., 1995).  HAPO methodology had several advantages 
over these earlier studies in confirming these findings. The HAPO study was 
larger, included a heterogenous group of women from various international 
centres and, importantly, included blinding of researchers, caregivers and 
participants to glycaemic measures in an attempt to limit bias (Metzger et al., 
2008).   
Using HAPO data, the IADPSG reached a new consensus on GDM diagnosis in 2010 
(International Association of Diabetes and Pregnancy Study Groups Consensus, 
2010).  They agreed maternal glycaemic cut-offs for GDM diagnosis based on 
OGTT data that showed a 75% increased risk of primary outcome (Large for 
gestational age (LGA), caesarean section, neonatal hypoglycaemia, neonatal 
hyperinsulinaemia) compared to the mean in the HAPO cohort. The IADPSG 
criteria for GDM diagnosis using a 75g OGTT between 24-28 weeks are as follows: 
• Fasting > 5.1 mmol/L 
• 1-hour > 10.0 mmol/L 
• 2-hour > 8.5 mmol/L 
Whilst the HAPO study examines glycaemic data from the later stages of 
pregnancy (24-32 weeks) where insulin resistance is known to be increasing, the 
IADPSG recognised that some women and populations would be at higher risk of 
developing GDM in earlier stages of pregnancy. They therefore agreed that, 
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whilst the above criteria are the gold-standard for diagnosis, clinicians can use a 
fasting plasma glucose in the earlier stages of pregnancy > 5.1 mmol/L (but 
lower than overt DIP (7.0 mmol/L)) to diagnose GDM if clinically felt to be at 
higher risk of GDM but its use in earlier pregnancy is controversial.  In a study of 
women with GDM with FBG >5.1 mmol/L in early pregnancy, less than 40% met 
diagnostic criteria for GDM when tested between 24-28 weeks (Zhu et al., 2013, 
Mcintyre et al., 2016).   In cases where earlier testing is adopted, it is important 
that clinicians follow up women who test negative for GDM in earlier pregnancy 
with repeat testing with the gold-standard 75g OGTT at 24-28 weeks 
(International Association of Diabetes and Pregnancy Study Groups Consensus, 
2010). 
1.1.3.3 Utilisation and comparison of IADPSG and other GDM diagnostic 
criteria 
These new IADPSG criteria are now the most widely used criteria for GDM 
diagnosis, and are endorsed by leading societies such as the WHO and FIGO 
(World Heatlh Organisation, 2013, Hod et al., 2015). They are used routinely 
across Scotland (Scottish Intercollegiate Guidelines Network, 2017). However, 
they are not universally adopted across the UK, nor in some other countries.  
The main criticism of IADPSG criteria is that it leads to significantly higher 
numbers of women diagnosed with GDM compared with Carpenter-Coustan, 
which in a sceptical view leads to medicalisation of pregnancy and increased 
financial and resource pressures on obstetric services. For example, in the HAPO 
cohort, prevalence of GDM would increase from 4% if diagnosed using Carpenter-
Coustan criteria but would be almost four-fold higher at 14% if the marginally 
tighter IADPSG criteria were used (Waters et al., 2016).   This same study 
showed that those diagnosed according to IADPSG criteria but not by Carpenter-
Coustan definitions, had significantly higher rates of adverse pregnancy outcome 
compared to women without GDM.  Specifically, they had higher rates of fetal 
overgrowth as measured by birthweight centiles and neonatal adiposity 
measures, higher rates of neonatal hypoglycaemia, increased need for caesarean 
section and greater risk of preeclampsia compared to women without GDM 
(Waters et al., 2016).  It is important to recognise that the HAPO group were an 
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untreated GDM group, since evidence has shown that treatment of mild GDM 
improves pregnancy outcomes (Landon et al., 2009, Crowther et al., 2005, Duran 
et al., 2014). Evidence of benefit of IADSPG versus Carpenter-Coustan criteria in 
real-world, non-blinded and treated GDM populations has proven more 
controversial.   Duran et al found that adoption of IADPSG criteria in a clinical 
setting led to higher prevalence of GDM, but also resulted in significantly lower 
rates of hypertensive disorder, caesarean section, small- and large- for 
gestational age infants, and neonatal ICU admissions (Duran et al., 2014), and 
therefore were cost-effective in that population.  Whilst other population 
surveys have shown no significant difference in prevalence of adverse obstetric 
outcome between IADPSG and Carpenter-Coustan (Feldman et al., 2016, Gariani 
et al., 2019) which raises questions about cost-effectiveness and concerns of 
overmedicalisation of pregnancy for women. Some societies, including ACOG 
have opted against recommendation of IADPSG criteria over more traditional 
screening.   
Furthermore, some societies such as ACOG opt for a two-step approach where 
women are initially screened with a non-fasted 1-hour 50g glucose challenge, 
and only proceed to a 100g OGTT for diagnosis if the initial challenge results in 
plasma glucose greater than 7.1 mmol/L.  Randomised control trial (RCT) data 
showed a doubling of GDM diagnoses in the American population using the one-
step IADPSG criteria, compared to the two-step approach yet both groups had 
similar rates of adverse outcomes (Hillier et al., 2021).  Adding further 
controversy, but acknowledging the important need for cost-effective screening 
tools in clinical practice, the National Institute of Health and Care Excellence 
(NICE) performed economic modelling of diagnostic thresholds for GDM and 
subsequent obstetric outcomes. In 2015, they published slightly different criteria 
(table 1.1) from the other methods in use that took this into account (National 
Insitute for Health and Care Excellence, 2015).  Observational data from a UK 
population has shown that using these guidelines over IADPSG would only miss a 
small proportion of women (4.1% NICE vs 4.6% IADPSG prevalence), but these 
missed women had significantly higher risk of adverse outcome compared to the 
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control non-GDM group (3-fold higher risk for LGA, 7-fold higher risk for 
polyhydramnios, >2-fold higher for preeclampsia) (Meek et al., 2015).  
In summary, the HAPO study was a landmark study that demonstrated 
prospectively an increase in adverse pregnancy outcomes with increasing levels 
of maternal hyperglycaemia, even at the milder end of the range.  This led to 
more universal recognition that some of the diagnostic thresholds used 
previously were too high, with risk of missing high numbers of women who could 
benefit from treatment and increased surveillance that a diagnosis of GDM would 
afford. However, some diagnostic criteria, such as Carpenter Coustan, are only 
marginally different to IADPSG and the evidence from population cohorts of the 
benefit of the lower IADPSG thresholds is variable.  Heterogeneity of treated 
populations in these largely retrospective studies make comparison between the 
two difficult, and so some expert clinical societies have struggled to derive 
evidence of benefit that is applicable to their population. Furthermore, all of 
these studies explore the risk of adverse obstetric outcomes.  With time, we 
would hope to establish evidence to identify if any of the GDM diagnostic criteria 
better differentiate longer term risk of metabolic sequelae in mothers and their 
offspring.  
1.1.4 Complications of pregnancy complicated by diabetes 
Pregnancy complicated by hyperglycaemia, whether that be DIP or GDM, is 
associated with increased risk to the health of the mother and her offspring, 
both during and after pregnancy. Overall risks during pregnancy are higher in 
women who have pre-existing diabetes entering pregnancy, than in those with 
newly diagnosed GDM.  However, adverse outcomes are noted with increased 
frequency in both groups compared to the general obstetric population.  
1.1.4.1 Fetal overgrowth  
Macrosomia (defined as infant birthweight >4000g or >4500g depending on the 
study) or LGA (>90th centile birthweight corrected for gestational age) is the 
most common complication of pregnancy complicated by diabetes.  It is of 
36 
 
concern in pregnancy due to the associated risks of obstructive labour with birth 
injury, need for caesarean section to prevent or treat delivery complications 
associated with large infants, and an increased risk of neonatal hypoglycaemia 
(Yamamoto et al., 2017).  Studies have shown that up to 50% of mothers with 
T1DM will deliver an LGA infant, with lower rates seen in obstetric populations 
with T2DM (approximately 25-30%) (Evers et al., 2002, Maresh et al., 2015, 
Ladfors et al., 2017). Rates are also significantly elevated in GDM with up to a 
third of women delivering LGA infants (Ehrenberg et al., 2004). These are 
significantly above the background rates of LGA, which by definition should be 
approximately 10% if referenced to a similar population.  Fetal overgrowth has 
long been recognised as a problem in such pregnancies.  In 1952, Pedersen 
hypothesised that glucose transfer across placenta resulted in fetal 
hyperglycaemia and hyperinsulinaemia, resulting in increased lipogenesis and 
accelerated fetal adiposity growth (Pedersen, 1952). Maternal glycaemia has an 
important association with risk of macrosomia.  In women with T1DM, the risk of 
macrosomia was higher in those with higher post-prandial blood glucose in later 
stages of pregnancy (20% in mothers with post-prandial <6.7 mmol/L compared 
with 35% in those with post-prandial > 8.9 mmol/L) (Jovanovic-Peterson et al., 
1991). Glycaemia in the second and third trimester is one of the strongest 
predictors of fetal overgrowth in T1DM (Maresh et al., 2015, Ladfors et al., 2017, 
Jovanovic-Peterson et al., 1991). Importantly, greater glycaemic variability 
throughout the day has been shown to have an association with LGA over and 
above that of measures of average glycaemia, such as HbA1c (Law et al., 2015, 
Scott et al., 2020).  In T2DM and GDM, higher glycaemia is also associated with 
macrosomia, and treatment of high blood glucose is associated with improved 
rates of macrosomia (Crowther et al., 2005, Landon et al., 2009, Ladfors et al., 
2017).   
Maternal BMI is a further risk factor for LGA regardless of diabetes type or status 
(Kong et al., 2019, Stogianni et al., 2019).  Obesity is prevalent amongst women 
with GDM and T2DM, but prevalence is increasing more generally worldwide and 
so affects many pregnancies complicated by T1DM also. Ideally, weight should be 
optimised before women enter pregnancy, but this is difficult for women to 
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achieve.  Studies have shown that overweight women who reduce their weight in 
between pregnancies are less likely to deliver LGA infants.  One such 
observational study showed a 31% risk reduction in LGA for overweight women 
who reduced their BMI >1 kg/m2 prior to their second pregnancy (Ziauddeen et 
al., 2019).   Others have explored the effects of healthy weight gain during 
pregnancy. Excessive gestational weight gain is associated with increased risks of 
LGA in all types of diabetes (Morrens et al., 2016, Bianchi et al., 2018) and in 
the wider general obstetric population (Siega-Riz et al., 2009).  The studies 
exploring this have wide variations in population, methodology and weight gain 
descriptors but as a general message, high gestational weight gain can be 
associated with a 2-3 fold increase in the risk of LGA birthweight infants (Siega-
Riz et al., 2009). Accordingly, the Institute of Medicine (IOM) have produced 
guidelines detailing recommended weight gain for women during pregnancy 
stratified to their pre-pregnancy BMI.  These guidelines where initially developed 
from observational data recognising that poor gestational weight gain in mothers 
was associated with higher risks of fetal growth restriction and stillbirth, but 
have been adopted more widely in the acknowledgement that excessive weight 
gain can have deleterious effects on pregnancy also (Institute of Medicine, 
2009). The IOM guidelines for gestational weight gain are shown in table 1.3.  
Observational data from a Canadian population with predominantly healthy pre-
pregnancy BMI (62%) have shown that women who exceed the IOM weight gain 
recommendations in the third trimester have >2-fold risk of LGA, but 
importantly that those who exceed the recommended weight gain in the second 
trimester but subsequently lower weight to within recommendations in the third 
trimester halve that risk (Bouvier et al., 2019). 
Obesity intervention is challenging for public health teams to implement given 
the complex interaction between medical, genetic, social and local 
infrastructure factors that are needed for success in obesity programmes. There 
is the added complication that almost half of pregnancies are unplanned (Health 
Matters: Reproductive Health and Pregnancy Planning (Public Health England), 
2018).  Lifestyle intervention in the form of combined antepartum and 
postpartum counselling sessions alone have proven ineffective at reducing 
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excessive gestational weight gain, even in a seemingly motivated trial population 
with approximately 90% participation in 4 sessions across all trimesters (Kunath 
et al., 2019).   Meta-analysis of dietary intake and physical activity has shown 
that dietary interventions, particularly those involving calorie counting have the 
largest effects on gestational weight reduction in the overweight population.  
However, the optimal implementation in terms of  recommended calories and 
macronutrients is less clear.  Interventions in the RCTs studied included calorific 
intake ranging from 1200-2060 kcal/day (Shieh et al., 2018). In the same 
metanalysis, physical activity alone did not have significant effects on weight 
loss.  
 
Table 1.3: Institute of Medicine Guidelines for recommended healthy gestational weight gain 
according to maternal BMI entering pregnancy 
Pre-pregnancy BMI category Recommended gestational weight gain 
Underweight (BMI <18.5 kg/m2) 12.5-18 kg 
Healthy weight (18.5-24.9 kg/m2) 11.5-16 kg 
Overweight (25.0-29.9 kg/m2)  7-11.5 kg 
Obese (>30.0 kg/m2) 5-9 kg 
Adapted from Institute of Medicine 2009 guidelines (Institute of Medicine, 2009) 
 
 
1.1.4.2 Neonatal hypoglycaemia 
Normal physiology demonstrates that at birth, the healthy infant has blood 
glucose levels that are approximately 70% of maternal blood glucose, but rapidly 
falls to levels around 3.1 mmol/L one hour post birth, rising to 3.8 mmol/L by 4 
hours postnatally and further increases to >4 mmol/L by 72 hours of age 
(Srinivasan et al., 1986).  Fetal hyperinsulinaemia occurs in utero in response to 
maternal hyperglycaemia (Pedersen, 1952).   In diabetes, when an infant is 
removed from the hyperglycaemic intrauterine environment, they are at risk of 
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hypoglycaemia as the hyperinsulinaemia persists transiently in the absence of 
high glucose substrate and exaggerates this normal physiology.  The most widely 
accepted definition of neonatal hypoglycaemia is blood glucose <2.6 mmol/L but 
there is debate internationally with some societies recommending lower and 
higher treatment thresholds, depending on age of the infant and need for 
treatment above normal infant feeding regimes. Controversy exists due to a 
paucity of high quality evidence on hypoglycaemic thresholds and their 
treatment on developmental outcomes, particularly in the asymptomatic infant 
(Dani and Corsini, 2020). Using the 2.6 mmol/L diagnostic threshold, up to 40% 
of infants born to mothers with diabetes (PGDM, DIP and GDM) will experience 
hypoglycaemia postnatally (Simmons et al., 2000, Yamamoto et al., 2019, 
Voormolen et al., 2018).  Important risk factors for neonatal hypoglycaemia 
include higher maternal glycaemia in the second and third trimesters of 
pregnancy (Yamamoto et al., 2019), higher maternal glycaemia at diagnosis of 
GDM indicating a more severe diabetes phenotype (Simmons et al., 2000), and  
LGA birthweight which increases risk 2-3 fold when compared with appropriate 
for gestational age birthweight infants (Voormolen et al., 2018, Yamamoto et 
al., 2019).   
Neonatal hypoglycaemia is not only life threatening at the time, but has 
additional implications for healthcare resource (increased need for neonatal 
specialist care admissions) and there are concerns of adverse effects on longer 
term neurological sequelae for offspring (Shah et al., 2019). A systematic review 
showed that neonatal hypoglycaemia was associated with a 3-fold risk of visual-
motor impairment, 2.5-fold risk of impaired executive function in early 
childhood, >3-fold risk of neurodevelopmental problems and 2-fold risk of low 
literacy and numeracy attainment (Shah et al., 2019).  Studies in this review 
included hypoglycaemia ranges from  less than 1.1-2.6 mmol/L, and quality of 
evidence was deemed low highlighting a need for ongoing work here to better 
define acceptable lower limits of glycaemia in neonates. Furthermore, studies 
included multiple risk factors for hypoglycaemia and were not diabetes specific.  
Two diabetes specific cohorts within this metanalysis showed conflicting results, 
with one group showing reduced motor, attention and perception functions at 
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age 8 years following neonatal hypoglycaemia and the other showing no 
difference in development by age 4.5 years (Stenninger et al., 1998, Haworth et 
al., 1976). A larger more recent study has confirmed an association with 
neonatal hypoglycaemia and impaired executive and visual motor function, and 
in particular is associated with severe or recurrent hypoglycaemia.  Severe and 
recurrent hypoglycaemia was found more commonly in infants born to mothers 
with diabetes than those without (14% versus 6%) (Mckinlay et al., 2017).  
1.1.4.3 Congenital anomaly 
In pregestational diabetes, rates of congenital anomaly are significantly higher 
than that seen in the background obstetric population (2 to 10-fold higher) 
(CEMACH, 2005, Hawthorne et al., 1997, Casson et al., 1997).  The aetiology of 
this is related to direct toxic effects of hyperglycaemia on embryogenesis. There 
is a linear association with higher maternal HbA1c in early and immediate pre-
pregnancy stage and the risk of congenital anomaly (Guerin et al., 2007, 
Ludvigsson et al., 2018).  Metanalysis has shown that those mothers with 
pregestational diabetes and peri-conceptual HbA1c of 5.5% (37 mmol/L) have a 
2% absolute risk of congenital anomaly in their offspring, but this rises massively 
to 20% risk if HbA1c > 13.9% (128 mmol/L) (Guerin et al., 2007, Kitzmiller et al., 
1991). The most common major anomalies seen in pregnancy complicated by 
diabetes are cardiac malformations, neurological (including neural tube defects) 
and spinal abnormalities, urogenital and gastrointestinal tract abnormalities, 
and musculoskeletal anomalies (Guerin et al., 2007).  Folic acid supplementation 
(400 µg per day) has been shown in the general obstetric population to reduce 
incidence of neural tube defects by up to 70%, with an RCT showing high dose (4 
mg per day) to have beneficial effects on prevention in high risk non-diabetic 
pregnancies (1991). Diabetes would be considered a high-risk pregnancy. Taken 
together, good glycaemic control and high dose folic acid supplementation is 
therefore recommended in the preconceptual and first trimester period to 
minimise the risk of congenital anomaly.  
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Some of the medications used for vascular risk management in diabetes in the 
non-pregnant population may have a teratogenic effect.  Examples of these 
include Angiotensin Converting Enzyme (ACE) Inhibitors which have been linked 
with increased risk of cardiac and neurological anomalies when used in 
pregnancy and statins where increased risk of anomaly is more debated (Cooper 
et al., 2006, Godfrey et al., 2012).  Preconceptual preparation for pregnancy 
should ensure discontinuation of such medicines to minimise risk of harm to the 
developing fetus.    
1.1.4.4 Pre-eclampsia 
The risk of diabetes complicating pregnancy discussed so far have largely been 
determined by direct toxicity or direct physiological effects of glucose on the 
fetus in utero.  However, some of the complications of pregnancy complicated 
by diabetes are less understood and pathophysiology is more complex involving 
interactions between the maternal and fetal metabolic environments, immune 
and cardiovascular systems.  Specifically, preeclampsia and stillbirth risk are two 
such conditions that are significantly increased in pregnancy complicated by 
diabetes with suspected intertwined metabolic and vascular pathologies (Gibbins 
et al., 2016). Improved understanding of potential mechanisms in these two 
conditions form a significant basis of this thesis.  
Preeclampsia occurs in 12-20% of pregnancies complicated by T1DM, reflecting 
levels that are 3-5-fold higher than the background population (Jensen et al., 
2004, Owens et al., 2015).  In T2DM, 10-15% of pregnancies are affected (Owens 
et al., 2015, Groen et al., 2013). GDM also increases risk as reflected by the 
HAPO study (Metzger et al., 2008), and importantly, treatment of 
hyperglycaemia in pregnancy reduces risk by up to 60% (Landon et al., 2009, 
Crowther et al., 2005).  Coexisting microvascular complications further augment 
risk.  In a Danish population with T1DM, rate of preeclampsia rose to 40% for 
women with microalbuminuria, and up to 60% for those with frank nephropathy 
(Ekbom et al., 2001). 
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Mechanisms of disease in preeclampsia including links to glucose physiology are 
discussed in detail in chapter 1.2.     
1.1.4.5 Stillbirth and perinatal mortality 
Women with pregestational diabetes have a 2-5 fold higher rate of stillbirth than 
the population with diabetes (National Pregnancy in Diabetes Audit Report (NHS 
Digital), 2019, Feig et al., 2014).  Controversy exists as to whether GDM 
increases perinatal mortality.  Some large population-based cohorts have shown 
that stillbirth risk is no higher in GDM (Feig et al., 2014), whilst others have 
suggested an increase (Rosenstein et al., 2012).  A recent UK study showed that 
recognition and treatment of GDM lowered stillbirth risk.  Specifically, women 
who had risk factors for GDM but not screened showed a 50% increased risk of 
stillbirth compared to those with no risk factors.  When this group was examined 
retrospectively, those with a raised fasting plasma glucose and diagnosed as GDM 
had a 4x lower risk of stillbirth compared to those who had raised plasma 
glucose but went undiagnosed during pregnancy. The GDM treated group had 
comparable stillbirth rates to those women without GDM (Stacey et al., 2019).  
The Australian Carbohydrate study also showed a trend towards reduced 
perinatal mortality with treatment of mild GDM (5 deaths (1%) in the untreated 
group versus none in the treated group p=0.06), although the study was not 
powered to detect mortality differences (Crowther et al., 2005).  
Aetiology of stillbirth in diabetes is multifactorial.  In around a third, congenital 
anomaly is the underlying cause, but for the remainder it can be more difficult 
to establish (Lauenborg et al., 2003, Wang et al., 2019).  Features of placental 
and umbilical vasculopathy are common in these pregnancies suggesting 
placental vascular insufficiency is a major contributor.  A small fetal post-
mortem study showed that stillborn infants from mothers with diabetes had a 
14-fold increase in fetal hypertrophic cardiomyopathy compared to stillborn 
infants to mothers without diabetes (Lynch et al., 2020). This suggests a 
sustained hypoxic insult in utero, and further links into the hypothesis of 
fetoplacental vascular insufficiency as underlying pathology. 
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Glycaemia is a key risk factor in stillbirth.  A study published only this year, 
showed that third trimester HbA1c (>48 mmol/mol), highest deprivation quintile 
and having T2DM versus T1DM were all independently associated with perinatal 
mortality (odds ratio 3.06, 2.29 and 1.65 respectively) (Murphy et al., 2021).  
1.1.5 Management of diabetes in pregnancy 
Management of diabetes in pregnancy focuses on achieving tight glycaemic 
control, monitoring and management of cardiovascular risk factors, close 
observation of fetal growth parameters and timing delivery to reduce the 
complications discussed.  
Ideally, women enter pregnancy having optimised metabolic factors, but we 
know that this is universally difficult to achieve.  The National Pregnancy in 
Diabetes (NPID) audit showed that less than 1 in 5 mothers with T1DM and 1 in 3 
mothers with T2DM achieved the preconceptual HbA1c target of <48 mmol/mol.  
High dose folic acid supplementation is also advised for 3 months 
preconceptually, and during the first trimester to reduce risk of congenital 
neural tube defects but again <50% of mothers with T1DM and 20% of mothers 
with T2DM achieved this. Taken together, only 1 in 8 women with diabetes are 
considered well prepared for pregnancy ((National Pregnancy in Diabetes Audit 
Report (NHS Digital), 2019).  
Women are seen from as early in pregnancy as possible by specialist 
multidisciplinary teams involving diabetologists, obstetricians, diabetes 
specialist nurses and midwives and dieticians.  They are seen far more 
frequently than pregnant women without diabetes, sometimes as often as 
weekly, to ensure timely management of the ever-changing glucose physiology in 
pregnancy, and allow prompt recognition of complications.  
1.1.5.1 Glycaemic control 
In T1DM, insulin is an essential and lifesaving treatment.  In T2DM and GDM, 
glycaemic control can be achieved using dietary carbohydrate restriction, 
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metformin and/or insulin.  Treatment of T2DM and GDM tends to escalate in this 
pattern.  As discussed, there is a continuous relationship with maternal blood 
glucose and the various complications of diabetes.  Management of 
hyperglycaemia therefore aims to achieve as close to normoglycaemia as 
possible, without increasing the burden of hypoglycaemia.  For many women, 
this is assessed grossly by pre- and post-prandial capillary blood glucose 
monitoring and/or HbA1c, although the latter is not recommended in pregnancy 
due to altered red blood cell survival. International guidelines have slight 
variations on capillary blood glucose targets to achieve this, but are broadly in 
the region of fasting levels < 5.3-5.5 mmol/L and two-hour post-prandial levels 
<6.4 mmol to 7 mmol/L ( Diabetes in Pregnancy (National Institute for Health 
and Care Excellence), 2015, Management of Diabetes (Scottish Intercollegiate 
Guidelines Network) 2017).  A Cochrane review found that evidence comparing 
glycaemic targets was very limited.  Their meta-analysis of three small studies 
found that ‘loose’ control defined by a fasting glucose of greater than 7 mmol/L 
showed evidence of increased adverse outcomes, but at levels below this it was 
less clear what target was optimal (Middleton et al., 2016).   
In recent years, there has been a growing evidence base for use of continuous 
glucose monitoring (CGM) in insulin requiring diabetes.  CGM studies have 
strengthened our knowledge base of the relationship of glycaemia and adverse 
outcomes.  The CONCEPPT trial demonstrated that women who used CGM from 
early pregnancy had significantly lower rates of LGA, neonatal hypoglycaemia, 
lower rates of neonatal ICU (NICU) admission and a shorter hospital stay 
compared to women using capillary blood glucose monitoring.  The numbers 
needed to treat to prevent each of these outcomes is remarkable at 6 for LGA 
and NICU admission, and 8 for neonatal hypoglycaemia (Feig et al., 2017). CGM 
studies have also afforded us better knowledge of the influence that glucose 
variability has on fetal growth.  Despite achieving similar HbA1c, women who 
deliver LGA infants had significant differences in glucose variability across the 
day in each trimester (Law et al., 2015).  It has since been recognised that time 
in range (TIR) (defined as glucose 3.5-7.8 mmol/L) is increasingly important to 
obstetric risk in these pregnancies.  International guidelines have suggested a 
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target of 70% TIR (Using Diabetes Technology in Pregnancy (Diabetes Technology 
Network UK), 2020). This can be difficult to achieve, but data from the 
CONCEPPT trial have shown that an improvement of 5% TIR in the second and 
third trimesters significantly reduces risk of adverse neonatal outcome (Murphy, 
2019, Feig et al., 2017). Following on from this landmark trial, the UK 
governments announced in 2020 that CGM should be made available to all 
mothers with T1DM in pregnancy. 
1.1.5.2 Aspirin for preeclampsia prevention 
Low dose Aspirin at a dose of 75-150mg is recommended in pregnant women with 
diabetes from 12 weeks gestation (National Institue for Health and Care 
Excellence QS35, 2013).  This is to improve placental vascular function and 
prevent preeclampsia   The mechanisms underpinning this are discussed in 
chapter 1.2.  
1.1.5.3  Timing of delivery 
Timing of delivery is somewhat individualised in women with diabetes, although 
international guidelines recommend varying timepoint for routine delivery in 
women with diabetes.  Women are seen frequently in the third trimester to 
monitor glycaemia, blood pressure (BP) and fetal wellbeing.  Serial fetal 
ultrasound is performed throughout the third trimester to monitor growth 
trajectory and aid decisions around obstetric intervention in those with 
accelerating or faltering growth, two groups of infants that are at increased risk 
of adverse outcome. Obstetricians will use this information to make personalised 
decisions around delivery and in healthy pregnancies will aim for delivery at 
term. However, in cases where there is concern for fetal or maternal wellbeing, 
pre-term delivery may be offered. In the case of pregestational diabetes, various 
international guidelines recommend delivery between 37-40 weeks for women 
with diabetes in order to prevent stillbirth and macrosomia related delivery 
complications (Diabetes in Pregnancy (National Institute for Health and Care 
Excellence), 2015, Management of Diabetes (Scottish Intercollegiate Guidelines 
Network) 2017, Pregestational Diabetes (American College of Obstetricians and 
46 
 
Gynaecologists) 2018).  In the general obstetric population, stillbirth risk 
increases beyond 40 weeks, and vulnerable placentas such as may be seen in 
diabetes can be at increased risk in these later weeks (Muglu et al., 2019).  
Earlier intervention, particularly before 37 weeks, can however lead to 
increased neonatal complications such as respiratory distress syndrome (RDS) 
and hypoglycaemia.   
Observational studies have shown that women with PGDM undergoing induction 
of labour at 38 weeks similar rates of shoulder dystocia and caesarean delivery 
but had increased rates of NICU admission, primarily for hypoglycaemia and 
jaundice, compared to expectant management up to 39 weeks.  However, those 
with earlier delivery had been selected for intervention by additional risk factors 
of higher BMI and more likely to require insulin treatment suggesting more 
challenging diabetes, and confounding effects on neonatal outcomes (Brown et 
al., 2019). A large observational study of over 100,000 women with GDM 
explored risk of stillbirth at each gestational week, compared to the risk of 
neonatal death in the following week to better understand the balance of risk of 
induced delivery versus expectant management at each gestational week.  The 
risk of induced delivery was higher than the risk of expectant management from 
delivery at 36 weeks and reached equivalent risk around 37 weeks.  By 39 weeks, 
the risk of stillbirth from expectant management was higher than neonatal death 
with induced delivery suggesting that optimal delivery timing on a population 
level for these women lies between 37-39 weeks (Rosenstein et al., 2012). Of 
course, these observational data have several limitations in that it does not 
account for the confounders that could have informed obstetric decision making 
across the population, and does not take into account morbidity for mothers or 
their offspring.  
A large Canadian cohort explored risk of neonatal morbidity and mortality at 
each gestational week in diabetes.  Specifically, adverse neonatal outcome was 
described as any of stillbirth, neonatal death, adverse neurological outcomes in 
infant, birth injury, fetal or birth asphyxia and RDS.  Women with T2DM, had a 
1.2-1.5 adjusted risk ratio of severe neonatal adverse outcomes if iatrogenic 
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delivery at or before 37 weeks gestation compared to expectant management at 
that stage, with no increased risk seen beyond that.  In T2DM, iatrogenic 
delivery at 36 weeks was associated with 1.5 risk ratio and no difference from 37 
weeks onwards.  In the GDM group, iatrogenic delivery in 36th and 37th weeks 
increased neonatal risk, but beyond that was associated with reduced risk of 
severe adverse neonatal outcome (Metcalfe et al., 2020). Most of our 
information that guides current recommendations around timing of delivery is 
from observational studies that cannot account for confounders, and are drawing 
conclusions from a group of mothers that are undergoing obstetric intervention 
for a variety of reasons. It seems clear that for the majority of women with 
diabetes, allowing pregnancy to continue post-40 weeks seems undesirable, and 
observational data would support delivery sometime between 37-39 weeks.  
Specifically, where within that window requires further evidence and remains an 
unanswered question.  This is evident in the slightly differing guidelines 
internationally.  For women with diabetes requiring insulin or medication, NICE 
guidelines currently suggest delivery between 37+0 to 38+6 weeks gestation, 
whilst Scottish guidelines suggest delivery between 38 and 40 weeks (Diabetes in 
Pregnancy (National Institute for Health and Care Excellence), 2015, 
Management of Diabetes (Scottish Intercollegiate Guidelines Network), 2017).  
The ACOG guidelines are slightly more conservative suggesting delivery is not 
routinely needed before 39 weeks if glycaemic control is good ( Pregestational 
Diabetes Mellitus (American College of Obstetricians and Gynaecologists) 2018,  
Gestational Diabetes Mellitus (American College of Obstetricians and 








1.2.1 Preeclampsia definition and prevalence 
Preeclampsia is a multi-system condition of pregnancy defined as new-onset 
hypertension occurring after 20 weeks gestation in the presence of proteinuria 
or other signs of end-organ damage.  Pregnancy-induced hypertension (PIH) is 
new onset hypertension in the second half of pregnancy occurring in the absence 
of end-organ dysfunction. PIH can affect up to 10% of pregnancies in developed 
nations, with preeclampsia occurring in 1.4-4% (Duley, 2009, Wallis et al., 2008).  
Globally, preeclampsia features consistently in the top three causes of maternal 
morbidity and mortality, typically as a result of progression to eclamptic 
seizures, organ failure or HELLP (haemolysis, elevated liver enzymes and low 
platelets) syndrome.  It is also associated with adverse fetal outcomes such as 
intrauterine growth restriction (IUGR), premature birth and stillbirth (Duley, 
2009).  A Swedish population cohort study identified a rate of 5.2 stillbirths for 
every 1000 births complicated by preeclampsia (Harmon et al., 2015).   
Placental-derived conditions such as these have also been linked with long-term 
metabolic and cardiovascular consequences for mother and her offspring (Burton 
et al., 2016). 
 
1.2.1.1 Preeclampsia definitions 
Prior to 2013, a diagnosis of preeclampsia required the presence of proteinuria 
and hypertension occurring at or beyond 20 weeks gestation (Tranquilli et al., 
2013).  However, over time it became apparent that inclusion of proteinuria as 
an essential criterion for preeclampsia diagnosis had significant clinical 
limitations. Firstly, accelerated de-novo hypertensive end-organ damage could 
occur in pregnancy despite absence of proteinuria, and was associated with 
adverse obstetric outcome. Secondly, false positive proteinuria was not 
uncommon, especially when measured grossly using urine dipstick testing.  In 
recognition of this, the major obstetric societies updated their criteria for 
preeclampsia diagnosis.  The most current definitions for hypertensive disorders 
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in pregnancy are shown in table 1.4 (Brown et al., 2018, Gestational 
Hypertension and Preeclampsia (American College of Obstetricians and 
Gynaecologists, 2020). The International Society for the Study of Hypertension in 
Pregnancy (ISSHP) and ACOG guidelines for preeclampsia diagnosis are broadly 
similar.  There are subtle differences in biochemical cut-offs for end-organ 
damage assessment.  The ACOG guidelines have two major differences to ISSHP 
in that fetal growth restriction is not included as a diagnostic parameter for 
preeclampsia but do include guidance to what constitutes signs of severe 
preeclampsia (Gestational Hypertension and Preeclampsia (American College of 
Obstetricians and Gynaecologists), 2020, Brown et al., 2018).  
HELLP syndrome is also included on the spectrum of placental insufficiency and 
preeclampsia and is a marker of more severe disease.  HELLP can occur in the 
absence of hypertension in up to 18% of cases (Sibai, 2004).  HELLP is associated 
with maternal mortality (around 1%), significantly higher maternal morbidity 
from critical complications, and perinatal mortality in up to 34% of cases (Haram 
et al., 2009, Sibai, 2004).  
Clinically, early-onset and late-onset preeclampsia are distinguished by a cut off 
of 34 weeks gestation.  This is relevant since women with early-onset 
preeclampsia are more likely to give birth to a growth restricted infant, show 
evidence of placental vascular insufficiency and are at higher risk of multi-organ 
dysfunction and associated maternal and neonatal mortality (Raymond and 








Table 1.4: The International Society for the Study of Hypertension in Pregnancy (ISSHP) 2018 
and American College of Obstetricians and Gynaecologists (ACOG) 2020 diagnostic criteria for 
hypertensive disorders in pregnancy  
 ISSHP 2018 guidelines (Brown et al., 
2018) 
 
ACOG 2020 guidelines (2020) 
Preeclampsia New onset hypertension (>140/90mmHg) 
after 20 weeks gestation accompanied by 
any of  : 
 
1. New proteinuria (urine 
protein:creatinine >30 mg/mmol, 
or 24-hour urine protein >300 mg 
or 2+ proteinuria on dipstick 
testing) 
2. New maternal end-organ damage 
such as: 
- Renal insufficiency 
(creatinine>90 µmol/L) 
- Elevated liver transaminases 
>2x upper limit normal 
- Neurological abnormalities 
- Low platelets <150,000/dL 
- Disseminated intravascular 
coagulopathy 
3. Uteroplacental dysfunction 
- Fetal growth restriction 
 
New onset hypertension 
(>140/90mmHg) after 20 weeks 
gestation on 2 occasions at least 
4 hours apart, and any of: 
 
1. Proteinuria (>300 mg in 
24 hour or 
protein:creatinine >0.3 
mg/dL or 2+ on dipstick 
(dipstick least 
preferred) 
2. Maternal organ damage: 
- Renal impairment 
(creatinine >100 
µmol/L or doubling 
of creatinine) 
- ↑ transaminases 
>70µL or >2x upper 
limit normal 
- Severe upper 
abdominal pain 
without other cause 
- Cerebral or visual 
symptoms 
- Low platelets 
<100,000/dL 




 BP > 160/110 mmHg on two 
occasions 4 hours apart and/or 
any of the non-proteinuria 





De novo hypertension (>140/90 mmHg) 
occurring after 20 weeks gestation in 
woman with previously normal BP without 
proteinuria or end-organ manifestations 
of PE 
New onset BP >140/90 mmHg (2 
readings 4 hours apart) 
occurring after 20 weeks 
gestation in woman with 
previously normal BP, and in 
absence of proteinuria or end-
organ damage  
 




Hypertension (>140/90 mmHg or on 
treatment) diagnosed pre-pregnancy or 
before 20 weeks gestation  
 
Superimposed preeclampsia can occur in 
these patients 
Hypertension (>140/90 mmHg or 
on treatment) diagnosed pre-
pregnancy or before 20 weeks 
gestation  
 
Superimposed preeclampsia can 





1.2.2 Pathophysiology of preeclampsia 
The pathophysiology is complex and not yet fully understood but ultimately is 
thought to be a result of impaired placental vascular development and function, 
and dysregulated placental perfusion.  In early onset preeclampsia (<34 weeks), 
abnormal placental development resulting in placental ischaemia is a likely 
primary pathology, compared with late onset where maternal vascular insults 
lead to reduced placental perfusion, although overlap exists (Raymond and 
Peterson, 2011).  
There are two distinct phases of preeclampsia development beginning with 
abnormal  invasion of trophoblast cells into the uterus post-conception with 
impaired remodelling of maternal uterine spiral arteries in early pregnancy, 
resulting in high resistance uteroplacental circulation.  This is followed by 
impaired placental perfusion causing release of inflammatory cytokines and 
angiogenic mediators into maternal circulation resulting in maternal systemic 
endothelial dysfunction (Burton et al., 2019).   
Numerous triggers for pathogenic embryo implantation have been identified. 
These include an exaggerated immunological reaction between maternal and 
fetal tissues, a preceding impairment of maternal circulation and altered 
placental vascular development due to imbalanced angiogenic and growth 
factors. Several markers of angiogenesis, endothelial dysfunction and 
inflammation are disrupted in preeclampsia (Carty et al., 2008, De Vivo et al., 
2008, Zeisler et al., 2016, Sheikh et al., 2016).  Maternal risk factors for 
preeclampsia include nulliparity, older age, obesity, autoimmune disease, 
smoking and diabetes, all of which can contribute to disruption in these 
regulatory pathways (Kaaja, 2008).    
The mechanism and presentation of disease is heterogeneous which hinders 
development of early predictive, diagnostic and therapeutic markers.  The next 
focus of this chapter will discuss normal placental and maternal vascular 
development, the hormonal, angiogenic and inflammatory factors that influence 
52 
 
this, and put into context how these factors might be disrupted in preeclampsia 
and diabetes. 
1.2.2.1 Normal pregnancy and placental vascular development 
The placenta is a unique vascular organ that develops during pregnancy and is 
responsible for transport of nutrients and gas exchange from the maternal 
circulation to the developing fetus, and removal of waste products from the 
fetal circulation. It also acts as a selective barrier to protect the fetus from 
some harmful molecules crossing from maternal to fetal circulation, and has 
endocrine functions that help support the development of a healthy pregnancy.   
Placental development begins with implantation of the blastocyst in early 
pregnancy.  When the ovum is fertilised by a sperm cell in the fallopian tube, a 
zygote is formed.  This zygote undergoes multiple cellular divisions by mitosis, 
and at approximately day five following fertilisation reaches a critical cell mass 
and is termed the blastocyst. The blastocyst is a fluid filled structure with two 
layers of cells, the innermost cell mass called the endoderm which will develop 
into fetal tissue, whilst the outermost layer contains trophoblast cells which will 
later become placental tissue.  Blastocyst formation is regulated by various 
genes concerned with ion channel activation and production of growth factors 
(Watson, 1992). 
At day 6 to 7 post-fertilisation, the trophoblast imbeds on the uterine 
endometrial surface and begins the process of implantation.  During this, the 
trophoblast cells proliferate into two layers.  The outer layer forms from fused 
trophoblast cells that form multinucleated aggregates called syncytium. Beneath 
the syncytium, is a layer of proliferating cytotrophoblast cells. Under the 
influence of progesterone, the endometrium undergoes remodelling in early 
pregnancy to become the decidua.  During the first couple of weeks of 
implantation, the syncytium invades into the decidua until the blastocyst is 
completely embedded within it (Turco and Moffett, 2019). 
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The underlying cytotrophoblasts continue to proliferate through the syncytium to 
produce primary villi channels surrounded by an outer layer of 
syncytiotrophoblasts. Branching continues to create secondary villi surrounded 
by vacuoles known as the intervillous space. The cytotrophoblasts then invade 
through the syncytium and surrounds the embryo creating a shell in contact with 
the maternal decidua. The embryo is now surrounded by three layers – the 
innermost layer which is the chorionic plate, the villous layer in the middle and 
the cytotrophoblastic shell on the outside.  This is all complete within the first 
three weeks following fertilisation. The innermost layers will form the 
fetoplacental circulation, whilst the shell is instrumental in forming the 
uteroplacental circulation (Turco and Moffett, 2019). 
At around 8-10 weeks of gestation, extravillous cytotrophoblasts from the 
cytotrophoblastic shell migrate further into the maternal decidua, and 
importantly into the uterine spiral arteries at 14-16 weeks.  Here, they replace 
maternal endothelium and destroy smooth muscle structure in the high 
resistance, low capacitance spiral arteries and turn them into low resistance, 
high capacitance arteries with reduced vasoreactivity. Such features are 
important to maximise blood flow and perfusion of the uteroplacental unit. The 
extravillous cytotrophoblast cells temporarily plug the spiral artery during 
remodelling to prevent blood flow into the intervillous space until development 
of functional uteroplacental and fetoplacental circulations (Turco and Moffett, 
2019). This is typically around end of the first trimester. Figure 1.1 
demonstrates early placental development. Following formation of this basic 
placental unit, the placenta continues to undergo angiogenesis through to third 




Figure 1.1: Placental development 
This figure details trophoblast invasion and the different cell types involved in first trimester 
placental development. The inner cell mass of the trophoblast is surrounded by an inner layer of 
cells called the villous cytotrophoblast (green) which will form the chorionic villi and chorionic 
plate.  This will form the fetoplacental circulation.  This is surrounded by an outer membrane of 
multinucleated syncytiotrophoblasts (blue) which is the interface between maternal and fetal 
circulation across which diffusion of nutrients and gas exchange will occur and also forms a 
physical barrier to some harmful substances to the fetus.  The outermost layer is the 
cytotrophoblastic cell (yellow) which invades into the maternal decidua and the spiral arteries 
within this.  The invading extravillous cytotrophoblasts (yellow) within this replace maternal 
endothelium and smooth muscle cells to remodel spiral arteries in the myometrium into low 
resistance, high capacitance vessels to optimise blood flow from mother to fetus.  This is the 
uteroplacental circulation.   The purple cells show uterine glandular cells that can also be 
invaded by trophoblast cells and secrete products into the intervillous space.  
 
1.2.2.2 Placental anatomy 
The finished placental unit contains two separate circulatory systems that do not 
mix.  The placenta is connected to the maternal circulation via the interface 
between the decidua and placenta, and to the fetus via the umbilical cord.  The 
55 
 
uteroplacental circulation (maternal side) concerned with perfusion of the 
placenta by diffusion of oxygen and nutrients from maternal blood (via spiral 
arteries and intervillous space) and return of deoxygenated blood to the 
maternal circulation.  The fetoplacental circulation’s role is to allow transfer of 
oxygen and nutrients from placenta to the fetus (via umbilical and chorionic 
veins) and the removal of toxins and deoxygenated blood from fetus back to the 
placenta for reoxygenation (via umbilical and chorionic arteries). Figure 1.2 
shows the maternal and fetal placenta macroscopic appearances.   
The umbilical cord consists of two umbilical arteries and one umbilical vein 
bound in one cord structure by a jelly-like substance, and connects the fetal side 
of the placenta to the fetus.  The umbilical arteries and vein form smaller 
branches on the fetal surface of the placenta (chorionic plate) before 
transcending deeper into the villous placenta. Umbilical cords in most cases 
insert centrally on the placenta, but in up to 10% of pregnancies can insert more 
peripherally (Ismail et al., 2017).  This is termed marginal insertion when it 
inserts peripherally but still attaches within the chorionic plate, or velamentous 
when the cord inserts most laterally into the fibrous placental membranes 
(amnion) resulting in vulnerable chorionic vessels crossing between the amniotic 
membrane and chorionic placenta.  Marginal and velamentous cord insertions 
are associated with higher rates of adverse pregnancy outcome relating to 
preterm delivery, IUGR and intrauterine death (Ismail et al., 2017).  
Velamentous cord insertion is the highest risk abnormal cord insertion, and 






Figure 1.2: Macroscopic appearances of the placenta 
The top figure shows the macroscopic appearances of the fetal side of the placenta (chorion) 
with marginal insertion of the umbilical cord.  Branching chorionic plate vessels (arteries and 
veins)  are visible on the chorionic plate surface and the attached white fibrous membranes of 
the amnion are visible.  The bottom figure demonstrates the maternal side of the placenta 
that attaches to the uterus.  The maternal side consists of multiple perfusion lobules called 
cotyledons that are easily visible to the naked eye. Each individual cotyledon is supplied by a 
spiral artery and associated anatomically with perfusion of a villous tree. In this image, an 
area of fibrin is noted in the upper right quadrant.   Fibrin deposits are a common finding on 
pathological examination of placentas (up to 20%) and usually benign, but if extensive enough 
to cause reduced placental function can cause adverse fetal outcome (Ernst and Faye-
Petersen, 2014).   
Image taken by Dr Kirsty McIntyre and reproduced in this thesis with permission from her 




1.2.2.3 Normal maternal vascular adaptation in pregnancy 
At the same time as the placental vasculature is developing, the maternal 
systemic circulation undergoes changes from early pregnancy to optimise 
conditions for supporting the pregnancy.  From early pregnancy, there is 
expansion of maternal circulating volume and cardiac output increases by 50% 
compared to the pre-pregnant state.  This occurs in association with an almost 
30% increase in maternal heart rate throughout pregnancy, and a 20% increase 
in stroke volume (Mabie et al., 1994, Sibai and Frangieh, 1995). The majority 
of these physiological adaptions occur in the first half of pregnancy, but 
continual changes take place into late third trimester.  In parallel to these 
changes, the blood flow to the uterine circulation is maximised through local 
vasodilation in the uteroplacental unit, and to a lesser extent through 
systemic vasodilation in the maternal circulation. During pregnancy, up to 25% 
of cardiac output is directed to the uterine circulation (Mandalà, 2020). This 
leads to a reduced peripheral vascular resistance and lowering of BP with 
advancing gestation.  These systemic changes occur under neurohumoral 
control (Goulopoulou, 2017).  The effects of key pathways and hormones are 
discussed below. 
1.2.3 Endothelial function in pregnancy 
The endothelium is a monolayer of specialised cells located on the innermost 
surface of blood vessels. It is supported by the internal elastic lamina and 
together they form the tunica intima.  Underneath the tunica intima lies the 
tunica media, which consists largely of vascular smooth muscle cells (VSMCs) 
with some intertwined elastic fibres.  The outermost layer of the blood vessel 
is the tunica adventitia which is a network of collagenous connective tissue 
supporting the vessel’s structure.  Figure 1.3 shows arterial anatomy. 
Endothelial cells are a key regulator of vascular homeostasis.  In response to 
physical and metabolic stimuli, they produce vasoactive substances that 
control vascular tone, platelet adhesion, angiogenesis and cellular 













            
 
 
Figure 1.3:  Anatomy of an artery 
The innermost tunica intima layer consists of a single layer of endothelial cells, shown in 
pink, with a thin layer of elastic tissue (blue).  Underneath this lies the tunica media layer 
which consists mostly of VSMCs.  The outermost adventitia consists of collagen and 
fibroblasts that provide structural support to the vessel, as well as other important cell 
lines such as dendritic and progenitor cells that are involved with angiogenesis and immune 
function. 
 
1.2.3.1 Nitric Oxide  
Nitric oxide (NO) is a compound produced by endothelial cells from the 
oxidisation of L-arginine by the enzyme endothelial nitric oxide synthase 
(eNOS) coupled with its cofactor tetrahydrobiopterin. NO production is 
stimulated by mechanical force exerted on endothelium by blood flow (shear 
stress), or by binding of ligands to membrane receptors that stimulate 
intracellular calcium release and thus eNOS activation.  Such ligands include 
but are not limited to acetylcholine, bradykinin, histamine and calcitonin gene 
related peptide (CGRP) (Förstermann and Münzel, 2006, Tousoulis et al., 
2012). 
Once produced, NO diffuses across into VSMCs to activate cyclic guanosine 
monophosphate (cGMP) pathways, which in turn lower intracellular calcium 










through a variety of mechanisms. Firstly, it activates protein kinase G (PKG) 
which stimulates cellular efflux of potassium through calcium-gated potassium 
channels (KCa) and inhibition of calcium release from endoplasmic reticulum 
within the cell.  This leads to VSMC repolarisation and vasorelaxation.  It also 
causes dephosphorylation of the myosin light chain fibres in VSMC, preventing 
the interaction between the smooth muscle actin and myosin fibres that are 
required to maintain vascular contraction (Tousoulis et al., 2012). Figure 1.4 
demonstrates some of the key endothelial and VSMC pathways involved in 
vasodilatation.   
NO activity is significantly reduced in the presence of reactive oxygen species 
(ROS), such as superoxide (O2-).  O2- forms when eNOS becomes uncoupled, for 
example as a result of reduced tetrahydrobiopterin or L-arginine substrates. 
When formed, O2- and NO form the powerful oxidant peroxynitrite (ONOO-) 
which causes oxidisation and nitration damage to cells (Alp and Channon, 
2004).       O2- can be catalysed by the enzyme superoxide dismutase (SOD) to 
form O2 and hydrogen peroxide to prevent against the toxic effects of ROS 
generation.   Healthy vascular homeostasis requires a balance of ROS 
production and such defence mechanisms, with imbalance leading to oxidative 
stress and vascular disease (Sena et al., 2018).   
Experiments using nitrite and nitrate concentrations as a measure of NO 
activity have shown that NO concentrations in maternal serum increase from 
early pregnancy through to the late 3rd trimester, with levels up to 10-fold 
higher than that seen in non-pregnant women (Choi et al., 2002, Owusu 
Darkwa et al., 2018). This is largely mediated by endothelial stimulation from 
increasing concentrations of pregnancy hormones such as oestradiol (Sudhir et 
al., 1996).  In the fetoplacental vasculature, laminar flow through the vessel 
(shear stress) induces vasodilation, an effect which is reduced if eNOS activity 
is inhibited (Learmont and Poston, 1996).  Immunohistochemistry studies from 
term pregnancies have localised eNOS expression within cytotrophoblast and 
syncytiotrophoblasts of the placental (Schiessl et al., 2005), and NO 
metabolites are found in umbilical venous blood (Lyall et al., 1995).   Taken 
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together, this suggests that NO expression is important for both systemic and 
placental vascular homeostasis in pregnancy. 
1.2.3.1.1 Nitric oxide in preeclampsia and IUGR 
  
In preeclamptic pregnancies, flow-mediated dilatation (FMD) of the brachial 
artery, a non-invasive method of assessing endothelial NO release, is 
attenuated compared with healthy pregnant controls.   This marker of 
endothelial function is reduced prior to, during and after a diagnosis of 
preeclampsia has been made (Weissgerber et al., 2016).  Higher levels of the 
endogenous eNOS inhibitor, asymmetric dimethylarginine (ADMA) have been 
found to be increased in women with abnormal uterine artery Doppler studies 
who later develop preeclampsia (Savvidou et al., 2003).  This suggests that 
women who develop preeclampsia have alterations in systemic endothelial 
function that may contribute to deleterious effects on vasodilatation and 
vascular health. Disruptions in placental endothelial function in preeclampsia 
are more disputed.  Some have shown that NO and eNOS expression is 
increased in the feto- and uteroplacental circulation in preeclampsia and 
growth restricted pregnancies as a presumed compensatory mechanism to 
protect fetoplacental perfusion whilst others have shown that levels are 
decreased (Lyall et al., 1995, Lyall et al., 1996, Schiessl et al., 2005, Sánchez-
Aranguren et al., 2014).  It has also been shown that mothers with 
preeclampsia have lower L-arginine reserves (Kim et al., 2006), and some 
limited studies in L-arginine supplementation have shown potential to prevent 
preeclampsia (Dorniak-Wall et al., 2014). 
1.2.3.1.2 Nitric Oxide and diabetes in pregnancy 
 
Endothelial dysfunction in diabetes has long been implicated in the 
development of diabetes and its neurovascular complications.  Hyperglycaemia 
is known to decrease NO activity and increased oxidative stress through 
production of reactive oxygen species (ROS). Several mechanisms contribute to 
this including: oxidisation of glucose to form O2-, enhanced lipid peroxidation 
promoting ROS formation and glycation of lipids and proteins to form advanced 
61 
 
glycation end (AGE) products. AGE products subsequently bind to receptors on 
the endothelial cell (RAGE)  and have a number of toxic effects mediated 
through protein kinase C. These include reduced mitochondrial NADPH activity 
and activating proinflammatory pathway mediators (Maritim et al., 2003).  It is 
reasonable to propose that diabetes in pregnancy could have similar 
detrimental effects on vascular function in the maternal and placental 
circulation. 
Two papers exploring differences in FMD of the brachial artery as a measure of 
endothelial dysfunction in women with GDM have shown conflicting results. 
The studies were small comparing 20 women per group, and at the time of 
starting my own research, only one had been published.  One study showed 
that a single FMD taken between 25-39 weeks gestation was lower in GDM 
mothers compared with pregnant controls, but the FMD measures were not 
matched for gestational age (De Resende Guimarães et al., 2014).  The second 
study demonstrated no difference between GDM mothers and controls for 
serial FMD measurements across first, second and third trimesters (Garg et al., 
2017).  
In the fetoplacental vasculature, nitrite concentrations have been shown to be 
significantly higher in GDM than non-GDM pregnancies suggesting increased NO 
production in these vessels (Figueroa et al., 2000). eNOS in human umbilical 
vein endothelial cells (HUVECs) is also upregulated in GDM (Di Fulvio et al., 
2014).  However, the NOS isoform, inducible NOS (iNOS) is also upregulated in 
GDM placental tissue which is pathological.  iNOS is produced by endothelial 
cells in response to inflammatory and toxic insults, and whilst it acts to 
stimulate large amounts of NO production, it simultaneously promotes ROS 
generation (Lind et al., 2017). 
Work by Sobrevia et al showed that high glucose and high insulin exposure 
independently increase cGMP expression and L-arginine transport in HUVECs 
suggesting that both insulin and glucose can stimulate NO production. 
However, when hyperglycaemic conditions were maintained for several hours 
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and insulin subsequently added, cGMP levels were significantly attenuated 
suggesting that endothelium-induced vasodilation is impaired by sustained 
hyperglycaemia (Sobrevia et al., 1996).  Similar insulin resistance within 
HUVECS was demonstrated when they compared cGMP production from HUVEC 
from normal pregnancies compared with GDM pregnancies (Sobrevia et al., 
1998).   
1.2.3.2 Prostacyclin and thromboxane 
Prostacyclin (PGI2) is an endogenous prostaglandin with potent vasodilatory 
capacity.  It is produced in endothelial cells by the metabolism of arachidonic 
acid by the cyclooxygenase (COX) pathway.  Arachidonic acid is converted to 
prostaglandin H2 and thereafter can undergo isomerisation by prostacyclin 
synthase to form PGI2, or metabolised by thromboxane synthase to form 
thromboxane A2 (TXA2). PGI2 acts to promote vasodilatation and inhibit 
platelet aggregation, whilst TXA2 has the opposite actions.  PGI2 binds to G-
protein coupled receptors on VSMC, activating cAMP and protein kinase A 
pathways.  As shown in figure 1.4, this reduces intracellular calcium by 
preventing release from sarcoplasmic reticulum stores, inhibits MLCK activity 
responsible for myosin phosphorylation and activates various K channels on the 
cell membrane to promote ion efflux and repolarisation. These effects cause 
VSMC relaxation. Activation of cAMP and PKA pathways in platelets also 
inhibits platelet function and thrombus formation (Mitchell and Kirkby, 2019). 
PGI2 expression is significantly higher in the second and third trimesters of 
pregnancy compared with the non-pregnant state (Goodman et al., 1982).  
Whilst PGI2 levels increase across pregnancy, there is a simultaneous decrease 
in TXA2 (Wang et al., 1991).  In vitro studies have shown that oestradiol 
stimulates PGI2 expression in HUVECs (Sobrino et al., 2010).  PGI2 contributes 
beneficial vascular effects in pregnancy promoting vasodilatation and 
inhibiting platelet aggregation and contributes to the reduced responsiveness 
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to angiotensin II in pregnancy. It also promotes relaxation of uterine smooth 
muscle thereby quiescing uterine contractile activity.  
1.2.3.2.1 Prostacyclin and thromboxane in PE 
 
In preeclampsia, PGI2 expression (measured by urinary metabolites) is reduced 
whilst TXA2 expression is several folds higher compared with healthy 
pregnancy.  Furthermore, these changes occur far earlier in pregnancy than 
when preeclampsia becomes clinically apparent, signalling that endothelial 
dysfunction is occurring before disease is evident.  This creates an imbalance 
between the PGI2 vasodilatory effects and vasoconstrictive TXA2 in favour of a 
procontractile and prothrombotic phenotype (Mills et al., 1999).  The cause 
for this imbalance is not yet fully elucidated.  One contributing factor is that 
oxidative stress and ROS production is increased in preeclampsia which leads 
to increased production of lipid peroxides.  Lipid peroxides promote COX 
activity but downstream of this inhibit prostacyclin synthase (Warso and 
Lands, 1983).  Circulating lipid peroxides are increased in the serum of women 
who have preeclampsia (Madazli et al., 1999).  There may also be direct or 
indirect hormonal influences. In preeclamptic placentas, incubation with high 
doses of progesterone inhibited prostacyclin production (Walsh and Coulter, 
1989).  
1.2.3.2.2 Prostacyclin and thromboxane in diabetes in pregnancy 
 
Similar disruptions to prostacyclin and thromboxane have been demonstrated 
in hyperglycaemic pregnancy.  Prostacyclin and COX-2 expression is 
downregulated in HUVECs from mothers with insulin-treated diabetes 
compared to healthy controls (Bolego et al., 2006).  Thromboxane metabolites 
are also increased in the urine of mothers with T1DM (Vanassche et al., 1993).  
Prostacyclin metabolites have been found to be lower in the umbilical artery 
in GDM to a similar level seen in severe PIH (Johnstone et al., 1988).  
Antioxidant levels are lower in women with GDM than healthy controls and 
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may contribute to reduced antagonism of lipid peroxidation (Parast and 


















Figure 1.4:  Endothelial and VSMC vasodilation pathways 
In order for VSMCs to contract, they require a combination of increased intracellular calcium 
concentrations, cellular depolarisation and phosphorylation of myosin light chains to allow 
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vasorelaxation and dilatation.  Vasodilatation can be produced through an endothelium-
dependent manner or endothelium-independent.  
NO is one of the main endothelium dependent vasodilators.  NO is produced in the endothelial 
cell from the oxidisation of L-arginine by endothelial NO synthase (eNOS).  eNOS is activated 
in the presence of raised intracellular calcium stores and by phosphorylation from tyrosine 
kinase pathways. eNOS can be activated by “shear stress” (mechanical force from blood flow 
on cell), inflammatory cytokines, or by ligands binding to membrane receptors that activate 
the calcium and tyrosine kinase pathways.  Once produced, NO diffused across the endothelial 
cell wall into the neighbouring VSMC where it activates soluble guanylate cyclase (GC) to 
increase cGMP pathways.  cGMP activates protein kinase G which has several mechanisms: 1) 
Activates calcium gated K+ channels promoting K+ efflux and cellular repolarisation 2) 
inhibition of Ca++ release from the sarcoplasmic reticulum thereby reducing intracellular 
calcium stores 3) inhibits the enzyme myosin light chain kinase (MLCK) which is responsible for 
phosphorylation of myosin light chains. Together, these actions promote vasorelaxation. 
Prostacyclin as another vasodilator produced within endothelial cells from the breakdown of 
arachidonic acid by the cyclooxygenase (COX) enzymes. Prostacyclin binds to G-protein (Gα) 
receptors on the VSMC that then activate cyclic AMP (cAMP).  cAMP in turn activates protein 
kinase A which acts similar to protein kinase G by 1) activating K+ channels to promote ion 
efflux and repolarisation 2) decreasing release of Ca++ from intracellular organelles 3) 
inhibiting MLCK activity.  
Independently of endothelial production of NO or prostacyclin, ligands can bind to receptors 
on the VSMC wall to activate cAMP and cGMP pathways.    
 
1.2.3.3 Endothelin 
Endothelin-1 (ET-1) is a peptide produced by endothelial cells that promotes 
vasoconstriction, cellular proliferation and inhibits cellular death. It is 
produced from enzymatic cleavage of the inactive precursor, big-ET1. ET-1 
expression is upregulated by low shear stress, hypoxia, adrenaline, angiotensin 
II, thrombin, free radicals and inflammatory cytokines,  whilst NO, cGMP and 
PGI2 inhibit its release (Kowalczyk et al., 2015). ET-1 binds to G-protein 
coupled receptors on endothelial and VSMC membranes. There are two 
subtypes of receptors – type A (ETA) and type B (ETB).   
When ET-1 binds to ETA on the VSMC, it acts to promote calcium influx 
through ion channels and promotes phospholipase C pathways which stimulate 
calcium release from the sarcoplasmic reticulum.  The net effect is of a rise in 
intracellular calcium concentrations promoting contraction.  ET-1 also 
activates protein kinase C and mitogen activated protein kinase (MAPK) to 
promote calcium-independent contraction and  cellular proliferation 
(Kowalczyk et al., 2015). ETB receptors are found on endothelial cells (ETB1) 
and VSMC (ETB2).  When bound to the ETB1 receptor, NO release is stimulated.  
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When ETB2 is bound, it has similar procontractile effects on the VSMC cell as 
described for ETA but simultaneously promotes PGI2 expression (Kowalczyk et 
al., 2015). 
ET-1 and ETB receptors have been localised to several cell lines in the 
placenta – the endothelial cells, the syncytiotrophoblasts and cytotrophoblasts 
and does not appear to alter with gestational age (Wilkes et al., 1993, Barros 
et al., 2001). This is demonstrated in other studies that show no significant 
trend in plasma ET-1 levels across healthy pregnancy (Wolff et al., 1997).  In 
normal pregnancy, ET-1 and Big-ET1 levels are reduced compared with non-
pregnant controls (Sudo et al., 1993). 
1.2.3.3.1 Endothelin-1 in preeclampsia 
 
Circulating ET-1 and Big-ET1 levels are higher in women who have 
preeclampsia compared to healthy controls (Sudo et al., 1993, Aggarwal et al., 
2012, Taylor et al., 1990).  Numerous triggers can account for this.  In 
preeclampsia pregnancies, the ratio of Big-ET1:ET1 is reduced suggesting that 
there is reduced converting enzyme (Sudo et al., 1993). Also, one of the key 
features of preeclampsia is the placental production of anti-angiogenic 
factors, inflammatory cytokines and hypoxia inducible factors (HIF) prior to 
development of preeclampsia  These subsequently stimulate ET-1 expression. 
As such, there has been interest in whether antagonism of ET1 receptors might 
be of therapeutic benefit in preeclampsia but animal models have shown 
deleterious effects on fetal survival (George and Granger, 2011).  
1.2.3.3.2 Endothelin-1 in diabetes in pregnancy 
 
There is a paucity of studies exploring ET-1 and receptor expression in 
pregnancy complicated by diabetes and results are conflicting. ET-1 levels 
have been shown to be elevated in the serum of women with insulin-
dependent diabetes across all stages of pregnancy (Wolff et al., 1997). Insulin 
is also a  known stimulator of ET-1 expression. However, as Wolff et al 
explain, insulin secretion is higher in normal pregnancy than in the non-
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pregnant state, yet ET-1 levels are reduced. Another study showed no 
difference in ET-1 levels in T1DM nor GDM, but importantly these women had 
very well controlled diabetes as reflected by HbA1c (Swiderski et al., 2010).  
There was a moderate correlation with HbA1c and ET-1 suggesting that 
hyperglycaemic pregnancy may influence ET-1 production (Swiderski et al., 
2010). There is evidence of ET-1 activation in diabetes in non-pregnant 
subjects so it makes sense that similar changes can occur in pregnancy.  
Subcutaneous arteries from women with T1DM show reduced contractility to 
ET-1 (Ang et al., 2001), an effect which has been hypothesised to result from 
reduced ET-1 receptor expression.  To my knowledge there are no studies 
investigating ET receptor expression in the same vascular bed, but in placental 
tissue, ET receptor expression is reduced in GDM which may reflect a 
protective mechanism from ET-1 overexpression (Dieber-Rotheneder et al., 
2012).  
1.2.4 Hormonal influences on vascular and glycaemic adaptation 
in pregnancy 
This next section describes some of the important hormonal alterations that 
occur in pregnancy and their effects on glucose physiology and vascular 
function in pregnancy. 
1.2.4.1 human chorionotropic gonadotrophin (hCG) 
hCG is a peptide hormone produced by the trophoblast cells and peaks at the 
end of the first trimester of pregnancy.  One of its main roles is to promote 
progesterone production from the corpus luteum which subsequently primes 
the endometrium for implantation (decidualisation).  hCG has a critical role in 
placental development as it stimulates further cytotrophoblast invasion (Lee 
et al., 2013), and aids cytotrophoblast differentiation into 
syncytiotrophoblasts.   In vitro experiments have also shown that hCG 
promotes angiogenesis, HUVEC and VSMC proliferation (Berndt et al., 2009), an 
effect which is at least partially due to altered expression of proangiogenic 
factors such as vascular endothelial growth factor (VEGF) (Brouillet et al., 
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2012).  The role of VEGF in placental development is discussed in section 
1.2.5.  In non-pregnant women, hCG administration decreased uterine artery 
resistance suggesting vasodilatory capabilities that could be beneficial in 
optimising uterine blood flow in the early stages of pregnancy.  These effects 
were accompanied by an increased expression of the endothelial derived 
vasodilator(Toth et al., 1994).  
1.2.4.2 Oestradiol 
In the early stages of pregnancy, oestrogens are produced from the corpus 
luteum but as the placenta develops, it takes over as the main source of 
oestrogen.  There are 4 different oestrogens produced: oestrone (E1), 
oestradiol (E2), oestriol (E3) and oestetrol (E4). Of these, E2 is the most 
abundant with levels increasing with advancing gestation to reach 
concentrations up to 100 times higher than seen in the non-pregnant state.  
Interestingly, the placenta lacks the enzymatic activity required to convert 
progesterones to androgen precursors, and so is reliant on maternal and fetal 
adrenal glands as a source of dehydroepiandrosterone (DHEA).  This DHEA can 
then be converted to testosterone and subsequently aromatised by the 
syncytiotrophoblasts (Costa, 2016).  The steroid pathways are shown in figure 
1.5, with the lack of placental enzymes highlighted.  
E2, and other oestrogens, act on oestrogen receptors present in the placenta, 
uterus and uterine artery endothelial cells and VSMCs. Oestrogens are 
important stimulators of endometrial proliferation, but they also have 
important effects on vascular and glycaemic physiology in pregnancy.  E2 
enhances vasodilatory capacity of arteries through upregulation cAMP 
pathways and increased production of eNOS (Storment et al., 2000, Napso et 
al., 2018).  It also promotes angiogenesis in rodent uterine arteries and in 
HUVEC cultures (Morales et al., 1995).  Taken together, oestrogens have 
important roles in endometrial priming for pregnancy, but also help regulate 
uterine blood flow in pregnancy.   
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Oestrogen has important effects on glucose physiology in pregnancy also.  In 
animal models where oestrogen effects are blocked, there is notably 
decreased insulin sensitivity and increased adiposity.  Conversely, high 
oestrogen environments lead to improved insulin sensitivity, reduced hepatic 
gluconeogenesis and protective effects from oxidative stress and preservation 
of β-cell mass (Napso et al., 2018, Tiano and Mauvais-Jarvis, 2012).  Several 
studies have found lower oestradiol concentrations in pregnancy complicated 
by diabetes (PGDM and GDM) (Montelongo et al., 1992, Qi et al., 2017) and 
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Figure 1.5:  Steroid hormone pathway with highlighted enzymes that are lacking in 
placenta 
This figure demonstrates steroid hormone production from a cholesterol precursor.  Several 
hydroxylase enzymes are involved at each stage of the steroid conversion pathway.  Those 
enzymes highlighted in red are essential for conversion of pregnenolone and progesterone to 
androgen steroid hormones, but these enzymes are not produced within the placenta.  
Therefore, placental production of androgens and subsequent aromatisation to oestradiol 
requires another source of androgen hormone.  DHEA androgen is produced by the maternal 









In the first weeks of pregnancy, the corpus luteum (temporary remnant of the 
ruptured ovarian follicle post-ovulation) produces high levels of progesterone 
under the influence of hCG.  After 6-8 weeks gestation, hCG levels decline and 
the syncytiotrophoblasts takes over production.  Progesterone levels increase 
with advancing gestation, reaching a plateau in late third trimester.  One of 
the main roles of progesterone is to stimulate decidualisation, a key process in 
preparing the uterus for implantation and supporting placental development.  
Progesterone promotes immune tolerance of the pregnancy by inhibiting the 
cytotoxic effects of natural killer cells, enhancing T-helper 2 (Th2) lymphocyte 
activity over T-helper 1 (Th1) activity, resulting in lower production of 
deleterious cytokines (Raghupathy et al., 2005).  In vascular studies, 
progesterone attenuates agonist-induced vasoconstriction and promotes 
vasodilatation suggesting beneficial vascular effects in the high concentrations 
seen in pregnancy.  Mechanisms to achieve this include production of NO from 
endothelial cells and reducing intracellular calcium influx into VSMCs 
(Barbagallo et al., 2001, Pang et al., 2015).  The vascular effects of oestrogens 
are thought to be more potent than those of progesterone. Considering the 
vascular and immunological effects, some  researchers have hypothesised a 
role for progesterone supplementation in preventing hypertensive disorders of 
pregnancy.  A Cochrane review summarising four trials that had investigated 
this found that preeclampsia was neither prevented by progesterone 
supplementation, nor was there evidence of benefit in reducing adverse 
outcomes in preeclampsia pregnancies (Meher and Duley, 2006).  
In glucose homeostasis, high progesterone levels act to increase insulin 
resistance in the liver, skeletal muscle and adipose tissue via its action on 
GLUT receptors.  It also enhances β-cell insulin secretion (Kalkhoff, 1982).  
Insulin resistance increases with advancing gestation as part of normal 
pregnancy, and this occurs simultaneously to increased expression of placental 
hormones that promote insulin resistance. Progesterone is one such hormone. 
Women who receive supplemental progesterone in pregnancy are at increased 
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risk of developing GDM compared with healthy pregnant controls (Rebarber et 
al., 2007). 
1.2.4.4 Human placental lactogen (hPL)   
Human placental lactogen (hPL) is a peptide hormone secreted by the 
syncytiotrophoblasts and to a lesser extent extravillous cytotrophoblasts 
(Tarrade et al., 2001).  Similar to progesterone, hPL expression increases with 
gestational age in normal pregnancy until reaches a plateau near term 
(Lindberg and Nilsson, 1973). It is a somatotropin that bears structural 
homology with prolactin, growth hormone (GH) and placental growth hormone 
(pGH).  hPL is a ligand for prolactin receptors, which are widely expressed in 
placental and fetal tissue.  They can also bind with lower affinity to growth 
hormone receptors. Several studies have shown that maternal hPL 
concentrations during pregnancy correlate positively with fetal and placental 
size (Small et al., 1987, Ma ̈nnik et al., 2010, Houghton et al., 1984, Sørensen 
et al., 2000).  The majority of hPL is found within the maternal circulation, 
where it acts alongside pGH to stimulate insulin-like growth factors.  It also 
alters maternal carbohydrate and lipid metabolism in order to maximise fetal 
nutrient transfer and growth.  Metabolic adaptations include increased 
maternal insulin resistance thereby increased glucose availability for the 
fetus, stimulated insulin production by maternal β-cells and enhanced lipolysis 
(Brelje et al., 1993, Beck and Daughaday, 1967).  Lipolysis produces free fatty 
acids and ketones which can then be used as energy substrates by the mother 
and fetus respectively (Costa, 2016).   
hPL has been implicated in the pathophysiology of GDM. Circulating plasma 
and placental homogenised hPL concentrations have been found to be higher 
in pregnant women diagnosed with GDM versus those without diabetes 
(Henderson and Divon, 1998, Muralimanoharan et al., 2016), a finding in 
keeping with its metabolic effects.  Since hPL is secreted by the 
syncytiotrophoblasts, others have been interested in whether levels are 
altered in conditions associated with placental dysfunction, such as 
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preeclampsia and IUGR.  Studies have shown conflicting results with hPL levels 
in preeclampsia.  Merviel et al showed no difference in the first half of 
pregnancy in preeclamptic pregnancies compared to those without 
preeclampsia (Merviel et al., 2001), whilst others have shown reduced levels in 
the third trimester compared to control and GDM pregnancies (Durković and 
Mandić, 2009, Letchworth and Chard, 1972). This likely reflects the 
heterogeneity and presence of concurrent metabolic risk factors within study 
groups, and the heterogeneity of preeclampsia pathophysiology itself.  The 
metabolic effects of lactogens are well researched, but the vascular effects 
are yet to be elucidated. In rodent aortas, hPL enhances endothelial 
dependent vasodilatation and increases endothelial NOS phosphorylation and 
NO production through its action on GH receptors (Gonzalez et al., 2015). To 
my knowledge, no such experiments have been published on uterine or 
placental vascular beds.    
1.2.4.5 Renin-angiotensin-aldosterone system (RAAS) 
  
The renin-angiotensin-aldosterone system (RAAS) is a critical hormonal 
regulator of circulating plasma volume, sodium concentration and vascular 
tone, regardless of pregnancy status.  The RAAS pathway is summarised in 
figure 1.6.  Renin is secreted by the zona glomerulosa cells of the kidney in 
response to perceived reduced renal perfusion or low sodium concentration in 
the renal tubules.  Angiotensinogen, a pro-hormone produced by the liver is 
cleaved by renin to form angiotensin I, which then undergoes further 
enzymatic cleavage by angiotensin converting enzyme (ACE) to form 
angiotensin II.  Angiotensin II has multiple actions.  In vascular endothelial 
cells, it activates angiotensin II type 1 receptors (AT1R) to activate 
intracellular calcium pathways and promote vasoconstriction thereby 
increasing vascular tone and BP.  It also stimulates the sympathetic nervous 
system leading to release of the vasopressor noradrenaline.  In the kidney, 
renal perfusion is increased by vasoconstriction and Na+ retention promoted 
through the activation of Na+/H+ channels. Furthermore, it stimulates the 
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adrenal glands to produce the mineralocorticoid, aldosterone. Aldosterone 
upregulates expression of Na+ channels and Na+K+ ATPase in the distal tubule 
and collecting ducts of the kidney to promote salt and water retention.  These 
combined effects act to restore circulating plasma volume, sodium 
concentrations and increase BP.  Increased RAAS activity has been a well-
recognised pathology in systemic hypertension for a long time, and many of 
our current antihypertensive treatments have been designed to target RAAS 
specifically (Patel et al., 2017). 
 




Figure 1.6: The renin angiotensin aldosterone system 
This figure shows the steps involved in converting angiotensinogen to angiotensin I, 
angiotensin II and aldosterone.  The enzymes are shown in red.  
Multiple changes in the RAAS system are recognised in pregnancy, and for the most part, is 
upregulated in normal pregnancy in response to increasing levels of oestrogen.  Renin, 
angiotensinogen and angiotensin II are all increased, although the rise in active renin is not 
seen until the second trimester (Immonen et al., 1983, Baker et al., 1990).  Such changes help 
facilitate the plasma volume expansion required to support a healthy pregnancy.  ACE2, is an 
enzyme structurally similar to ACE, that is found within endothelial cells and secreted by the 
syncytiotrophoblasts.  ACE2 hydrolyses angiotensin II, a powerful vasoconstrictor to 
angiotensin 1-7, a vasodilating compound.  Angiotensin I is also hydrolysed by ACE2 to form 
angiotensin 1-9, which is then converted to angiotensin 1-7 by the enzymes ACE and 
neprilysin.  Both angiotensin II and angiotensin 1-7 are increased in pregnancy, and ACE2 may 
therefore play an important role in regulating uteroplacental blood flow (Pringle et al., 2011).  
Furthermore, others have suggested that altered expression of the angiotensin II receptors in 
placental and systemic circulation may occur in pregnancy (Lumbers and Pringle, 2013).  Type 
1 receptors (AT1R) stimulate sympathetic nerve activity, aldosterone production and promote 
vasoconstriction, whereas binding to type 2 receptors (AT2R) causes vasodilatation and 
opposes cellular proliferation.  
 
Pregnancies complicated by preeclampsia have been shown to have decreased 
levels of serum angiotensin 1-7 with elevated levels of angiotensin II compared 
with normotensive pregnancies (Merrill et al., 2002). Angiotensin II has also 
Renin ACE 






been found to be higher in the fetoplacental circulation of preeclampsia 
pregnancies and acts through binding of AT1R in these vessels. This may 
contribute to a procontractile phenotype and higher resistance placental 
circulation that occurs in preeclampsia (Anton et al., 2008).  Paradoxically, 
aldosterone levels are lower in preeclampsia pregnancies, and appear to be 
associated with lower concentration of the proangiogenic compound VEGF and 
higher levels of its antagonist soluble fms-like tyrosine kinase 1 (sFlt-1) 
(Gennari-Moser et al., 2013, Shojaati et al., 2004).  
Mineralocorticoid activity in pregnancy is also mediated through non-
aldosterone sources.  Progesterone, which is in abundance in pregnancy, is 
converted to deoxycorticosterone (DOC).   DOC levels are higher in serum from 
preeclampsia mothers versus healthy, pregnant controls (Shojaati et al., 
2004).  
 
1.2.5 Pro-angiogenic and anti-angiogenic factors in pregnancy 
Normal placental vascular development is dependent on secretion of various 
angiogenic growth factors.  A careful balance between pro-angiogenic and anti-
angiogenic markers is key to optimising placental vascular development and 
function.  VEGF and placental growth factor (PlGF) are two angiogenic factors 
that have a key role in pregnancy and preeclampsia development, and are two 
of the most widely studied.    
1.2.5.1 Vascular Endothelial Growth Factor (VEGF), VEGF receptors and 
soluble fms-like tyrosine kinase-1 (sFlt-1) 
VEGF-A is a potent vascular growth factor critical to normal placental 
development that has many different isoforms. It is expressed by the trophoblast 
(cytotrophoblast and syncytiotrophoblast) and vascular endothelial cells, and is 
upregulated in hypoxic environments (Chen and Zheng, 2014, Krock et al., 2011, 
Namiki et al., 1995).  It exerts its effects primarily through binding to tyrosine 
kinase receptors, VEGFR1 (also known as fms-like tyrosine kinase-1 or Flt1) and 
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VEGFR2 (kinase insert domain receptor or KDR) found on endothelial cells 
(Pandey et al., 2018).    
In early pregnancy, VEGF contributes to trophoblast proliferation, migration and 
spiral artery invasion and promotes vasculogenesis through differentiation of 
mesenchymal cells into endothelial precursors called haemangioblasts (Chen and 
Zheng, 2014). Once new vessels have formed, it has a further role in promoting 
angiogenesis (new vessel formation from existing endothelium) and expansion of 
the placental vasculature (Chen and Zheng, 2014, Ong et al., 2000). In normal 
pregnancy, VEGF levels are higher in earlier pregnancy than in the third 
trimester (Ong et al., 2000). VEGF also activates NOS pathways in endothelial 
cells, upregulating the production of NO and thereby inducing vasodilatation 
(Kroll and Waltenberger, 1998). All of these actions contribute to maximising 
circulatory capacity within the placenta.   
sFlt1 is a splice variant of the VEGF-1 receptor, Flt-1, which when bound to 
VEGF acts to diminish its angiogenic effects. It is produced by trophoblasts and 
detectable in the maternal circulation (Clark et al., 1998).  Increased expression 
of sFlt-1 leads to increased binding of the pro-angiogenic ligands, VEGF and 
placental growth factor (PlGF) resulting in lower bioavailability of active free 
angiogenic factors VEGF and PlGF. sFlt-1 expression increases from around week 
30 gestation towards term (Palm et al., 2011). 
1.2.5.2  Placental growth factor 
PlGF is a pro-angiogenic factor produced most abundantly by the 
syncytiotrophoblast of the placenta during pregnancy, but is also expressed in 
lower amounts within other non-reproductive tissues such as heart, lungs, 
thyroid and bone. PlGF has affinity for the sFlt-1 VEGF receptor but is not bound 
by VEGFR2.  PlGF directly promotes angiogenesis.  It also has indirect effects on 
angiogenic pathways through binding to sFlt1, causing VEGF to have less binding 
capacity on sFlt1 and more to VEGFR2 which has more potent effects on tyrosine 
kinase pathways (Chau et al., 2017).  Tyrosine kinase activation promotes 
angiogenesis pathways and inhibits cellular apoptosis (Ranieri et al., 2017). In a 
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cohort of healthy pregnant women with no signs of preeclampsia, PlGF levels 
increased to a peak mean concentration of 536pg/mL (139-1815pg/mL 95% CI) at 
30 weeks before declining again (Saffer et al., 2013).  These trends have been 
replicated in other studies also (Palm et al., 2011).   
1.2.5.3 VEGF, sFlt-1 and PlGF in preeclampsia  
Placental development and vascularisation are dependent on the balance of 
angiogenic and anti-angiogenic factors.  Pregnancies complicated by 
preeclampsia, a condition associated with impaired trophoblast invasion and 
abnormal placental vascular development, have increased maternal circulating 
levels and increased placental expression of sFlt-1, with concomitant reduction 
in circulating levels of free VEGF and PlGF in maternal circulation (Levine et al., 
2004, Maynard et al., 2003, Robinson et al., 2006).    PlGF has also been shown 
to be lower in pregnancies complicated by severe preeclampsia compared with 
milder preeclampsia (Robinson et al., 2006, Levine et al., 2004).  Maynard et al 
also showed that human umbilical vein endothelial cells (HUVECS) cultured ex 
vivo in serum from preeclamptic mothers show reduced angiogenesis compared 
with serum from healthy pregnant controls.  Furthermore, those HUVECS 
cultured in normotensive control serum had similar attenuated angiogenic 
potential to the preeclampsia group when sFlt-1 added to the medium, but 
showed recovery of angiogenesis when VEGF and PlGF were added to the 
incubating solution (Maynard et al., 2003).  Rodent models mimicking high sFlt-1 
and low PlGF levels similar to that seen in preeclamptic pregnancy have shown 
numerous similar clinical features  to that seen in human preeclampsia 
syndrome, with hypertension, growth restriction, endothelial dysfunction and 
glomerular endotheliosis (Maynard et al., 2003, Kumasawa et al., 2011). 
As described, circulating levels of sFlt-1 (higher) and PlGF (lower) in particular, 
have been recognised to be altered in maternal serum at the time where the 
clinical syndrome of preeclampsia has been diagnosed. Levine showed that the 
normal increase in sFlt-1 and lower PlGF associated with advancing gestation 
was exaggerated in those women who subsequently developed preeclampsia in 
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pregnancy compared with normotensive controls.  The amplified rise in sFlt-1 
and subsequent decrease in PlGF began up to five weeks before clinical 
manifestations of preeclampsia were evident (Levine et al., 2004).  
Furthermore, the differences in sFlt-1 and PlGF were more marked in those 
individuals with severe preeclampsia or those with growth restricted pregnancies 
(Levine).  
1.2.5.4 sFlt-1, PlGF and sFlt-1:PlGF tests in preeclampsia diagnosis  
Researchers have since explored the role of incorporating sFlt-1 and PlGF testing 
in women presenting with suspected preeclampsia  This has been borne out of a 
pressing clinical need to improve detection of preeclampsia since management 
often involves expedited delivery of the fetus, and if incorrectly diagnosed or 
management  mistimed can lead to increased maternal and neonatal morbidity 
and mortality.  The PROGNOSIS trial (Prediction of Short-term Outcomes in 
Pregnant Women with Suspected PE) showed that in women presenting with 
suspected preeclampsia a sFlt-1:PlGF ratio cut-off < 38 (measured on Roche 
Elecsys ™ immunoassay) had a high negative predictive value (NPV) of 99.3% for 
confirmed preeclampsia diagnosis within a week, and performed with a 
moderately high sensitivity and specificity (80% and 78% respectively). The 
converse was not true, with sFlt-1:PlGF > 38 showing poor prediction of 
imminent preeclampsia (positive predictive value (PPV) 37% for preeclampsia 
within 4 weeks) (Zeisler et al., 2016).  
Another group showed that in women presenting with suspected preeclampsia 
prior to 34 weeks gestation, higher sFlt-1:PlGF was associated with adverse 
maternal and fetal outcomes in the subsequent two weeks (Rana et al., 2012). 
Adverse maternal outcome was defined by this group as hypertension  >140/90 
mmHg on two occasions plus any of: deranged transaminases, low platelets, 
disseminated intravascular coagulopathy, acute renal failure, placental 
abruption, intracranial haemorrhage, pulmonary oedema or maternal death.  
Neonatal adverse outcomes included expedited delivery for maternal 
hypertension, small for gestational age infant, abnormal umbilical artery 
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doppler, or fetal/neonatal death. A sFlt:PlGF ratio > 85 improved short term 
prediction of adverse outcomes in women presenting with suspected 
preeclampsia (<34 weeks gestation) when added to the classical preeclampsia 
signs of hypertension and proteinuria (area under curve (AUC) 0.93 combined 
model versus 0.84 for hypertension and proteinuria alone), and was associated 
with a 15-fold risk of expedited delivery within a two week period (Rana et al., 
2012). 
The PELICAN study explored whether PlGF (measured by Alere Triage ™ assay) 
could improve short term prediction of preeclampsia in women.  This 
prospective trial included women presenting with suspected preeclampsia and 
investigated how serum PlGF levels taken at time of presentation related to 
development of preeclampsia and adverse outcome 14 days later.  This study 
demonstrated that PlGF <5th centile for gestation before 35 weeks gestation had 
high sensitivity and high negative predictive value for development of 
preeclampsia within 14 days (0.96 [0.89-0.99] sensitivity, 0.98 [0.93-0.99] NPV) 
but similar to sFlt-1:PlGF studies had lower specificity (0.55 [0.48-0.61]) making 
the test useful for excluding imminent preeclampsia diagnosis within 14 days, 
but less robust in confirming preeclampsia diagnosis.  The sensitivity of PlGF<5th 
centile was less reliable beyond 35 weeks, but exploratory analysis showed that 
similar sensitivity was reached if PlGF cut off <100 pg/mL was used in these 
later presentations (>35 and <37 weeks gestation).  Interestingly, despite its low 
specificity for preeclampsia within 14 days, low PlGF levels had a superior AUC 
(0.87 [0.03]) at detecting imminent preeclampsia than other routinely used 
clinical parameters (BP, maternal urate levels, maternal alanine transaminase 
concentration, dipstick proteinuria (range 0.61-0.76 AUCs) (Chappell et al., 
2013).  This both highlights the lack of good predictive tests for impending 
preeclampsia but also highlights promising potential here for these assays in 
future research.  
Taking these landmark trials together, there is increased recognition from 
learned societies that sFlt:1 and PlGF based assays can be utilised alongside 
clinical assessment to predict risk in women presenting with suspected 
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preeclampsia   As an example, NICE now recommend that the Elecsys™ sFLt-
1:PlGF immunoassay or Triage™ PlGF assays can be used to rule out an imminent 
preeclampsia diagnosis in women presenting with suspected preeclampsia 
between 20 and 34+6 weeks gestation (National Institute for Health and Care 
Excellence, 2016). Table 1.5 shows the diagnostic cut offs recommended to rule 
out imminent preeclampsia diagnosis.  Due to lower specificity, there is concern 
that using PlGF assays to rule-in or diagnose imminent preeclampsia may 
unintentionally bias clinical decision making leading to increased unnecessary 
obstetric intervention and subsequent morbidity.   As such, PlGF based testing is 
not currently recommended in UK guidelines to rule in or diagnose preeclampsia  
Their future potential in diagnosis is accepted though and further work 
encouraged to explore how their use in preeclampsia diagnosis might affect 
clinical outcomes (PlGF-based testing to help diagnose suspected preeclampsia 
(National Institute for Health and Care Excellence), 2016).  
Table 1.5:  PlGF and sFlt-1:PlGF assay interpretation recommendations for ruling out 
preeclampsia diagnosis according to NICE guidelines 
Assay Gestation Result interpretation 
Triage™ PlGF test 20+0 -34+6 weeks >100pg/mL rule out 
preeclampsia with delivery in 
14 days 
 
Elecsys™ sFlt-1:PlGF test 24+0-36+6 weeks <38 rule out preeclampsia 
development within next 
week 
 




A recent UK multicentre RCT led by Professor Lucy Chappell investigated how 
PlGF testing incorporated into real-world clinical practice affected pregnancy 
outcomes. Over 1000 women with suspected preeclampsia underwent PlGF 
testing in this study and were randomised to either blinding of clinical teams to 
the PlGF results or otherwise.  The concealed results group confirmed the 
findings of previous studies that PlGF <100 pg/mL had high sensitivity (94.9%) 
and high NPV (98.3%) for women developing preeclampsia needing delivery 
within the subsequent 14 days. The group in whom the PlGF result was known to 
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clinical teams, the time to diagnosis of confirmed preeclampsia was significantly 
lower (1.9 versus 4.1 days) with less frequent adverse maternal outcomes, but 
importantly was not seen to increase adverse neonatal outcomes, gestational 
age at delivery nor operative delivery (Duhig et al., 2019).  Following on from 
this, the same group are currently conducting a trial to investigate whether 
monitoring trends in PlGF in the clinical setting can further aid clinical decision 
making in suspected preeclampsia and adverse pregnancy outcome (PARROT-2 
trial) (ISRCTN Registry, 2019). 
  
1.2.5.5 Angiogenic markers in other adverse outcome pregnancy 
sFlt-1 and PlGF as biomarkers in adverse outcome pregnancy has the most 
established evidence base for preeclampsia However, low PlGF is a recognised 
marker of placental dysfunction and so others are interested to see if there is a 
role in other adverse pregnancy outcomes.   
Low PlGF in the second trimester has been associated with IUGR pregnancies 
independent of preeclampsia diagnosis (Ghosh et al., 2013, Wallner et al., 
2007).  High sFlt-1:PlGF ratios and low PlGF in the second half of pregnancy are 
associated with IUGR (Schoofs et al., 2014, Birdir et al., 2018, Cetin et al., 
2017). Low PlGF in growth restricted pregnancy is associated with higher rates of 
pre-term and operative delivery when compared with normal PlGF in growth 
restricted pregnancies (mean 31.6 weeks for very low PlGF, 34.6+2.4 weeks for 
low PlGF and 38.4+1.3 weeks for normal PlGF pregnancies; 83% urgent caesarean 
for very low  PlGF group, 75% for low PlGF group, 33% for normal PlGF group) 
(Cetin et al., 2017).  In another study of growth restricted pregnancies, a model 
that included low PlGF combined with other clinical risk factors and uterine 
artery ultrasound parameters had a modest 62% detection rate for adverse 
outcome (fetal death, emergency caesarean and peripartum markers of fetal 
distress), but importantly, despite an independent association of PlGF with 
adverse outcome, it did not perform better at predicting this than clinical and 
uterine artery imaging parameters alone (Miranda et al., 2017). This prediction 
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was also lower when the model was applied more widely to the general obstetric 
population.  
Lower PlGF concentrations in the second trimester of pregnancy have also been 
demonstrated in pregnancies that end in stillbirth as a result of placental 
dysfunction (Aupont et al., 2016). The authors of this paper explored the 
performance of PlGF measured at 19-24 weeks gestation, in addition to maternal 
risk factors, fetal growth and uterine artery ultrasound doppler parameters as 
predictors of stillbirth.  When included in a model with these parameters 
addition of PlGF to the model improved detection of stillbirths caused by 
impaired placentation to 83.6% (with a 10% false prediction rate) from 74.8%.  
However, PlGF did not alter the detection rate in the whole stillbirth cohort (all 
causes) (Aupont et al., 2016).  A Cochrane review suggested that PlGF was the 
most accurate at predicting stillbirth, with a diagnostic odds ratio of 49.2 
(Heazell et al., 2019).  When applied to a hypothetical population of 1000 
women with stillbirth prevalence of 1.7 per 1,000 births, low PlGF would only 
miss 1-2 stillbirths but would result in excess of 100 false positives with 
subsequent increased maternal and clinician anxiety and risk of unnecessary 
intervention (Heazell et al., 2019).  
sFLt-1 and PlGF are altered in IUGR and stillborn pregnancies, but clinical 
application of these tests is currently limited. Triallists are currently planning 
further work to establish how these biomarkers can be used in routine clinical 
practice in at risk growth restricted pregnancies to guide management around 
obstetric surveillance and timing of delivery (Gent et al., 2020). 
1.2.6 Cytokines in pregnancy 
During pregnancy, the maternal immune system must adapt to develop immune 
tolerance to the developing fetus and prevent rejection of the pregnancy as 
foreign. At the same time, it must also maintain an ability to recognise and fight 
harmful antigens. One of the mechanisms by which it does this is to alter 
cytokine production in pregnancy.  Cytokines are produced from CD4 T-
lymphocytes, otherwise known as T-helper cells.  T-helper cells can be further 
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divided into T-helper 1 (Th1) which produce proinflammatory cytokines that 
stimulate phagocytosis and promote cytotoxic lymphocyte activity, and T-helper 
2 (Th2) cells that antagonise the Th-1 response, produce a combination of anti-
inflammatory, IgE and eosinophilic mediated reactions and regulate antibody 
production.  In simplistic terms, pregnancy requires a dampening of Th-1 
response relative to Th-2 responses to maintain a pregnancy (Berger, 2000, 
Wegmann et al., 1993).  As with most biological systems, homeostasis of both 
systems is crucial.  Examples of cytokines produced by each Th subtype are 
shown in table 1.6, although this is not an exhaustive list.  There are numerous 
cytokines, and discussion of them all is not in the remit of this thesis.  
Table 1.6:  Examples of T-helper 1 and T-helper 2 regulated cytokines 
T-helper 1 cytokines T-helper 2 cytokines 
 
Tumour necrosis factor α (TNF-α) 
Interleukin 1β (IL-1β) 
Interferon-γ (IFN-γ) 
Interleukin-2 
Interleukin 6 (IL-6) 
Interleukin 4 (IL-4) 
Interleukin 5 (IL-5) 




Some researchers have explored cytokine array analysis across pregnancy and 
the post-partum period in normal and pathological pregnancy.  In pregnancy, 
there is a reduction of proinflammatory cytokines from all types of Th cells 
(sCD40L, IL-6, IL-17, IP-10, eotaxin, and MCP-1) with a simultaneous 
upregulation of growth factors (Holtan et al., 2015, Shimaoka et al., 2000).  
Whilst both Th-1 and Th-2 responses are reduced in pregnancy, relative to each 
other the balance is altered in favour of the latter (Szarka et al., 2010). In pre-
eclampsia, there is a shift towards a pro-inflammatory phenotype with elevated 
TNF-α, IL-6, IL-1β and IFN-γ associated chemokines (Szarka et al., 2010).  
1.2.6.1 Tumour Necrosis Factor α  
Tumour necrosis factor α (TNF-α) is a proinflammatory Th-1 cytokine produced 
by macrophages, adipose tissue and in pregnancy, the placenta. It promotes 
apoptosis and inflammation and inhibits tumourigenesis. In pregnancy, it 
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promotes blastocyst implantation and uterine artery remodelling, and may have 
a role in preventing continued gestating of malformed fetuses, and levels are 
higher in pregnancy compared with the non-pregnant state (Toder et al., 2003, 
Staun-Ram and Shalev, 2005). In preeclampsia and IUGR due to placental 
vascular insufficiency, TNF-α levels are significantly higher than seen in healthy 
pregnancy (Azizieh and Raghupathy, 2015).  TNF-α has been implicated in 
hypertension more widely.  Mechanisms for TNFα effects include inhibition of 
endothelial-dependent vasodilation and upregulation of iNOS and ROS production 
in endothelial cells, promotion of COX vasoconstrictor pathways and 
atherogenesis (K and I, 2015, Zhang et al., 2009).  TNF-α is also an important 
promoter of insulin resistance, and does so by phosphorylation of insulin 
signalling proteins, which then affects downstream insulin effects (Borst, 2004). 
Pregnancy is a state of insulin resistance, and in GDM and T2DM this is 
exaggerated.  TNFα levels are higher in GDM pregnancies than in controls, and 
this is independent of BMI suggesting that enhanced adiposity is not the only 
contributing factor to increased levels (Xu et al., 2014, Atègbo et al., 2006). 
TNF-α secretion is also stimulated by a high glucose environment, further 
perpetuating increased secretion (Gonzalez et al., 2012).  Hypoxia is another 
stimulant of TNF-α expression, which may be a contributing factor to 
preeclampsia pathophysiology.  
1.2.6.2 Interleukin-6 
Interleukin-6 is a widely expressed pleiotropic cytokine. Its many roles include 
activation of the acute inflammatory response, pyrogenic effects, inhibition of 
TNFα and upregulation of TNFα antagonists such as IL-10, promoting B cell 
antibody production, promotion of cellular proliferation (Tanaka et al., 2014). In 
pregnancy, it has many diverse functions also.  Preconceptually, IL-6 increases 
post-ovulation and in response to seminal fluid and is thought to modulate the 
endometrial immune environment in preparation for implantation.  Thereafter, 
IL-6 is inhibited by the pregnancy hormones oestradiol and progesterone.   
During placental formation, IL-6 helps regulate trophoblast invasion and promote 
angiogenesis. IL-6 stimulation of syncytiotrophoblasts enhances hCG and 
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lactogen release, hormones essential to gestational health. As pregnancy 
progresses, IL-6 levels increase and may contribute to the physiology of labour 
(Prins et al., 2012).  Interestingly, IL-6 levels in pregnancy have been shown to 
correlate with neurodevelopment of the fetus and child (Graham et al., 2018). 
IL-6 levels in maternal circulation have been found to be two-fold higher in 
women who have preeclampsia compared to healthy pregnant controls (Szarka 
et al., 2010, Mtali et al., 2019). Raised IL-6 and IL-8 concentrations have been 
detected in amniotic fluid significantly earlier than when preeclampsia becomes 
apparent (Nakabayashi et al., 1998).  In the vasculature, raised IL-6 encourages 
endothelial dysfunction with reduction in NO activity, upregulation of ROS and 
AT1 receptor expression (LaMarca et al., 2011) Similarly to TNF-α, hypoxia 
stimulates endothelial cells to produce IL-6 (Ala et al., 1992), as does 
angiotensin II (Gomolak and Didion, 2014), both of which are dysregulated in 
preeclamptic pregnancy.  
Higher IL-6 concentrations are also associated with GDM (Amirian et al., 2020).  
However, the effects of IL-6 on glucose homeostasis are not fully understood, 
and seem to differ according to source and concentration of IL-6.  A review by 
Lehrskov et al summarises it nicely.  In short, adipokine IL-6 associated with 
obesity alters insulin signalling that may be detrimental to hepatic insulin 
sensitivity, and if very high levels of IL-6 are seen will activate counterregulatory 
hormones to stimulate gluconeogenesis.  However, short term exposure to raised 
IL-6, such as seen in exercise, can promote insulin sensitisation of skeletal 
muscles and delay gastric emptying (Lehrskov and Christensen, 2019).   
1.2.6.3 Interleukin-1β 
IL-1β is a potent proinflammatory cytokine.  It binds to its receptor on a 
multitude of cells and acts to promote acute phase response proteins, 
upregulate COX pathways and prostaglandin production and further potentiates 
release of cytotoxic cytokines (TNFα) to work in synergy with its own cytotoxic 
mechanisms (Essayan et al., 1998). In endothelial cells, NO production is 
upregulated via iNOS, promotes expression of cellular adhesion molecules, 
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angiogenesis and is prothrombotic (Fahey and Doyle, 2019).  These 
pharmacological effects are evident in septic shock where IL-1β is a key 
mediator of profound vasodilation and systemic inflammatory response.  
Longitudinal assessment of IL-1β in normal pregnancy has produced conflicting 
results, but the larger studies support a decreasing trend in circulating levels 
with advancing gestation (Ferguson et al., 2014, Holtan et al., 2015). This is 
plausible when we consider the established roles of IL-1β seem to focus on early 
pregnancy development. IL-1β is thought to play a role in implantation.  In IVF 
pregnancies, those with detectable levels had higher rates of implantation 
compared to those with undetectable levels (Karagouni et al., 1998).  It has also 
been shown that IL-1β promotes decidualisation through upregulation of 
prostaglandin and growth factor binding synthesis.  Oestradiol, which is in 
abundance in later pregnancy, inhibits the harmful effects of IL-1β in endothelial 
cells (Schaefer et al., 2005).  
In preeclampsia some researchers have shown increased placental expression 
and circulating levels of IL-1β compared with healthy pregnant controls 
(Kalinderis et al., 2011, Amash et al., 2012).  Conversely, others suggest a lack 
of evidence to support this (Deng et al., 2020).  
In GDM, IL-1β expression is higher and its endogenous receptor antagonist lower 
than in non-GDM mothers (Vitoratos et al., 2008, Katra et al., 2016). Lower 
levels of the receptor antagonist were also associated with progression to T2DM 
post-partum (Katra et al., 2016). IL-1β has several effects in glucose physiology.  
Blocking of IL-1β function improves glycaemia in mice through a decrease in 
counterregulatory steroid production which would act to improve insulin 
sensitivity (Schulze et al., 2020).  In animal and in vitro models, high levels of IL-
1β have also been shown to promote β-cell destruction. As such, IL-1β blockade 
has been a focus in recent T1DM research although advances here have been 
limited by negative studies in humans (Mandrup-Poulsen et al., 2010).    
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1.2.7 Prevention of PE 
There is a major unmet need for better intervention to predict and prevent 
preeclampsia, but most therapeutic strategies have proven ineffective. 
1.2.7.1 Aspirin 
Low dose aspirin (75-150mg) is widely used clinically from 12 weeks gestation to 
prevent preeclampsia in women at high risk of the condition (Hypertension in 
Pregnancy (National Institute for Health and Care Excellence), 2010, Gestational 
Hypertension and Preeclampsia (American College of Obstetricians and 
Gynaecologists), 2020).  Therapeutic mechanisms inhibit the COX pathway 
reducing platelet derived thromboxane production and its pro-thrombotic and 
vasoconstrictive effects, and improving placental perfusion. Numerous RCTs 
have been conducted but include different timings of prescribing in pregnancy, 
and doses that vary from 60-150mg.  Clinical outcomes in these trials have 
varied.  The ASPRE (Aspirin for evidence-based preeclampsia trial) is one of the 
largest and most recent studies.  This double-blind RCT assigned high-risk 
women to either aspirin 150mg daily or placebo between 11-36 weeks gestation, 
and demonstrated that aspirin 150mg  resulted in a 62% reduction in 
preeclampsia with secondary analysis showing a knock on effect in reduction of 
babies born severely preterm (<32 weeks ) and therefore lower NICU stays 
(Wright et al., 2018, Rolnik et al., 2017).  Studies using a lower 60mg dose have 
shown more conflicting results (Caritis et al., 1998, Sibai et al., 1993).  In 2014, 
the US Preventative Services Taskforce assessed available evidence at the time, 
and their metanalysis suggested that Aspirin (60-150mg) is beneficial and should 
be prescribed to high risk women (as identified in table 1.7) although are less 
prescriptive about specific dose recommendations (Lefevre, 2014). At that time, 
they cited lack of evidence to show advantageous effects of any particular dose 
over another, nor was there evidence to support beneficial effect in timing of 
prescribing (pre- and post-16 weeks).  Further independent meta-analysis has 
since been conducted, and includes the more recent RCTs.  That suggests that 
the benefits of aspirin in preeclampsia prevention have a dose effect, where 
doses of 60mg and less show no benefit whilst there increasing doses (up to 
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150mg) correlate with lower rates of preeclampsia severe preeclampsia and 
fetal growth restriction.  These effects are more pronounced when therapy 
initiated prior to 16 weeks gestation, as initiation after this was only associated 
with reduced incidence of preeclampsia but no impact on the other outcomes 
(Roberge et al., 2017). 
Table 1.7:  Recommendations of the US Preventative Services Taskforce for low dose aspirin 
in preeclampsia prevention (Lefevre, 2014) 
Risk category Definition Recommendation 
 
High Any 1 of: 
- Previous PE 
- Multiple pregnancy 
- Pregestational diabetes 
- Renal disease 
- Autoimmune disease 
- Pregestational hypertension 
 
Aspirin (60-150mg) daily 
recommended 
Moderate More than 1 of: 
- First pregnancy 
- BMI >30kg/m2 
- First degree relative with PE 
- Maternal age > 35 
- Previous adverse outcome 
pregnancy due to placental 
issues 
- >10-year pregnancy interval 
- High risk ethnicity e.g., Black 
-  
Aspirin (60-150mg) daily 
should be considered 
Low Previous uncomplicated pregnancy 
 
Aspirin not recommended  
 
 
1.2.7.2 Antioxidants  
Since oxidative stress is a hallmark of preeclampsia pathophysiology, researchers 
have been interested in antioxidants as a preventative strategy.  However, 
results from these studies have largely been disappointing. Antioxidants explored 
include vitamin B, vitamin C, vitamin E, Selenium and leucopene.  Meta-analysis, 
including a Cochrane review has shown no evidence of benefit in either 
preeclampsia or severe preeclampsia prevention with antioxidants (Rumbold et 
al., 2008, Salles et al., 2012).  Women who were prescribed antioxidant therapy 
were more likely to present with gastrointestinal side effects (Salles et al., 
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2012).  Lack of effect of vitamin C and E supplementation in preeclampsia 
prevention has also been shown in T1DM (Mccance et al., 2010). 
 
1.2.7.3 Vitamin D and calcium supplementation  
Maternal vitamin D deficiency is associated with increased preeclampsia risk 
(Bodnar et al., 2007). Vitamin D has several important actions in healthy 
pregnancy.  These include regulation of fetal bone growth and development, 
inhibition of T-cell proliferation and promotion of a Th2>Th1 response and 
enhances VEGF expression and angiogenesis (Grundmann et al., 2012, Aranow, 
2011).  In addition, vitamin D deficiency has also been associated with higher 
incidence of GDM, and higher risk of fetal growth restriction (Aghajafari et al., 
2013, Van Der Pligt et al., 2018).  Vitamin D supplementation has been shown to 
52% reduction in preeclampsia incidence on meta-analysis of 4 studies involving 
499 participants. In the same metanalysis, 4 studies that included 1100 women 
receiving combined vitamin D and calcium supplementation showed a similar risk 
reduction, but importantly signalled an increase in pre-term birth (De-Regil et 
al., 2016).  These studies universally used cholecalciferol for vitamin D 
supplementation, but doses varied between 400 units daily to single high-dose 
25,000 unit administration, and were given at different time points in 
pregnancy. Most of the studies are also observational and confounding factors 
often accompany vitamin D deficiency, such as ethnicity, smoking status and 
comorbidity.     
Taken together, vitamin D has numerous beneficial effects on pregnancy and 
may reduce preeclampsia risk.  As such, sufficient vitamin D levels appear 
important to the health of a pregnancy.  The Royal College of Obstetricians and 
Gynaecologists (RCOG) therefore make pragmatic recommendations for vitamin 
D supplementation in pregnancy.  Whilst optimal dosing remains to be 
established, they suggest 400 units daily, doubling to 800 units daily in women 
who are deemed at higher risk of vitamin D deficiency (darker skin tone, lack of 
sunlight exposure) (Vitamin D in Pregnancy (Royal College of Obstetricians and 
Gynaecologists), 2014).  
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1.2.7.4 Low molecular weight heparin 
Low molecular weight heparin (LMWH) has more recently been studied for 
preeclampsia prevention. Coagulopathy and thrombophilia defects are common 
in preeclampsia and so negating the effects of these with anticoagulation is a 
plausible hypothesis.  Recent studies have shown that LMWH administration in 
pregnancy is associated with improved markers of endothelial function and pro-
angiogenic markers PlGF and sFLt-1 (Mclaughlin et al., 2017).  Clinical trials 
however have been limited by small studies and marked heterogeneity in study 
populations.  Studies have largely focused on women who have had a past history 
of previous placental pregnancy complications.  A Cochrane review analysis 
identified 7 studies reporting preeclampsia as an outcome in LMWH studies.  
Individual study numbers ranged from 20-224 participants, and recruited women 
from a variety of clinical backgrounds.  These included previous preeclampsia, 
abnormal placental function on routine pregnancy imaging, previous placental 
abruption, previous intrauterine death and a diagnosis of glomerulonephritis 
(Dodd et al., 2013).  Whilst LMWH seemed to reduce preeclampsia on combined 
analysis of this group, the heterogeneity makes it difficult to apply the principles 
to the general obstetric population.  LMWH is not currently recommended for 
preeclampsia prevention in the UK (Hypertension in Pregnancy (National 
Institute for Health and Care Excellence), 2010).  High quality RCTs in larger 
populations would help identify groups in whom LMWH may be suitable in.  
1.2.7.5 Glycaemic control 
While part of preeclampsia risk in pre-existing diabetes may relate to existing 
complications and endothelial dysfunction there also appears to be an intimate 
and dynamic relationship between glycaemia and preeclampsia risk.  
Preeclampsia risk increases linearly across the range of normal maternal glucose 
(Metzger et al., 2008). Third trimester maternal Hba1c in T1DM is associated 
with risk of preeclampsia over and above risk associated with existing diabetes 
complications (Holmes et al., 2011).  More importantly glucose lowering 
attenuates preeclampsia risk.  Two large treatment trials of women with mild 
GDM have both shown a reduction in risk of preeclampsia by 55% and 33% 
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respectively with glucose lowering by dietary and/or insulin intervention 
(Landon et al., 2009, Crowther et al., 2005). This is particularly striking as in 
this case a treatment started later in pregnancy (generally after 24 weeks) is 
reducing risk. 
There has also been interest in whether specific treatments for diabetes in 
pregnancy might confer benefit to preeclampsia risk.  Individual study results 
are conflicting but meta-analysis shows that metformin confers a 46% reduction 
in PIH, with a non-significant trend towards lowering preeclampsia risk in women 
with GDM compared to insulin-treated counterparts. These differences are not 
explained by differences in glycaemic control (Zhao et al., 2015, Barrett et al., 
2014).  Others have investigated whether metformin would alter placental and 
endothelial function using in vitro and ex vivo approaches and have shown that it 
does.  Metformin reduces placental angiogenic factors via its actions on the 
mitochondrial electron transport chain (Brownfoot et al., 2016).  Han et al also 
confirmed that in vitro metformin reduces trophoblast pro-inflammatory 
cytokine production in high- and low-glucose environment (Han et al., 2015).  
Whilst these effects of metformin appear independent to glycaemia, their 
effects on preeclampsia risk does not appear to confer similarly on women who 
do not have diabetes.  Metformin in polycystic ovarian syndrome does not appear 
to reduce preeclampsia risk (Tan et al., 2016).  Studies where women are 
selected for obesity also show conflicting results, with one RCT showing 
reduction of preeclampsia but not PIH, and no difference in another (Syngelaki 
et al., 2016, Chiswick et al., 2015).   
 
1.2.8 Preeclampsia treatment 
The only curative treatment for preeclampsia is delivery of the infant and 
placenta, thereby removing the stimulus of placentally derived factors being 
released into maternal circulation.  However, preeclampsia can present from as 
early as 20 weeks and so clinical decisions around the timing of delivery need to 
balance the imminent risk of preeclampsia to mother and fetus, against those of 
preterm delivery.  In term infants, delivery would be the preferred option, but 
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in earlier gestations, attempts to delay delivery with expectant management of 
BP and careful monitoring should be considered.   
Clinical decisions around expedited delivery can be challenging.  Some 
prediction scores have been developed to help clinicians stratify risk, but they 
focus on maternal risk only.  The fullPIERS model is a risk score developed to 
predict maternal mortality and severe maternal adverse outcome.  Using clinical 
parameters, it generates a percentage risk for an individual to have adverse 
outcome in the short term, and categorises women according to low risk (<2.5%), 
intermediate (2.5-30%) and high risk (>30%).  Initial studies showed an AUC 0.88 
in predicting adverse outcome within 48 hours (>0.7 within 7 days) (Von 
Dadelszen et al., 2011). Independent review has suggested that it performs well 
in identifying women in the high risk group who should be admitted, with less 
robust evidence in predicting absence of adverse risk in the low and 
intermediate groups (Hypertension in Pregnany NG133 (National Institute for 
Health and Care Excellence), 2019).  It has not been validated in predicting 
adverse fetal outcome. Taken together, the UK guidelines suggest that such risk 
scores may be utilised to guide clinicians in assessment and management of 
preeclampsia but purposefully avoid descriptive guidance on how they should be 
used (Hypertension in Pregnancy (National Institute for Health and Care 
Excellence), 2010).  Instead, they suggest considering delivery if concerning 
fetal or maternal features.  These might include resistant BP control despite 
three antihypertensive agents, progressive biochemical and haematological 
abnormality, eclampsia, placental rupture or non-reassuring fetal assessments.  
1.2.8.1 Blood pressure management 
In pregnancy, guidelines define hypertension as BP >140/90 mmHg, and severe 
hypertension as >160/110 mmHg. There is international consensus that severe 
hypertension needs to be treated, but controversy about treatment of milder 
hypertension in pregnancy exists.  UK guidelines currently suggests that both 
hypertensive groups should be treated, with a target BP 135/85 mmHg, aiming 
to keep diastolic (DBP) above 80 mmHg to prevent placental hypoperfusion 
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(Hypertension in Pregnancy (National Institute for Health and Care Excellence), 
2010).  An RCT of non-severe, non-proteinuric hypertension in pregnancy showed 
that treatment to a DBP target <100 mmHg (achieving a mean 90 mmHg) versus 
85 mmHg (achieving target) conferred no benefit to severe maternal 
complications, fetal mortality or NICU admissions.  However, women in the more 
tightly controlled group were significantly less likely to develop severe 
hypertension later in pregnancy (28 versus 41%) (Magee et al., 2015).  A 
Cochrane review suggested similar with treatment of mild to moderate 
hypertension halving the risk of women subsequently developing severe 
hypertension, but with limited evidence to suggest any effect on neonatal or 
maternal outcomes otherwise (Abalos et al., 2018).  
Pharmacotherapy options for hypertension in pregnancy include labetalol, 
nifedipine, methyldopa and hydralazine, with the first two being used 
preferentially.  Magnesium sulphate intravenously is used in preeclampsia as an 
adjunct to antihypertensive treatments, and in the prevention and treatment of 
eclamptic seizures.  Magnesium sulphate has several mechanisms that are 
beneficial in preeclampsia.  In VSMCs it blocks calcium channels preventing 
cellular influx and promoting systemic vasodilatation, and may also enhance 
endothelial function (Darooghegi Mofrad et al., 2018). It alters blood brain 
barrier function and alters central nervous system receptors offering maternal 
neuroprotection against seizures, and in the preterm infant promotes brain 







1.3   Aims of thesis 
In summary, there are increased rates of adverse outcome in pregnancy 
complicated by diabetes.  Some of this risk is related to fetal hyperinsulinaemia 
and overgrowth or direct teratogenic effects of glucose on the developing fetus, 
but mechanisms associated with other complications related to placental 
function such as stillbirth and preeclampsia are less understood.  Evidence from 
previous work indicates a linear relationship between maternal glycaemia and 
preeclampsia even in the later stages of pregnancy, and furthermore treatment 
of this glycaemia lowers this risk.  One potential mechanism for increased 
preeclampsia and stillbirth risk is altered placental perfusion and/or function 
from hyperglycaemia in pregnancy. Hypertensive disorders are also more 
common in the pregnant population with diabetes.  In the non-pregnant state 
systemic vascular endothelial function is impaired by a persistent 
hyperglycaemic environment, and it would be plausible that similar changes may 
occur in the systemic and placental vascular beds in hyperglycaemic pregnancy.  
Reduced placental perfusion or vascular dysfunction could lead to fetoplacental 
ischaemia and such complications in pregnancy. 
The aims of thesis are therefore to: 
1. Establish the prevalence of obstetric complications in the Scottish 
population with diabetes compared to the pregnant population without 
diabetes, and whether current clinical care is improving outcomes 
2. Establish what demographic and clinical risk factors are associated with 
stillbirth in the pregnant population with diabetes 
3. Determine if maternal systemic endothelial function is altered in GDM 
pregnancy compared to normoglycaemic pregnancy as a potential 
mechanism for vascular dysfunction and increased risk of hypertensive 
disorders, preeclampsia and stillbirth. 
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4. Determine if placental vascular function is altered in GDM pregnancy 






































2 Chapter 2: Methods 
2.1 Epidemiological studies 
2.1.1 Clinical databases 
The epidemiological studies in this thesis were granted from, and carried out in 
collaboration with the Scottish Diabetes Research Network (SDRN) Epidemiology 
group. The SDRN is a Chief Scientist Office (CSO) commissioned group of clinical 
and non-clinical researchers with an interest in diabetes research.  The group 
have roles in promotion of high quality, collaborative diabetes research in 
Scotland (Scottish Diabetes Research Network).   
The SDRN epidemiology group, in collaboration with Information Services 
Division (ISD) Scotland, have produced and maintain a server with linked, 
anonymised data of patients with diabetes from major clinical databases in use 
across Scotland.  The linked datasets are updated every one to two years to 
ensure information is up to date and undergo regular audit and scrutiny by the 
research teams to ensure accuracy of clinical data. Researchers can apply to the 
SDRN for access to anonymised linked data from the SDRN server.  Prior to 
access, researchers must complete online learning on data handling and general 
data protection regulations.  Suggested studies must be submitted to and 
approved by the SDRN and must also be approved by the appropriate ethics or 
Caldicott committees prior to access. For the work contained within this study, 
data linked from the national inpatient maternity database, Scottish Maternity 
Records 02 (SMR02) and the national diabetes database, SCI-Diabetes was 
requested. The linked databases are accessed in a pseudonymised format 
remotely from the server using PuTTY.exe software 
(https://www.chiark.greenend.org.uk/~sgtatham/putty/).  Ethical approval for 
the work to be carried out on behalf of the SDRN Epidemiology group was 
granted by the Caldicott Guardians of all Health Boards in Scotland and ISD 
Privacy Advisory Committee.  
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2.1.2 Scottish Care Information (SCI) Diabetes 
SCI Diabetes is the national diabetes electronic health record used across all 
regions of Scotland.  It is used by clinicians across Scotland as part of routine 
clinical practice to document diabetes diagnosis, routine clinical care and 
outcomes of patients with diabetes.  The database includes information on 
physician assigned diabetes diagnosis, diabetes prescription history, annual 
diabetes screening data (micro- and macro-vascular disease), use of diabetes 
technologies and diabetes education received. Patients are identified within this 
database using their unique patient identifier, the Community Health Index (CHI) 
number.  CHI numbers are used routinely in medical records across all NHS 
systems in Scotland, therefore allowing easier linkage of records regardless of 
healthcare setting.  
Development of a national diabetes database was first detailed in 2001 in the 
Scottish Diabetes Framework, as a means to promote a collaborative and 
improved approach to diabetes care in Scotland.  Prior to this, regional diabetes 
databases were utilised in some health boards across Scotland.  In 2004, a web-
based national database was rolled out and since then has been integrated in 
routine clinical care for patients with diabetes across all health boards in 
Scotland (McKnight et al., 2008).  Data from pre-2004 were added to SCI-
Diabetes using a variety of sources from primary, secondary care and 
biochemistry records, but may not include patients who moved out of Scotland 
or died before this date.  
Diabetes diagnosis is primarily entered into SCI Diabetes as a clinician assigned 
diagnosis, but the linked data undergoes further validation by SDRN algorithm 
utilising age at diagnosis and prescription history to improve accuracy.  
Specifically, the algorithm would reassign patients who had a clinician-assigned 
diagnosis of T1DM as T2DM if not received insulin therapy within a year of 
diabetes diagnosis.  Similarly, would reassign as T1DM if clinician-assigned T2DM 
but diagnosed under the age of 30 years AND required insulin therapy within one 
year of diagnosis.  Published work has shown that when validated against 
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inpatient medical records, the database includes information from over 99.5% of 
the Scottish population and diabetes diagnosis is validated in over 99% cases 
(Anwar et al., 2011). Other work validating attendance at retinal screening has 
suggested similar high levels of accuracy of diabetes diagnosis in SCI-Diabetes 
(Scottish Care Information Diabetes Collaboration).   
2.1.3 Scottish Maternity Records 02 (SMR02) 
The Scottish Maternity Records 02 (SMR02) database is a national database that 
includes clinical data relating to all obstetric inpatient admissions. The database 
has existed since 1975 and consists of information that is submitted from all 
maternity hospitals in Scotland.  Comparison of delivery data with births 
registered on the national birth registry suggest good population coverage with 
>98% of all births captured (Births in Scottish Hospitals (Informations Services 
Division Scotland)).  The SMR02 will not include those who delivered in a non-
maternity hospital setting.    
Data relating to maternal demographics, delivery details and neonatal 
characteristics are included in SMR02.  Table 2.1 shows the data requested as 
part of this work, and accuracy of the data within SMR02 according to a 2008/09 
audit of the database (Assessment of maternity data (SMR02) 2008-2009 
(Information Services Division Scotland), 2010).  
Other items that would have been of interest but had poor accuracy when 
audited included height and weight of mothers (72% and 77% respectively) and 
ethnicity (11% accuracy) ( Assessment of maternity data (SMR02) 2008-2009 
(Information Services Division Scotland), 2010).   For mothers with diabetes, pre-
pregnancy BMI was therefore taken from SCI-Diabetes which would have been 





Table 2.1:  Accuracy of data items within SMR02 audited by ISD Scotland in 2008/09 (adapted 
from SMR02 (Information Services Division Scotland, 2010). 
SMR02 item % accuracy 2008/09 ISD audit 
 
Number of deliveries this pregnancy 100 
 
Pregnancy outcome 100 
 




Previous pregnancies 94 
 
Gestational age at delivery 93 
 
Maternal smoking status during pregnancy 90 
 
Mode of delivery 87 
 
Maternal smoking status at booking 80 
 
 
2.1.4 Diabetes and Pregnancy Outcomes in Scotland methodology 
Access to data from the linked SMR02 and SCI-Diabetes was requested from years 
1998 to 2013.  At the time of setting up the project, 2013 was the latest excerpt 
of complete linked data. All information within the linked databases is visible 
only in a pseudonymised format.  The aim of this study was to explore the 
prevalence of diabetes in pregnancy, associated obstetric outcomes in these 
pregnancies and how they compared to the obstetric population without 
diabetes, and the temporal trends in this data. 
Initial examination of the linked data revealed a very low number of mothers 
with a diagnosis of diabetes that was not T1DM or T2DM (249 of 813,000 
deliveries).  GDM diagnosis is also grossly underestimated in SCI-Diabetes as it is 
not used routinely in obstetric clinics across Scotland and so this study was 
restricted to exploring outcomes in mothers with pregestational T1DM and T2DM 
only.   
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2.1.4.1 Study time period 
The time period beginning 1st April 1998 through to 31st March 2013 was used for 
a number of reasons.  Firstly, absolute numbers of women with diabetes 
delivering infants per year are modest in Scotland, and so a larger time period is 
required to detect meaningful differences in some less common adverse 
outcomes such as stillbirth.  As 2013 was the latest complete set of linked data 
available at this time, a period of 15 years prior to this seemed a good 
timeframe to provide a large enough population to investigate outcomes, and to 
allow additional analysis for time trend.   Furthermore, two previous national 
paper audits had been published in 1998/99 and 2002/03 and so comparison of 
our data against these was useful for additional validation of our data 
(Kernaghan et al., 2006, Penney et al., 2003). 
In Scotland, fiscal years are often used to describe national statistics, as these 
coincide with national budget timeframes and can be used to map outcomes 
against health policy planning.  The Scottish and UK fiscal year runs from 1st 
April one year to end of March the following year, and so time data in this study 
are presented in this format.  
2.1.4.2 Study population 
All women who delivered an infant, live or stillborn, at or beyond 24 weeks 
gestation in a Scottish maternity hospital were included. Gestational age 
inclusion criteria were decided based on legal definitions for stillbirth in 
Scotland.  Deliveries that happened outside of a hospital will have been few, but 
these data would not have been included as an SMR02 inpatient episode and so 
could not be included. Figure 2.1 details the study population numbers. 
2.1.4.3 Pregnancy outcome data 
An analysis plan for determining pregnancy outcomes in T1DM and T2DM was 
outlined at the beginning of the study.  Firstly, I wanted to establish the 
prevalence of diabetes in pregnancy in the Scottish population and the maternal 
demographic it affected.  Then, the rates of key adverse outcomes in the 
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population.  The pre-defined factors are listed in table 2.2. The predefined 
analysis was to understand the absolute rates of these in the population and 
whether rates were different depending on diabetes diagnosis.  Secondly, to 
understand if rates changed across time. Following peer review for publication, 






Figure 2.1  Population data included for study exploring obstetric outcomes in population 
with and without diabetes 
This figure shows the number of records available within SMR-02 and used for the 
epidemiological study exploring rates of adverse obstetric outcomes in the population with 
diabetes compared to those without.  The final number of records available for inclusion were 
3229 deliveries to mothers with T1DM, 1,452 to mothers with T2DM and 808,953 deliveries to 











249 linked as 




38 no vital status 









Table 2.2:  Predefined variables of interest in defining rates of adverse outcomes in 
pregnancy complicated by diabetes 









SIMD deprivation score 
Singleton or multiple birth 
 




Birthweight LMS Z-score 
 




Mode of delivery 
 
Rates of pre-term delivery 
(<37 weeks) 
 
Rates of very preterm 




Definitions used to define these parameters are listed below: 
Scottish Index of Multiple Deprivation (SIMD) 2012 score  is a non-linear 
numerical scale of material deprivation based on postcode of residency. The 
SIMD ranges from 0.94 to 89.89 with higher numbers representing residential 
areas with the most material deprivation and socioeconomic inequality.   The 
score is generated by 38 indicators in 7 weighted domains including income, 
employment, health, education, crime, housing and access to services (Scottish 
Index of Multiple Deprivation (Public Health Scotland Data and Intelligence), 
2012).   
Z-score of birthweight was calculated in cells based on gestational age, sex and 
parity using LMS tables constructed from a reference population of all Scottish 
births from years 1998-2003 (Bonellie et al., 2008). 
Large for gestational age (LGA) is defined as an infant born with birthweight 
above the 90th centile (adjusted for gestational age, sex and mother’s parity) 
and is based on the same reference Scottish population from 1998-2003 (Bonellie 
et al., 2008).     
Small for gestational age (SGA) is an infant born with an adjusted birthweight 
below the 10th centile.  
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Stillbirth is legally defined in the 1992 amendment of the Births and Deaths 
Registration (Scotland) Act 1965 as a child born after 24 weeks gestation which 
did not breathe or show signs of life at delivery (Registration of Births, Deaths 
and Marriages (Scotland) Act. Sect. 56, 1965).  Prior to 1992, stillbirth was 
defined as 28 weeks. The crude stillbirth rate is used in this study and is 
presented as a rate per 1,000 total births.   
Perinatal mortality is the combination of stillbirths and infant deaths which 
occurred in the first seven days of life. This is also presented as a rate per 1,000 
total births.  
Hypertensive disorders diagnosed in pregnancy are of interest in this study, but 
were not included in full analysis in these studies due to limited reliability of 
data. Audits have shown that these disorders are underreported by up to 40% in 
SMR02, and any coding that did exist would be difficult to establish the 
diagnostic criteria used (Intelligence).  
2.1.4.4 Statistical analysis of pregnancy outcomes according to diabetes 
diagnosis 
Analysis was performed using SPSS version 22.0 (IBM Corp., USA).   
When analysing mode of delivery, gestational age at delivery and birthweight 
variables, only singleton deliveries are included since multiple births could have 
significant influence on these parameters unrelated to diabetes status.  The 
same influence can be seen with higher risk of intrauterine death in multiple 
births, however, stillbirth and perinatal mortality are uncommon and serious 
outcomes, and so all births are included in this analysis.   
Data are expressed as mean+SD, or percentages as appropriate. 
To compare demographics or pregnancy outcomes in mothers with T1DM, T2DM 
or without diabetes, ANOVA with post-hoc testing for between group differences 
is used for continuous parameters, and χ2 used for categorical variables.   
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When analysing time trends, logistic regression models are used that include 
terms for diabetes diagnosis (T1DM, T2DM or no diabetes), time (defined by the 
year of interest) and any interaction between the two.   Binomial distribution is 
used to calculate 95% confidence intervals.  
2.1.5 Diabetes and stillbirth risk factors methodology 
The same linked databases, SMR-02 and SCI-Diabetes are  used for this study. At 
the time of beginning this study, the latest excerpt included linked data to 30th 
June 2016.  Data over a longer period from 1st April 1998 to 30th June 2016 is 
therefore analysed. 
The main aim of is to define the risk factors associated with a stillbirth outcome 
in pregnancy complicated by diabetes.  The effect of maternal and fetal 
characteristics, and regional variation in factors linked to stillbirth are explored.   
2.1.5.1 Study population 
In this study, only singleton deliveries to mothers with pregestational T1DM or 
T2DM are included.  As in the first study, inpatient episodes that resulted in 
delivery of an infant at or beyond 24 weeks of gestation are included.    
Information relating to  maternal demographics, infant characteristics at 
delivery and data relating to glycaemic parameters measured during pregnancy 
are included.  Comparisons of these factors between pregnancies that ended in 
stillbirth and those which resulted in a livebirth are made to better understand 
the demographics of diabetic pregnancies at risk of severe adverse outcome.  
Analysis according to unit where pregnancy was delivered is also performed to 
assess for any differences in regional outcomes suggestive of inter-regional 
variability in population or obstetric practice. Regional analysis is performed in 
two ways.  Firstly, exploring differences according to health board area in which 
delivery occurred, and secondly exploring the size of delivering unit defined 
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according to the average number of deliveries per annum of women with 
diabetes.  
2.1.5.2 Health board regions in Scotland 
Scotland is divided into 14 geographical areas whose healthcare policy and 
spending is overseen by a regional health board.  Central government funding is 
provided to these health boards who then have the responsibility of allocating 
resource and financing regional healthcare services for their population.   Figure 
2.2 demonstrates the 14 health board regions. They vary significantly both in 
terms of population size and demographic.  For example, NHS Orkney is the 
smallest health board with a population of just over 20,000 people and covers a 
rural, off-shore island whilst NHS Greater Glasgow and Clyde is the largest 
health board serving a population of 1.2 million in a smaller, densely populated 
region in West Central Scotland (Scotland's health on the web, NHS Scotland).  
NHS Highland covers a much vaster area at almost 40% of Scottish land mass, but 
serves a population approximately four times smaller than that of NHS Greater 
Glasgow and Clyde.  
Regional health care setups may differ in terms of access to specialist centres 
and experience of these centres in dealing with higher risk pregnancies. Whilst 
all have diabetes and pregnancy clinic setups, some of the more peripheral 
regions may decide to send particularly high-risk women to more central tertiary 
centres in the large Scottish cities.  This is one of the reasons that migration of 
patients across health board regions may occur.  Patients may also migrate due 
to patient choice of delivery centre or because resident close to boundary of two 
regions.  
Taking into consideration potential differences in access and experience of 
specialist diabetes and pregnancy services across Scotland, and the potential for 
patient migration between across health board boundaries to receive obstetric 
care, I analysed the effects of health board area of delivery on outcome.  The 
outcomes of interest were specifically stillbirth rates, birthweight Z-score and 
gestational age at delivery.  Three of the smallest health boards (Western Isles, 
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Orkney and Shetland) are excluded due to low numbers of deliveries to women 
with diabetes determined either by <5 deliveries to women with diabetes per 
annum pre-analysis (1 region), or exclusion post-analysis (2 regions) when 
visualised mean outcome and very large confidence intervals.  Health boards are 
represented as anonymised regions A-K.   
2.1.5.2.1 Outcomes by size of unit of delivery 
 
Obstetric units across Scotland will have varying degrees of experience in 
delivering women with pregnancy complicated by diabetes.  Some of the larger 
city hospitals can expect to deliver up to 50 infants to mothers with diabetes per 
annum, whilst some of the smaller units will deliver less than 5 per annum.  Size 
of delivering unit is therefore categorised according to number of women with 
diabetes delivered there per annum across the study period.  They are defined 
as <5, 5-9, 10-19, 20-29 and 30-50 deliveries/annum.  Those units in which 
number of deliveries are so small (<5 deliveries across the entire study period) 






                        
                     
 
Figure 2.2:  Health board geographical regions of Scotland 
This map of Scotland outlines the geographical areas covered by the 14 regional health boards.  
Each health board boundary is depicted by white boundary lines and is labelled according to the 
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The definitions for stillbirth, birthweight Z-score, LGA and SGA are the same as 
those described in section 2.1.4. SIMD2012 score is used again to estimate 
material deprivation. 
Maternal BMI is defined as the last recorded BMI in SCI-diabetes within the six-
month period preceding conception. Conception data are calculated using the 
date of delivery minus the gestational age at delivery. 
Maternal HbA1c data available from each trimester are analysed.  The last 
available HbA1c within each time frame is  used. Pre-2006, labs were not 
routinely DCCT-aligned and so some regional variation in assays may be expected 
prior to that time period.  
Pre-pregnancy is defined as up to six months preceding estimated conception.   
First trimester is defined as day 1-90 (up to 12+6 weeks) of pregnancy inclusive. 
Second trimester is defined as day 91-188 (13+0 to 26+6 weeks) of pregnancy 
inclusive. 
Third trimester is defined as day 189 (27+0 weeks) to delivery 
2.1.5.4 Statistical analysis of risk factor differences between stillbirth and 
livebirth pregnancies 
Data were analysed using Statistical Analysis Software (SAS) v 9.4 (Cary, NC, 
USA).  Risk factors and obstetric outcomes are presented separately for diabetes 
diagnosis (T1DM or T2DM).   
Outcomes of interest in stillbirth and livebirth pregnancies within each of these 
groups are presented as a mean + SD or frequency as appropriate.  Crude 
stillbirth rates (per 1,000 deliveries) are presented.  Gestational age of stillbirth 
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is defined as the gestational age at delivery of the infant, but death may have 
preceded this time.  
For comparison of maternal and infant characteristics between live and stillbirth 
groups, generalised mixed linear models are used, with a random effect 
incorporated for mother ID.  This was recommended following peer-review of 
the data to account for any effect of mothers having more than one pregnancy in 
this time frame, and contributing intrinsic but unmeasured stillbirth risk from 
the mother.  The majority of women had one or two pregnancies only in this 
time period (67% one pregnancy, 94% one or two pregnancies).   
Analysis of regional variation in stillbirth rates combines data for both T1DM and 
T2DM pregnancies due to low absolute numbers.  Analysis of regional and unit 
size variation of birthweight and gestational age at delivery outcomes are 
analysed separately for T1DM and T2DM.  Analysis is performed using logistic 
regression analysis for categorical outcomes, and general linear model for 
continuous variables.  
For data relating to timing of delivery and stillbirth risk at each gestational 
week, crude stillbirth rates with a denominator of number of ongoing 
pregnancies at that particular week of gestation are used.  






2.2  Maternal vascular function in gestational diabetes 
studies 
2.2.1 Aims 
As described in chapter 1, women with diabetes in pregnancy are significantly 
more likely to suffer conditions associated with vascular dysfunction, such as in 
preeclampsia.  Glucose lowering in pregnancy reduces the risk of preeclampsia 
but the mechanism of this is not clear.  I aim to explore whether GDM is 
associated with impaired maternal and placental vascular function, and whether 
treatment of blood glucose in later pregnancy alters vascular function.  This 
chapter focuses on the maternal vascular function study methodology, although 
participants were recruited for wider participation in combined maternal and 
placental vascular studies (chapters 5 and 6).   
The aims of the maternal vascular studies are to: 
1. Demonstrate if maternal endothelial function (as measured by FMD 
brachial artery) is impaired in pregnancy complicated by GDM 
compared with non-diabetic pregnancy 
2. Demonstrate if maternal endothelial function (as measured by FMD 
brachial artery) changes with advancing gestation 
3. Determine associated effects of glycaemia on maternal endothelial 
function (as measured by FMD brachial artery) 
4. Determine differences in circulating maternal angiogenic biomarkers in 
women with GDM compared to non-GDM 





2.2.2 Ethical approval  
All work pertaining to the maternal and placental vascular studies in this thesis 
received ethical approval from Berkshire B Regional Ethics Committee, and local 
Research and Development approval from the sponsor NHS Greater Glasgow and 
Clyde.  
2.2.3 Study Population 
Women were recruited from the Princess Royal Maternity Hospital in Glasgow, 
and the Queen Elizabeth University Hospital Maternity outpatient departments in 
Glasgow.  
The study was designed to include three groups of women and were recruited 
according to: 
1. 30 women with GDM diagnosed according to IADPSG and national SIGN 
guidelines (fasting plasma glucose >= 5.1 mmol/L and 2-hour post 75g 
glucose load level of >= 8.5 mmol/L). 
2. 15 women who had been referred for OGTT with risk factors for GDM but 
who had a normal OGTT result by IADSPG criteria (CONTROL 1) 
3. 15 women with no risk factors for gestational diabetes (CONTROL 2) 
Since risk factors for GDM such as obesity may be seen to influence vascular 
function independent of diabetes, two control groups (risk factor and healthy 
controls) are included as comparators for the GDM group. 
Women in Scotland are referred to the maternity hospital outpatient department 
for OGTT between 24-28 weeks if they have risk factors for GDM, defined in 
table 2.3 (Management of Diabetes (Scottish Intercollegiate Guidelines 
Network), 2017).  Women who were referred for routine GDM screening were 
considered for this study.  For the healthy control group, these women would 
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not routinely be offered OGTT screening as part of routine clinical care.  These 
women were instead recruited at their routine 20-week anomaly ultrasound 
scan, following a normal ultrasound report. Markers of glycaemia (fasting plasma 
glucose, HbA1c and fructosamine) were measured in all women at study visit 1 
to account for lack of OGTT screening in this group.  
 
Table 2.3:   Risk factors that should prompt referral for GDM screening in Scotland 
BMI>30 kg/m2 
Previous GDM 
First degree relative with diabetes 
Previous macrosomic baby 
High risk ethnicity (South Asian, Middle Eastern, Black Caribbean). 
 
 
At initial study setup, it was intended those women with GDM and risk-factors 
for GDM would be recruited from between 24-28 weeks when GDM screening 
should take place, with the aim that the first visit should be completed between 
24-28 weeks.  However, after the study had commenced it became apparent 
that due to variations in timing of OGTT and obstetric clinic schedules, women 
diagnosed prior to this time, and slightly later were being missed. We amended 
the protocol during the study to allow entry of women up to 32 weeks and 6 days 
provided that the first study visit could be completed in this time.  
Obstetric ultrasound and OGTT clinic lists were screened by the research 
midwifery team and eligible women approached in the outpatient department 
and provided a patient information leaflet.  If women were open to 
consideration of the study, they were asked to read the patient information 
leaflet at home and leave contact details.  Women who were agreeable were 
given at least 24 hours to consider the study before telephone contact to 




2.2.3.1 Inclusion and exclusion criteria 
Women were deemed eligible for this study if they were: 
• Aged 18+ years with singleton pregnancy 
• Normal 20-week anomaly scan 
• Able to provide written, informed consent 
They were excluded from participation if met any of the following: 
• Aged <18 years of age 
• Multiple pregnancy 
• Pre-existing diabetes (not including previous gestational diabetes) 
• Pre-existing hypertension diagnosed prior to study entry 
• Women on potentially vasoactive medications, or other medications that 
may be deemed by the investigator to potentially interfere with study 
procedures or results (excluding Aspirin, levothyroxine, folic acid, 
vitamins)   
• Significant pre-existing illness, particularly if known vascular effects  
• Congenital anomaly 
• Identified placental pathology 
• Unable to give informed, written consent 
• Unable to understand written English language 
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2.2.4 Study visits 
2.2.4.1 Study visit schedule 
Four antenatal study visits were scheduled to coincide with routine antenatal 
clinical appointments to maximise participant retention.  The initial study 
protocol was designed such that the baseline visit would occur shortly after 
OGTT performed as part of routine clinical care between 24-28 weeks, and 
immediately prior to their routine obstetric clinics. Due to local variation in 
timing of OGTT and obstetric clinic schedules, the protocol was later extended 
to allow women to enter the study up to the 32 weeks and 6 days gestation.   
Visit 1 largely occurred between 24-30 weeks gestation with one participant 
outlying with entry to study at 220 days gestation. Visit 2 took place between 32 
and 33 weeks of pregnancy. Visit 3 two weeks later between 34 and 35 weeks of 
pregnancy and visit 4 a further two weeks later between 36 and 37 weeks of 
pregnancy.  
All study visits and study procedures were conducted independently by principal 
investigator (Sharon Mackin) in a temperature-controlled room in the Queen 
Elizabeth University Hospital Clinical Research Facility, Glasgow. 
2.2.4.2  Study visit procedures outline  
Figure 2.3 outlines study procedures according to visit number. 
Visit 1: Participants were asked to attend after an overnight (minimum 8 hour) 
fast and to have refrained from caffeine and nicotine containing products.  
Clinical information and maternal demographics were collected using a 
combination of patient interview and routine electronic health records (Clinical 
Portal™ and BadgerNet™). Data were collected on current gestation, OGTT 
results in GDM and risk factor groups, previous and current pregnancy details 
(including complications), past medical history, current medications and smoking 
status.  Data were recorded on the case report form which is included in 
Appendix 1.  
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Women were weighed on calibrated clinical-grade scales (Seca™ Germany), and 
details of their early pregnancy (obstetric booking appointment) weight was 
recorded from BadgerNet clinical database. Participants underwent BP 
measurement and FMD brachial artery (right arm) analysis as detailed in section 
2.2.5.    
Venepuncture was then performed with samples taken in EDTA, serum and 
sodium fluoride vacutainer tubes (see section 2.2.6 for details of sample 
processing and storage). These samples were later analysed for measures of 
glycaemic control (HbA1c and fructosamine), insulin resistance (HOMA-IR), lipid 
profiles, inflammatory cytokines IL-6 and IL-1β and circulating angiogenic factors 
sFlt-1, PlGF and TNF-α. 
 
Figure 2.3.  Study visit procedures according to study visit number 
Study visit procedures listed according to study visit number.  Visit 1 occurred at 24-30 weeks 
gestation and included clinical history, weight and BP measurement from participants, FMD of 
brachial artery and venepuncture performed for maternal markers of glycemia, insulin 
resistance, lipids and circulating angiogenic factors. At visit 2 (32-33 completed weeks gestation) 
and Visit 3 (34-35 completed weeks gestation), participants updated on changes to their clinical 
history and medications since the previous visit, and underwent BP and FMD brachial artery 
measurement.  At visit 4, participants updated on changes to their clinical history and 
medication since their last visit, had their weight, BP and FMD brachial artery measurements 
performed, and underwent venepuncture.  Bloods taken were again processed and stored for 
























Visit 2 and 3: Participants attended fasted (minimum of 4 hours as no fasting 
bloods required) but must have avoided caffeine and nicotine that day. Clinical 
information was collected on current gestational age, presence of new 
medical/obstetric diagnoses and current medications.  Participants with GDM 
were recording home capillary blood glucose readings as part of routine clinical 
care and this information was collected. BP and FMD of brachial artery were 
again measured. 
Visit 4: Participants attended following an overnight fast (minimum 8 hours) and 
asked to avoid nicotine and caffeine products prior to their visit. Clinical 
information relating to new obstetric and medical problems, and medication use 
were updated.  Women were again weighed on calibrated scales (Seca™, 
Germany).  BP and FMD of brachial artery were measured as before.  
Venepuncture was again performed with samples taken in EDTA, serum, and 
sodium fluoride vacutainer tubes.  These were processed and stored and later 
analysed for the same biomarkers as visit 1 samples.  
2.2.5 Flow mediated dilatation of brachial artery protocol 
2.2.5.1 FMD brachial artery procedure 
FMD of brachial artery was chosen as a non-invasive, widely accepted and 
validated measure of assessing endothelial function in pregnant and non-
pregnant subjects (Foo et al., 2017).   The procedure involves measuring shear 
stress-induced vasodilation (as a % from baseline) induced by laminar blood flow 
post-arterial occlusion.  Shear stress induces NO release from endothelial cells 
which should lead to vasodilation.  Lower vasodilating capacity is associated with 
endothelial dysfunction and cardiovascular risk (Celermajer, 1998).    
The procedure was performed in a temperature-controlled room (23-260C) using 
the semi-automated FMD device UNEX EF 38G by a single researcher (Sharon 
Mackin). Figure 2.4 shows the UNEX EF device. FMD procedures were conducted 
according to Task Force guidelines for the ultrasound assessment of vasodilation 
of the brachial artery (Corretti et al., 2002).   
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FMD measurement is a highly specialised skill that can be prone to significant 
inter-user variability, particularly in cases where training is inadequate, the user 
is inexperienced or stringent study procedures are not followed to minimise 
vasoreactivity. The UNEX EF™ device is a novel piece of equipment that uses a 
stereotactic B mode ultrasound probe and in-built wall detection software to 
calculate semi-automated FMD measurement.  The semi-automated equipment 
was designed to minimise user error and variability in image interpretation seen 
in manual FMD measurement (Corretti et al., 2002).  I was trained and appraised 
locally by more experienced users of FMD, and practiced on healthy volunteer 




Figure 2.4: UNEX EF flow mediated dilatation technology 
Participants lay with their arm placed in a relaxed position across both arm rests.  Arm rests are 
attached to the stand using magnets to minimise movement.  Two cuffed metal electrode 
bracelets are attached to each wrist to allow detection and synchronisation of the device with 
the cardiac cycle. There is automated BP cuff which should be placed on the upper arm on the 
opposite side to the brachial artery being imaged. There is a second inflatable cuff that is placed 
on the forearm on the same side that FMD measurement is being measured, and will be inflated 
to above systolic pressure to cause arterial occlusion. There is a stereotactic linear ultrasound 
probe that can be locked in position after satisfactory images of the brachial artery and imaging 
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Participants attended the clinical research facility fasted (minimum of four 
hours) and having avoided all caffeine and nicotine-containing products that 
day. They were allowed to relax in a seated position for fifteen minutes whilst 
asked questions relating to their medical, obstetric and medication history.  
Participants then lay on a bed with the head raised to an approximate 15-300 
angle (to minimise vena cava obstruction from a gravid uterus), and their right 
arm rested perpendicular to the body on the UNEX EF arm rests.  
An automated BP cuff (connected to the UNEX EF device) was placed on the 
upper LEFT arm, and two cuff electrodes placed on both wrists to allow 
synchronisation of the FMD device to the cardiac cycle. A second inflatable cuff 
was applied to the extended RIGHT forearm.   
The automated BP cuff attached to the LEFT arm was inflated and the BP result 
obtained was automatically relayed to the UNEX EF machine.   
Using the ultrasound probe of the UNEX EF, the brachial artery was imaged 5-
15cm above the antecubital fossa.  The ultrasound probe was manually 
manoeuvred to provide a clear longitudinal image that allowed identification of 
the near and far intraluminal artery walls (intima), and two short axis images 
(proximal and distal) (see Figure 2.5).  The ultrasound probe was then locked in 
position and the participant asked to remain as still as possible for the 
remainder of the procedure.  Electronic markers were placed in the centre of 
the vessel on short axis views, and the UNEX EF device then used automated wall 
tracking technology to further improve probe position and optimise intraluminal 
vessel views.  A resting intraluminal brachial artery diameter was then recorded 
(from intima to intima) by UNEX EF over 10 consecutive heart beats, and an 
average of these provided as the “rest diameter”.   
The inflatable cuff on the RIGHT forearm was then inflated to 50mmHg above 
the participants measured systolic BP (SBP) for a total of five minutes, with the 
intention of occluding flow in the brachial artery for this duration.  Participants 
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were encouraged to remain still throughout.  After four minutes occlusion time, 
the UNEX EF device, began automatic retracking of the intraluminal vessel 
diameter in preparation for cuff deflation and subsequent measurements.  The 
intraluminal diameter in the 60 seconds pre-cuff deflation was recorded by UNEX 
EF as “base diameter.” Following cuff deflation, the UNEX EF device tracked 
beat to beat intraluminal diameter for two minutes.  The time and diameter 










Figure 2.5: Example of typical longitudinal and short axes images on UNEX EF 38G.   
The longitudinal and short axes are shown simultaneously on the 15” UNEX EF 38G screen. The 
longitudinal image is placed centrally and should show clearly lineated near and far internal 
vessel walls. Left and right short axis are shown accordingly on each side of the longitudinal 
image.  The green circles on short axis views highlight the markers placed centrally by the user 
over the vessel.  The UNEX EF 38G uses these markers to assist location of the vessel under the 
probe and optimise vessel images using automated tracking.   
This image was taken by principal investigator Sharon Mackin.  
 
2.2.5.2 FMD brachial artery automated analysis 
The UNEX EF provides an output with automatically calculated FMD. However, 
the UNEX EF reports variable FMD outputs dependent on the automated 
interpretation of images.  Scrutiny of automated results revealed that UNEX EF 
would also automatically calculate FMD despite some very poor quality images.    





UNEX EF offers a series of FMD outputs termed:  
• C-FMD: A measurement comparing pre-cuff deflation “base diameter” 
with maximum diameter based on longitudinal image measurements.  
Calculated as  
𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 − 𝑏𝑎𝑠𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟
𝑏𝑎𝑠𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟
× 100% 
• FMD: A measurement comparing pre-cuff inflation “rest diameter” with 
maximum diameter based on longitudinal image measurements.  This 
measurement provided alongside “C-FMD”. Calculated as: 
𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 − 𝑟𝑒𝑠𝑡 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟
𝑟𝑒𝑠𝑡 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟
× 100% 
• FMDs: A measurement comparing pre-cuff inflation “rest diameter” with 
maximum diameter based on short axis images.  Often used by the UNEX 
EF device if longitudinal images were felt be of inadequate quality for 
auto-interpretation of FMD. Calculated as: 
𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 − 𝑟𝑒𝑠𝑡 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟
𝑟𝑒𝑠𝑡 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟
× 100% 
Figure 2.6 A-D shows examples of the variable automatic outputs from UNEX EF. 
Due to variability in automated reporting methodologies used by UNEX EF, I 
identified a need to assess the reproducibility of UNEX EF reporting.  I taught 
three students on the use of automated UNEX EF measurement and subsequent 
manual analysis, and supervised them in a study validating the semi-automated 
UNEX EF measurements in healthy volunteers.  In this study, we compared 
reproducibility of two semi-automated FMD readings taken 20 minutes apart and 
subsequent reproducibility with manual reanalysis.  This confirmed  my 
hypothesis that manual measurements had good reproducibility (ICCC 0.679 with 
low CV 12%) compared to automated measurements (ICCC 0.103 with high CV 
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46%) (Dobbie et al., 2020).  Furthermore, a quarter of scans were non-diagnostic 
in the hands of these inexperienced users supporting the need for a manual 
quality check on images prior to inclusion of UNEX EF data in any study.  Given 
this superior reproducibility, I decided to perform manual quality assessment 
and measurement of FMD for all recordings in this study. I performed all manual 
analysis. 
 











Figure 2.6: Examples of acceptable and inadequate quality FMD outputs from FMD UNEX EF 
38G.  
Each UNEX-EF output provides two still longitudinal images of what it has interpreted as base 
diameter and max diameter.  The graphs on the bottom left of screen plot the intraluminal 
diameter (blue) in mm against time in seconds, whilst the detected flow rate through the vessel 
(cm/sec) is shown in the superimposed scatterplot (purple).  Figure 2.6A shows a C-FMD output 
with clear near- and far internal vessel walls demonstrated, allowing measurement of FMD from 
measured parameters. Assuming that video playback had consistent images like this, I would 





by the semi-automated UNEX-EF device, but on manual inspection it is clear that the device is 
picking up flow interference mid-lumen and interpreting this as vessel intima.  The UNEX-EF 
generated FMD result is therefore likely inaccurate in this case. Figure 2.6C shows images from a 
recording that the UNEX-EF device felt had too poor quality to generate an FMD result from 
longitudinal images, and therefore reverted to calculating FMDs using short axis images. On 
manual inspection of the still images and playback of video, I felt that the intraluminal diameter 
was consistently visible and after manual reanalysis was happy to include this in the study. 
Figure 2.6D on the other hand shows very poor quality images where the UNEX EF has generated 
an FMD value based on short axis images.  This image was excluded from any analysis.  
  
 
2.2.5.3 FMD brachial artery manual analysis   
I performed a manual quality check of each UNEX EF generated FMD 
measurement using UNEX EF PC analysis software (UNEX Corporation, Nagoya, 
Japan). This involved reviewing playback of all UNEX EF generated recordings 
and assessing quality of ultrasound images throughout the duration of 
experiment. FMD results were deemed of inadequate quality if the intima-to-
intima interface was not readily identifiable in the pre-cuff occlusion rest 
period, or consistently throughout the two minute post-cuff deflation period. 
Those considered of poor quality were excluded from further analysis.  
To achieve consistency in methodology, all remaining images were manually 
analysed. The rest diameter was manually measured from images obtained pre-
cuff inflation.  To measure the maximum diameter, the near and far vessel walls 
were identified on immediate post-cuff deflation images. Once marked on the 
UNEX EF images, the machine was instructed to “overwrite” and the images 
played forward.  The software used these pre-identified vessel wall markers in 
combination with wall tracking technology to overwrite the intraluminal 
diameter.  Images were then re-reviewed by me on playback to ensure that it 
was consistently measuring intraluminal diameter.  If deemed acceptable, then 
the diameter and time at which maximum dilatation first occurred was noted. 




2.2.6 Biochemical measures 
2.2.6.1 Sample preparation and storage 
Blood samples were collected from patients on visit 1 and visit 4.  Venepuncture 
was the last study procedure performed at these visits to minimise any effects 
on FMD measurement from stress or in the unlikely event of accidental arterial 
puncture.  For the visits that required venepuncture, women attended following 
an overnight fast (minimum 8 hours).  Approximately 20mL of blood was 
venesected into – 2x SST (serum), 2x EDTA and 1x Sodium Fluoride vacutainer 
tubes.   
Samples were centrifuged within a couple of hours at a speed of 15000 rpm at 
40C for 15 minutes.  The supernatant was aspirated and aliquoted into 0.5mL 
volumes in cryotubes, clearly labelled as serum (SST), plasma (EDTA) or sodium 
fluoride.  The buffy coat from the EDTA sample was aspirated and stored in a 
separate cryotube and the densest red blood cell portion aliquoted and labelled 
as red blood cells. Figure 2.7 shows the graded layers of the EDTA sample after 
centrifugation. All samples were stored in a -800C freezer until needed for assay. 
Thaw occurred immediately prior to any assay. A maximum of two thaws were 












Figure 2.7: Sample layers after centrifugation of plasma samples 
After centrifugation, plasma sample were aspirated into plasma, buffy coat and red blood cell 
samples before storage.  This figure shows the typical layered sample after centrifugation.  The 
yellow uppermost layer contains plasma fluid.  The buffy coat contains white cells and other 








2.2.6.2  Assays – Glycaemic parameters and lipids 
All glycaemic, lipid and albumin biomarkers were measured on the Roche Cobas 
C311 autoanalyser™.  I assisted Elaine Butler (laboratory technician at the 
Institute of Cardiovascular and Medical Sciences, University of Glasgow) with 
these assays. 
Plasma EDTA samples were used to measure fasting insulin levels (samples from 
patients on insulin were excluded from this) using a Roche Cobas™ 
electrochemiluminescence immunoassay.   
HbA1c was measured on red blood cell samples using the Tina-quant™ HbA1c 
assay from Roche Cobas™.   
Serum samples were used for lipid profiling (cholesterol, HDL and triglycerides), 
fructosamine using colorimetric assays from Roche Cobas™ (namely these were 
Cholesterol 2 gen, Triglycerides, HDL-Cholesterol 4 gen and Fructosamine kits) 
and an immunoturbidimetric assay for Albumin (AlbT2 kit from Cobas™).  
Sodium fluoride samples were autoanalysed using UV absorption assay to 
measure glucose (Glucose HK 3 kit from Cobas™).  
Further details on the properties of these assays can be found in appendix 2.   
2.2.6.3 Assays – Angiogenic and inflammatory markers 
sFlt1, PlGF and TNF-α concentrations in serum samples were using multiple 
analyte immunoassay magnetic bead technology (Milliplex™) from Merck™. The 
inflammatory cytokines IL-6 and IL-1β were assayed using the same technology. 
Dr Lesley Graham (Institute of Cardiovascular and Medical Sciences, University of 
Glasgow) taught me how to do these assays, and I performed them 
independently thereafter.  
The specific kits used were the Milliplex™ Human Angiogenesis Panel 2 
(HANG2MAG-12k™) for sFlt1, Human Cardiovascular Disease Magnetic Bead Panel 
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1 (HCVD1MAG-67k™) for PlGF, and the Human Cytokine/Chemokine Magnetic 
Bead Panel (HCYTOMAG-60k™) for TNF-α, IL-6 and IL-1β.    
Samples were prepared and incubated with detection antibodies on a 96-well 
plate according to the manufacturer’s instructions.  A full protocol for each kit 
can be found in appendix 3.  Each assay plate included a set of “standard” 
samples (provided in kit with known concentrations) to allow generation of a 
standard curve. Five-parameter logistic regression (5-PL) was used to generate 
the standard curve, or in some cases a 4-PL curve in the case of an ambiguous 
curve fit with 5-PL. Samples were analysed in duplicate on the MAGPIX xPONENT 
4.2 (Luminex™) analysis system.  For each sample well, a Median Fluorescence 
Intensity (MFI) was generated by the MAGPIX xPONENT system Median 
Fluorescence Intensity (MFI). Mean MFI for each duplicate sample was calculated 
and a corresponding analyte concentration obtained from the standard curve. 
The coefficient of variation of the MFI was calculated as a proxy assessment of 
test accuracy and reproducibility, with only those samples with <20% variation 
included in ongoing analysis.  
2.2.7 Statistical analysis 
The study was powered for the primary outcome of detecting a difference in 
FMD brachial artery between GDM and control groups.  Based on previous cross-
sectional work suggesting measures of FMD in GDM (9.2+6%) and pregnant 
controls (17.6+8%) (De Resende Guimarães et al., 2014), a power calculation for 
the primary outcome of difference in FMD% at baseline suggest that 16 women in 
GDM and control groups would have power (1-β)0.8 to detect a difference of 8% 
with α=0.05.  Statistical analysis was performed using IBM SPSS™ v 22.0 statistics 
package for the majority of analysis in maternal vascular studies.  GraphPad 
Prism™ v 8.0 was used to generate standard curves using logistic regression (5-PL 
or 4-PL depending on best fit curve) and corresponding analyte concentrations 
for the Milliplex™ biochemical analysis. 
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Maternal demographics are compared between GDM, risk factor and control 
groups using one way ANOVA for continuous variables, and χ2 for categorical 
variables.  For continual variables, normality was assessed using Q-Q plots and 
Shapiro Wilk tests.  
Time trend analysis of BP and FMD measurements are assessed using linear 
mixed models with terms for diabetes diagnosis and gestational age (in days) 
included as fixed effects, and participant ID as a random effect.  This approach 
was chosen to account for intra-subject variability in measurements, and to 
allow interpretation in the presence of missing data. No specific pattern was 
identifiable in BP and FMD trends, making random computation of missing results 
difficult. 
For biochemical analysis that was not normally distributed (assessed by Q-Q plots 
and Shapiro Wilk test), median values are presented and differences between 
groups assessed by non-parametric tests. 
For all analysis, statistical significance is assumed if p-value of <0.05.  
2.3 Placental vascular function in gestational diabetes 
studies 
Placentas were collected prospectively from the same cohort described in 
chapter 2.2.  Ethical approval for this study was submitted and approved under 
the same application as in chapter 2.2.  Approval was from Berkshire B ethics 
committee and NHS Greater Glasgow and Clyde Research and Development 
committee.  
 
2.3.1 Placental collection 
At study entry and following prospective informed consent for placental 
collection at delivery, participants had a clinical alert entered on their 
electronic health record (BadgerNet™) asking the clinical team to contact the 
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principal investigator (Dr Sharon Mackin) by telephone, when the woman was 
admitted for delivery.  All methods of delivery were included, and clinical teams 
were asked to contact the researcher regardless of time of day.   
Once aware that a participant had been admitted in labour or for planned 
delivery, the clinical team and principal investigator agreed further telephone 
contact at the following times to arrange timely placental collection.  
• Primiparous participants – when had reached 10cm cervical dilatation and 
just prior to commencing the second “pushing” stage of delivery, 
investigator should be contacted to attend hospital for impending 
delivery. 
• Multiparous – when reached 8cm cervical dilatation or beyond, 
investigator should be recontacted to attend hospital for impending 
delivery. 
• At any point where patient was being transferred for emergency 
caesarean section, the investigator was recontacted to attend labour 
suite. 
• For elective caesareans, the investigator attended hospital when 
expected to be taken to theatre.  
This allowed collection of the placenta and umbilical cord blood immediately 
post-delivery with minimal impact on the clinical team.  
2.3.2 Cord blood sampling 
Venous cord blood collection was consented for at entry of the study.  This was 
agreed for storage for any future studies including DNA storage.  No planned 
studies on cord blood formed the basis of the initial protocol and do not form 
part of this thesis. Cords were double clamped at delivery and using a sterile 
needle, 10mL maximum of blood was aspirated from the umbilical vein and 
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transferred into SST and EDTA samples.  It was centrifuged and aliquoted as in 
section 2.2.6.1 and stored at -800C. Participants had the option to complete the 
study but decline cord blood sampling.    
2.3.3 Placenta sampling technique 
In the laboratory, placenta were gently stripped of the chorionic membranes and 
cord and weighed on calibrated scales.  The chorionic plate surface was grossly 
visualised for an area that contained  small chorionic plate vessels, and a full 
thickness sample was cut from this area and placed in ice cold physiological salt 
solution (PSS: 0.25 mmol NaCl, 1 mmol KCl, 50 mmol NaHCO3, 2 mmol KH2PO4, 1 
mmol Glucose, 2.5 mmol CaCl2). Details of salt solutions used in these 
experiments are in Appendix 4.  
Using a sheet of acetate with 2x2cm squares marked on it, biopsies were taken 
from each quadrant 2cm distal to cord insertion.  These were flash frozen in 
liquid nitrogen and stored at -800C for any future experiments. These samples 
are currently being used for microRNA experiments conducted as part of my 
current lectureship, but not as part of this thesis.  
2.3.4 Chorionic plate artery (CPA) myography 
2.3.4.1  CPA preparation and myograph mounting 
From the first placental sample selected due to macroscopic visibility of 
chorionic plate vessels, chorionic plate arteries were dissected.  The biopsy and 
vessels were continuously bathed in petri dish containing cold PSS solution.   
Small third branch chorionic plate arteries (CPAs) were identified under a 
microscope.  Typically, arteries had slightly thicker walls than corresponding 
veins and tended to lie on top of the corresponding vein. Using specialist 
microvascular dissection tools, the artery was cut free from the chorionic 
surface and trimmed of visible connective tissue.  Care was taken at all times to 
minimise contact with the vessel.  
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Following dissection of CPAs, they were cut into eight 2mm sections.   These 
sections were mounted on two taut 40µm wires in separate Danish Myo 
Technology wire myograph baths (AD Instruments™, UK) containing 5mL of PSS.  
At resting position, wires were separated by approximately one wire width, 
enough to ensure no contact with the other wire but not applying stretch to the 
vessel.   
The baths were heated to a temperature of 370C and bubbled with 
5%02/5%CO2/N2 to mimic the low partial pressure of oxygen found in the fetal 
circulation (Wareing 2006). CPAs were allowed to equilibrate in this relaxed 
state for 60 mins at these conditions before undergoing a normalisation 
procedure using the AD Instruments UK™ normalisation module. Figure 2.8 shows 














Figure 2.8: Wire myography setup 
A dissected CPA of 2mm length is thread with two 40µm wires, which are pulled taut and 
screwed securely in place to the myograph. The resting position of the vessel, prior to 
normalisation, allows wires to lie as close to each other without touching. This is the resting 
state where no stretch is being applied to the vessel walls.   There are two jaws of the 
myograph, one which is mobile and attached to a screw micrometer and the other which is fixed 
and connected to a force transducer.  The screw micrometer is gradually adjusted to cause 
separation of the myograph jaws, and subsequent increasing stretch of the vessel. The other side 
is connected to a force transducer which measures the tension in the vessel wall. With each 
stretch of vessel, we can calculate the intraluminal diameter (2x40 µm plus the micrometer 
stretch from baseline).  Intramural pressure can be calculated at each stretch using LaPlace’s 









2.3.4.2  Normalisation 
Normalisation is the process of vessel stretching to an internal circumference 
that would achieve a baseline intramural pressure similar to those seen in vivo 
(Spiers and Padmanabhan, 2005).   For systemic vessels, this would typically be 
100 mmHg or 13.1 kPa. However, fetoplacental circulation is lower resistance 
than systemic vasculature (50 mmHg in the umbilical artery reducing to 30 
mmHg as it transcends the chorionic plate and into the villus capillaries) (Wang 
and Zhao, 2010).  Considering this, a target intramural pressure of 5.1kPa 
(approx. 40 mmHg) was chosen for these experiments, and is typical of 
methodology used in other placental myography studies. The internal luminal 
circumference of the vessel at this target pressure is called the IC100. Once 
calculated, the vessels were relaxed to 0.9 of IC100 to optimise the interface 
between the actin and myosin filaments and contractile potential of vessels. 
0.9L5.1kPa is the term that will be used in the remainder of this thesis to describe 
these normalisation conditions.  
2.3.4.3  Vessel viability 
Following normalisation, CPAs were allowed to rest for a further 15 mins, before 
assessment of vessel viability by measuring contractile response to 5mL of 62.5 
mmol potassium containing PSS (KPSS). CPAs which did not contract in response 
to KPSS, or who failed to achieve a vessel wall tension of 1 mN were considered 
non-viable, and not included in further analysis or experimentation.    
For viable vessels, the contractile response to KPSS was allowed to plateau, 
before washout with 5mL PSS (x3) and settling back to their resting baseline. 
Contractility to 62.5 mmol KPSS was repeated three times with interspersed 
washouts.  The maximum response of each CPA to 62.5 mmol KPSS contractions 
was recorded (mN).  
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2.3.4.4  Vasoconstriction - cumulative concentration response curve (CCRC) 
to U46619 (thromboxane mimetic) 
Viable vessels again underwent washout (x3) and allowed to settle to baseline 
tension. Vessel contractility was then assessed in response to increasing 
concentrations of U46619 ((Enzo Life Sciences, UK) 1x10-10 M to 3x10-5 M). 
Cumulative concentration of U46619 in the myograph was increased in half log 
increments every 5 mins, or after maximal contraction to the preceding 
concentration had being achieved (whichever is longest). Maximal tension at 
each dose of U46619 was recorded and expressed as a percentage of the 
maximal response to KPSS.  At the end of the U46619 CCRC, the vessels 
underwent a washout procedure (x3) and allowed to settle back to baseline 
resting tension.  
2.3.4.5  Vascular vasodilatation – CCRC to bradykinin, sodium nitroprusside 
(SNP), calcitonin-gene related peptide (CGRP) 
Following the above, CPAs were preconstricted with 3x10-7 M U46619 and 
maximal constriction recorded. Once maximal contraction had been reached, 
each vessel was exposed to cumulative increasing doses of either bradykinin, 
sodium nitroprusside (SNP) or calcitonin-gene related peptide (CGRP) as detailed 
below. 
The initial protocol had been designed to investigate endothelial-dependent 
vasodilatation of CPAs to bradykinin ((Sigma-Aldrich, UK) 1x10-10 M – 3x10-5 M), 
and endothelial independent vasodilation to SNP ((Sigma Aldrich, UK) 1x10-10 M -
3x10-4 M) .  Due to lack of endothelial dependent vasodilatory response from 
bradykinin in my initial samples, the protocol was amended to remove the 
bradykinin CCRC.  This is a finding reported by other laboratories (Mccarthy et 
al., 1994, Dordea et al., 2013).  A CCRC to human CGRP ((Tocris™, UK) 1x10-10 M 
-3x10-4 M), a potent vasodilator with endothelial-dependent and independent 
mechanisms, was added instead.  
To determine if CGRP effects were predominantly endothelial-dependent or 
independent in the CPAs, a separate CGRP curve was conducted following a 20-
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minute incubation with the 100 µM of NOS inhibitor, N(ω)-nitro-L-arginine 
methyl ester (L- NAME) (Sigma Aldrich). 
To prevent diminutive effects of repeated vasoconstriction and vasodilatation 
cycles and ongoing effects from previous agonist exposure, CPAs from each 
subject were split into groups so that each vessel was exposed to only one 
vasodilatory CCRC compound.   
Doses for each CCRC were incremented in half-log concentrations at 5-minute 
intervals or whenever the maximal vasodilatory response had occurred to the 
preceding dose. Maximal response to each concentration was expressed as % of 
maximal constriction to 3x10-7 M U46619. 
2.3.5 Statistical analysis 
Differences between maternal and fetal demographics, and placental weight 
were compared using one way ANOVA or χ2 as appropriate.  IBM SPSS™ statistics v 
22.0 was used for these analyses.   
For the CCRCs, raw tension data for each vessel were analysed using LabChart 
Reader™ software v 8.1.13 (AD Instruments, UK).  For each agonist and drug 
exposure, the mean tension was calculated for each subject.  Mean agonist 
responses were then expressed as either maximal vasoconstrictive response 
relative to maximum KPSS response (%) or as maximal vasodilatory response 
relative to the maximum pre-constrictive response to 3x10-7 M U46619 (%).    
 A best fit cumulative concentration curve was then fitted on Graphpad Prism v 
8.0 (GraphPad Software Inc™, USA) and comparison of curves between groups 
analysed using extra sum of squares F test. Maximal response to an agonist is 
expressed as Emax, whereas EC50 is the dose at which 50% of agonist response is 
achieved.  Differences in Emax and EC50 between groups were assessed using one 
way ANOVA.   Due to limitations in the numbers of control and risk factor 
placentas, analysis was conducted according to GDM and non-GDM groups. 
Statistical significance was assumed if p<0.05.  
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3 Chapter 3: Diabetes and pregnancy:  maternal 
and neonatal outcomes 
The work within this chapter has been published in Diabetologia, Jan 2018.  
61(5):1081-1088 (Mackin et al., 2018). 
3.1 Introduction 
As discussed in chapter 1, diabetes confers significant additional risk in 
pregnancy.  Rates of fetal overgrowth, operative and preterm delivery, and fetal 
and infant mortality  are all increased compared to the population without 
diabetes. This is evident in a number of real-world population-level studies 
(Evers et al., 2004, Penney et al., 2003, Macintosh et al., 2006, CEMACH, 2005).  
The deleterious effects of hyperglycaemia on pregnancy are well documented in 
clinical trials (Metzger et al., 2008).  Epidemiological data published since the 
1990s have raised concerns that clinical teams are struggling to improve upon 
some adverse outcomes (Johnstone et al., 2006).  This includes Scottish paper 
audits in 1998/99 and 2003/4 (Kernaghan et al., 2006, Penney et al., 2003) 
which show static infant mortality statistics. Despite marked improvement in 
perinatal mortality in previous decades, rates of stillbirth and perinatal 
mortality in pregnancy complicated by T1DM and T2DM remained stubbornly high 
at 3-5 times that of the background population  (Evers et al., 2004, Fadl and 
Simmons, 2016, de Valk et al., 2006, Diabetes and Pregnancy Group France, 
2003).  Conversely, data from the England and Wales population suggest a 
marked reduction in stillbirth rates for women with diabetes over the last two 
decades.  In England and Wales, stillbirth rates in T1DM have dropped from 25.8 
(18.3 to 33.3) per 1000 live births  in 2002/3 to 10.7 in 2013 , and from 29.2 
(16.3 to 42.2)  to 10.7  for women with T2DM (CEMACH, 2005, National Diabetes 
In Pregnancy Audit Report 2013, 2014). Importantly, this decrease has been 
sustained in their most recent 2018 audit (National Diabetes in Pregnancy Audit 
Report 2018, 2019).  We lack more recent data to determine whether mortality 
outcomes remain high in mothers with diabetes in Scotland.  Other outcomes are 
of interest also. A large single centre study in Scotland showed stable but high 
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mean birth weights in T1DM between 1960s and 1990s (mean birthweight Z-score 
1.4) (Johnstone et al., 2006).    
The focus of this study was therefore to analyse nationally collected data from 
Scotland to examine whether obstetric outcomes for mothers with T1DM or T2DM 
were improving in recent years, and to gain insight into the extent of ongoing 
challenges facing mothers with pregnancy and diabetes.   
3.2 Materials and methods 
3.2.1 Study population and clinical databases 
The national inpatient maternity database, SMR02 was linked to the national 
diabetes database SCI-diabetes, and accessed as described in chapter 2.1.  
From the SMR02 records, information on maternal and infant demographics, 
obstetric management and complications was collected for all females (>10 
years of age) who delivered an infant at or beyond 24 weeks gestation in a 
Scottish hospital between 1st April 1998 to 31st March 2013 inclusive. Cross-
linkage of this database to the national SCI-diabetes database allowed clinical 
data to be collected on diabetes diagnosis and clinical management for the same 
population.  Gestational diabetes is not considered in this study due to database 
limitations.    
3.2.2 Statistical analyses  
Pregnancy outcomes in women by diabetes status (T1DM, T2DM or no diabetes) 
were compared using ANOVA or logistic regression with post hoc testing between 
groups (ANOVA) or by χ2 test as appropriate. Trends for changes in outcome over 
time were assessed by ANOVA with terms for type of diabetes, time and 
interaction between these tested.  Annual time periods were selected, except in 
the case of stillbirth and perinatal mortality rates where absolute number of 
cases were small with significant variability between years. Three-year rolling 
averages were used for assessing these time trends.    
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All analyses were performed using SPSS Version 22.0 (Armonk, NY: IBM Corp)  
Data are presented for all deliveries for maternal variables, stillbirth and 
perinatal mortality (n=813,490) but confined to singletons for mode of delivery, 
gestational age at delivery including preterm birth and birthweight variables 
(n=801,263). 
3.3 Results 
3.3.1 Maternal population characteristics 
813,921 deliveries were recorded in Scotland across the audit period, of which 
38 were excluded due to unknown vital status of infant.  Among these, 4683 
(0.6%) were to mothers with pre-gestational diabetes, of which 3229 (69%) had 
T1DM for an average 13.3 years and 1454 (31%) T2DM for 3.3 years. Maternal and 
infant demographics are shown in table 3.1. A further 249 mothers were linked 
to SCI-diabetes with another diagnosis (including gestational diabetes, impaired 
glucose tolerance, maturity onset diabetes of the young) and were not 
considered further.  
Mothers with T1DM were on average 0.4 years older and more likely to be 
nulliparous than the obstetric population without diabetes. By contrast, mothers 
with T2DM were 4 years older than the general obstetric population, had higher 
deprivation scores and were more likely to have had a previous pregnancy (table 
3.1)  
The absolute number of births per annum to mothers with T1DM increased from 
1998/1999 to 2012/2013 from 205 to 264 deliveries per year, with a larger 
increase in T2DM from 59 to 110 deliveries per year. Both increases were 
statistically significant (p < 0.001) and suggested a 44% increase in deliveries to 
mothers with T1DM and a 90% increase in T2DM in fitted linear models over time.  
When represented proportionally to the number of total births in Scotland, T1DM 




Table 3.1 Maternal demographics according to pre-pregnancy diabetes status 
 Type 1 diabetes Type 2 diabetes 
No pre-gestational 
diabetesa 
Number of ongoing pregnancies 
after 24 weeks 3229 1452 808,953 
Maternal age at delivery, yearsa 29.2±5.7**, ††† 32.8±5.5*** 28.8±6.0 
Duration of diabetes, yearsa 13.2±8.4††† 3.3±3.6  
Paritya 
  Nulliparous, % (n) 50.4 (1604)***, ††† 30.5 (438)*** 45.9 (368,476) 
  Multiparous, % (n) 49.6 (1585) 69.5 (998) 54.1 (434,672) 
SIMD % (n)a 
  SIMD1 most deprived       25.0 (807)‡,§§§     31.0 (449)‡‡‡ 25.8 (208,221) 
       SIMD2 21.1 (680) 22.2 (321) 20.7 (167,327) 
       SIMD3 20.3 (656) 20.0 (290) 18.6 (149,684) 
       SIMD4 17.9 (576) 13.7 (198) 17.7 (143,065) 
       SIMD5 least deprived 15.7 (507) 13.1 (190) 17.2 (138,477) 









Values are presented as mean ± SD or % (n) as indicated. 
a Excluding 38 pregnancies missing vital status and 249 pregnancies with other maternal 
diabetes. 
b Missing data: Maternal age missing in 10 cases, duration of diabetes missing in 56 cases, parity 
missing in 5861 cases, SIMD missing in 2186 cases, maternal smoking missing in 65,866 cases. 
** p < 0.01, *** p < 0.001 vs no diabetes; †††p < 0.001 vs T2DM (Pearson’s χ² test for categorical 
variables, ANOVA for continuous variables) 
‡ p < 0.05, ‡‡‡ p < 0.001 vs no diabetes across SIMD classification (Pearson’s χ² test) 






Figure 3.1: Percentage of total deliveries (born at or beyond 24 weeks gestation) in Scotland 
with a mother affected by T1DM or T2DM 
The solid blue line depicts the percentage of deliveries in Scotland occurring at or beyond 24 
weeks of gestation, with a mother affected by pregestational T1DM in each year. The solid red 
line depicts the percentage of deliveries in the same time period with a mother affected by 
pregestational T2DM in each year. The corresponding dotted lines show a fitted linear trend, 




3.3.2 Pregnancy outcomes according to maternal pregestational 
diabetes status 
Table 3.2 shows infant and delivery characteristics. There were marked 
differences in pregnancy outcomes in women with diabetes compared with the 
obstetric population without diabetes.     
There were 102 perinatal deaths in offspring of mothers with diabetes across the 
15 years (64 in T1DM, 38 in T2DM) representing rates 3.3 and 4.3 times those 
observed in the population without diabetes (p<0.001). Stillbirth rates were 3.6-
fold higher in T1DM and 5.3-fold higher in T2DM than the non-diabetic 
















weeks respectively. Stillbirth rates were not improving over time in diabetes 
(p=0.3 for time trend T1DM, p=0.7 for time trend T2DM as shown in figure 3.2, 
despite a small decrease in rates in the non-diabetes population (1.4% relative 
risk reduction per annum). Perinatal mortality was also higher in pregnancies 
complicated by T2DM at 25.8 per 1,000 births compared with T1DM at 19.6 per 
1,000 births (p<0.01), and similarly showed no improvement with time in T1DM 
or T2DM (Figure 3.3). 
Table 3.2: Infant and delivery characteristics according to pregestational maternal diabetes 
diagnosis 
 Type 1 diabetes Type 2 diabetes 
No pre-gestational 
diabetesa 
Number of ongoing pregnancies 
after 24 weeks 
3229 1454 808,807 
Stillbirths n (n per 1000 births) 63 (19.5) *** 36 (24.8)*** 3966 (4.9) 
Perinatal mortality n (n per 1000 
births) 
65 (20.1) *** 39 (26.9) *** 5154 (6.4) 
Multiple pregnancy, % (n) 1.2 (40) 1.4 (21) 1.5 (12,166) 
Singleton babies % (n) 98.8 (3189) 98.6 (1431) 98.5 (796,649) 
Mode of delivery b    
       Elective caesarean section% 
(n) 
29.4 (956)*** 30.5 (445)*** 9.6 (76,776) 
       Emergency caesarean section    
        % (n) 
38.3 (1251)***, ††† 29.1 (430)*** 14.6 (118,284) 
Gestation at delivery, weeksb 36.7±2.3***, ††† 37.3±2.4*** 39.3±2.0 
Preterm delivery (<37 weeks) % 
(n)b 
35.3 (1126) ***, ††† 21.8 (311)*** 6.1 (48,576) 
Very preterm delivery (<32 weeks), 
% (n)b 
3.8 (121)*** 3.2 (46) *** 1.1 (8760) 
Mean birthweight, g 3466.7±802.8††† 3474.4±793.1*** 3398.8±587.9 
Z-score for birthweightb 1.33±1.34***, ††† 0.94±1.34*** 0.04±1.01 
LGA, % (n)b  50.9 (1623)***, ††† 38.4 (549) *** 10.5 (84,141) 
Values are presented as mean ± SD or %(n) unless indicated otherwise. 
a Excluding 38 pregnancies missing vital status and 249 with other diabetes. 
b Missing data: mode of delivery missing in 23 cases, birthweight missing in six cases, gestational 
age at delivery missing in 412 cases. 
** p < 0.01, *** p < 0.001 vs no diabetes; ††† p < 0.001 vs T2DM (Pearson’s χ² test for categorical 







Figure 3.2: Trends in stillbirth rates according to pregestational maternal diabetes diagnosis 
Figure 3.2 shows stillbirth rates per 1,000 births according to pregestational diabetes diagnosis. 
Due to small numbers, rates have been grouped across 5-year periods to improve visualisation of 
trend data.   The blue line denotes mothers with T1DM, the red line mothers with T2DM and 
those with no pregestational diabetes diagnosis are shown by the green line.  Mothers with T2DM 
have consistently higher stillbirth rates compared with both mothers with T1DM and those 
mothers without diabetes. Stillbirth rates did not change over time in T1DM (p=0.3 for time 
trend) or T2DM (p=0.7 for time trend).  
 
 
Figure 3.3:  Trends in perinatal mortality rates (per 1,000 births) according to pregestational 
maternal diabetes diagnosis 
Trends in perinatal mortality rates are shown across the study time period for mothers with 
T1DM (blue line), mothers with T2DM (red line) and mothers without pregestational diabetes 
(green line).  As with stillbirth rates, absolute numbers were low and so data is displayed in 5-
year time periods for ease of visualisation.  Perinatal mortality rates did not have a statistically 
significant change over time in mothers with T1DM or T2DM, but in the population without 
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On average, offspring to mothers with T1DM and T2DM were delivered 2.6 weeks 
and 2 weeks earlier than in the group without diabetes (Table 3.2). This 
reflected in higher proportions of preterm (less than 37 weeks’ gestation) and 
very preterm (less than 32 weeks’ gestation) deliveries in women with diabetes, 
with a fivefold increase in preterm delivery in T1DM and almost 4-fold increase 
in T2DM. The proportions of elective caesarean section (CS) and emergency CS 
were also greatly increased, with 67.7% of women with T1DM and 59.6% of 
women with T2DM undergoing operative delivery (Table 3.2) 
Despite significantly earlier delivery, mean absolute birthweights in T1DM and 
T2DM were higher than in those without diabetes (69 g and 76 g heavier in  T1DM 
and T2DM respectively).  The absolute difference was only statistically 
significant in T2DM (p < 0.001), however, when adjusted for gestational age, 
parity and sex, the difference in birthweights were dramatic. Offspring born to 
mothers with T1DM weighed on average 1.33 SD above those born to mothers 
without diabetes, and the offspring in T2DM 0.94 SD higher compared to the non-
diabetic population.  This was reflected in large proportions of LGA infants, with 
51% of babies born to mothers with T1DM and 38% born to mothers with T2DM 
considered LGA (Table 3.2). 
3.3.3 Trends in maternal factors and obstetric outcomes across 
time 
3.3.3.1 Trends in maternal factors 
Data were then examined for trends across the 15-year time period to assess for 
any meaningful impact of changing obstetric populations and clinical behaviours 
that may have occurred. Across the 15 years, mean maternal age at delivery 
increased by 0.6 years in mothers with T1DM and 1.6 years in mothers with T2DM 
(Figure 3.4). Maternal age also increased by 0.9 years in mothers without 
diabetes. The trend to increasing age across time was highly significant 
(p < 0.001) and was similar in mothers with and without diabetes (p = 0.56 for 
time*diagnosis). Mean duration of diabetes also increased, from 12.4 to 
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14.6 years in T1DM and from 2.6 to 3.8 years in T2DM (p < 0.001 for time trend, 
p=0.11 for time*diagnosis interaction). 
 
 
Figure 3.4:  Trends in maternal age across time according to diabetes diagnosis 
Mean maternal age in T1DM, T2DM and the non-diabetes obstetric populations increased across 
the audit period (p<0.001).  Mothers with T2DM, shown by the solid red line, were on average 
older than mothers with either T1DM (blue line) or no diabetes diagnosis (green line), and this 
remained consistent across the time period studied. The rate of increase in maternal age across 
the audit period was similar across all groups, irrespective of diabetes diagnosis (p=0.56 for 
diagnosis and time interaction terms). 
 
3.3.3.2 Trends in gestational age at delivery and mode of delivery 
Women with T1DM and T2DM were delivered at increasingly earlier gestations 
across the fifteen years.  In T1DM, the mean gestational age at delivery fell from 
36.7 weeks in 1998/99 to 36.4 weeks in 2012/2013 (p = 0.03), whilst in T2DM a 
similar fall in gestational age at delivery was noted from 38.0 to 37.2 weeks 
(p < 0.001).  Figure 3.5 depicts the annual trends in delivery age for women 



































Figure 3.5:  Time trends in mean gestational age at delivery according to diabetes diagnosis 
Mean gestational age at delivery according to year of delivery and diabetes diagnosis is shown by 
the solid lines, with a superimposed fitted linear model shown by the corresponding dotted line 
to allow visualisation of trend data. Mean gestational age at delivery remained constant at >39 
weeks for women with no pregestational diabetes diagnosis (shown by the green line), whilst 
women with both T1DM (blue line) and T2DM (red line) were both delivered increasingly earlier 
(p=0.03 and <0.001 respectively).  
 
As a reflection of this trend to earlier delivery, the proportion of women 
delivering singleton infants preterm (before 37 weeks gestation) increased for 
both groups, from 34.1% to 42.4% for T1DM (p=0.001), and a dramatic increase 
from 11.9% to 25.5% in T2DM (p=0.003). Very preterm deliveries (under 
32 weeks) were uncommon (Table 1) and showed no significant trends. 
The proportion of singleton deliveries involving CS also increased across all 
groups (p<0.001 for both elective and emergency CS) as shown in figure 3.6  For 
the obstetric population without diabetes, there was a significant increase from 
6.8% to 11.8% for elective CS and from 11.8% to 15.1% for emergency CS. 
Elective and emergency CS rates were far higher in mothers with T1DM and 
T2DM (p < 0.001 for both compared to those without diabetes), yet still showed 







































with T1DM for which the already very high rates (40%) remained stable over 
time.    
 
 
Figure 3.6:  Time trends in rates of elective caesarean section (Fig A) and emergency 
caesarean section (Fig B) according to diabetes diagnosis. 
Rates of elective CS increased with time in T1DM (blue line), T2DM (red line) and the non-
diabetes obstetric population (green line) as shown in figure A (p<0.001 for time).  The solid 
lines denote the rate of CS at each time point, whilst the corresponding dotted lines show a 
fitted linear trend.  Women with T1DM and T2DM had significantly increased baseline rates of 
Elective CS compared with mothers without diabetes, but despite this higher baseline continued 
on a similar increasing trajectory (p=0.15 for time*diagnosis interaction). Emergency CS rates are 
shown in panel B. Women with T1DM had the highest rates of emergency CS and remained stable 
at this rate over time, which is in contrast to the increasing rates seen in T2DM and women 



































































































3.3.3.3 Trends in birthweight outcomes 
Figure 3.7 shows changes in mean birthweight Z-scores (adjusted for gender, 
gestational age and parity) with time, according to diabetes diagnosis. Across 
the audit period, mean birthweight Z-scores appeared stable in offspring of 
women with T2DM (p=0.9 for time trend), but increased across time in T1DM 
from 1.22 to 1.47 SD above the reference population (p =0.001 for time trend). 
This was reflected in the proportion of LGA infants increasing from 47.1% to 





Figure 3.7: Trends in mean infant birthweight Z-scores across time according to maternal 
diabetes diagnosis 
Mean infant z-birthweight scores adjusted for gestational age, parity and infant sex are shown 
here, with the reference population data derived from published data on all Scottish births 
between the years 1998-2003 (Bonellie et al., 2008).  In both infants born to mothers with T1DM 
and to those mothers without diabetes, the mean birthweight Z-score increased with time 
(p=0.001 for time trend in T1DM and no DM groups), whilst in T2DM, it remained stable albeit 






























Figure 3.8:  Time trends in proportion of infants born LGA (>90th centile birthweight 
adjusted for gestational age, gender and parity) according to diabetes diagnosis 
This figure shows the rates of LGA infants born in each category of maternal diabetes status.  
The solid lines depict the absolute rates, as a percentage of total births within that category 
whilst the dotted line shows a fitted linear trend.  In keeping with the definition of LGA as an 
adjusted birthweight > 90th centile, infants born to mothers without diabetes have an 
approximate 10% incidence of LGA birthweights.  This appeared stable over time.  LGA rates 
were much higher in the population with T1DM and T2DM, at approximately 50% and 40% of 
births affected.  LGA rates increased significantly with time in the type 1 diabetes population 
(p<0.001), but did not change significantly in T2DM.  
  
Maternal smoking status was analysed for an association with birthweight. 
Smoking rates reduced significantly across the fifteen-year period from 
examined from 24.1% to 18% in T1DM, 22% to 14% in T2DM, and 27.9% to 19.3% in 
mothers without diabetes (p < 0.0001 for time trend with no difference between 
groups p=0.7). In a model that included time, maternal smoking status and SIMD 
deprivation scores, smoking was associated with lower birthweight in both T1DM 
(β=-0.181, p < 0.001) and T2DM (β=-0.083, p = 0.003).  Social deprivation (as 
represented by the SIMD) did not have an effect on birthweight. The trend to 
increased birthweight Z-score T1DM over time was attenuated by the addition of 







































Birthweight, prematurity, operative delivery and perinatal mortality represent 
key outcome measures in the management of pregnancy complicated by 
diabetes. The results of this study therefore raise concern for the clinical teams 
involved with managing these women in Scotland.   Specifically, already high 
stillbirth and perinatal mortality rates have remained stable over time, and 
birthweight is also increasing in T1DM.  Higher rates of operative delivery and 
falling gestational age at delivery suggest increasing obstetric intervention, 
likely as a preventative measure to reduce such outcomes but granular data on 
their impact are lacking.  
In Scotland, stillbirth rates in T1DM appear intermediate between 2002/2003 and 
more recent data from 2013 and 2018 in England and Wales (25.8 per 1000 births 
to 10.3-10.7 per 1000 births) (CEMACH, 2005, National Diabetes in Pregnancy 
Audit Report 2018, 2019, National Diabetes in Pregnancy Audit Report 2013, 
2014).  However, there is wide variation across European nations who each use 
differing data capture methodologies. In T1DM, Scottish stillbirth rates are 
similar to slightly older Swedish data showing 15 stillbirths per 1000 deliveries 
(1991–2003), but is lower than in the French or Dutch surveys (Persson et al., 
2009, Diabetes and Pregnancy Group France, 2003). Thankfully, absolute 
stillbirth numbers are low, but this limits the power of such surveys to detect 
meaningful trends in mortality outcomes. As such, direct comparison between 
nations is challenging.  Although stillbirth rates in T1DM in Scotland do not 
appear formally significantly different from England and Wales data, there is 
concern that we are not on a similar improving trajectory. This is especially true 
in T2DM, where the Scottish stillbirth rate is both significantly higher than seen 
in the Scottish T1DM and that observed in the 2018 England and Wales survey 
(16.7 per 1,000 births) (National Diabetes in Pregnancy Audit Report 2018, 
2019).  Notably, any difference appears to relate to stillbirth rather than 
neonatal mortality (death during the first 28 days of life), which is not changing 
greatly in England and Wales (10.4 per 1000 livebirths for all types of diabetes) 
and is highly comparable to Scottish perinatal mortality rates (National Diabetes 
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in Pregnancy Audit Report 2018, 2019, CEMACH, 2005). However, there are 
major caveats to direct comparison of Scottish rates with these data, not least 
due to differences in data collection methodologies (patient opt-out and clinical 
centre opt-in of data provision permitted in England and Wales versus whole-
population inclusion in Scotland).   The population of Scotland is also much 
smaller resulting in similar numbers of patients included in our analysis, but with 
data collected across a much wider range of years.  However, epidemiological 
data also suggest that the Scottish population experiences a higher burden of 
cardiometabolic disease than those in England (Scarborough et al., 2011), and on 
a whole population level have higher rates of obesity and smoking (Bromley and 
Shelton, 2010).  Whilst these data do not pertain specifically to the obstetric 
population, if similar phenotypes were evident in this group then it could 
contribute additional stillbirth risk.   
Operative delivery rates also appear high in Scotland (67.7% for T1DM, 59.6% for 
T2DM) and are higher than equivalent data from France, Sweden and the 
Netherlands (44.3–58.9%) (Evers et al., 2004, Persson et al., 2009, Diabetes and 
Pregnancy Group France, 2003). They are however similar when compared to 
England and Wales which has CS rates of 66% for T1DM and 56% for T2DM 
(National Diabetes and Pregnancy Audit Report, 2014). The rates of elective CS 
in T1DM and T2DM, and most strikingly emergency CS in T2DM, are also 
increasing over time. Although the proportions of emergency CS in T2DM (29%) 
appear very similar to those from England and Wales, this compares with a 
figure of just 10% in the Netherlands (de Valk et al., 2006), perhaps reflecting 
different obstetric behaviours between mainland UK regions and other similar 
developed nations. 
A potential driver for increasing obstetric intervention is the perceived risk of 
increasing birthweight and accelerated fetal growth often seen in pregnancy 
complicated by hyperglycaemia (Pedersen, 1952).  Average birthweight is greatly 
increased in the offspring of mothers with T1DM and T2DM in Scotland - despite 
the best efforts of individuals and their clinicians to optimise glycaemia. These 
data reinforce the already acknowledged clinical need to improve upon 
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glycaemia in pregnancy.  This is particularly true in women with T1DM where 
glycaemic excursions can be more frequent and more difficult to manage. In 
Scotland, the ‘average’ baby born to a mother with T1DM in Scotland has a 
birthweight just above the 90th percentile and half of them are born LGA, which 
is marginally higher than LGA rates in T1DM in England and Wales in 2013 
(46.4%). Rates of LGA infants in mothers with T2DM were also higher during the 
same time period (38% vs 24%) (National Diabetes and Pregnancy Audit Report 
2013, 2014). There will be important confounding factors other than diabetes 
and glycemia influencing birthweight that have not been measured due to 
limitations in the dataset.  For example, ethnicity will have become more 
diverse over the time period, particularly for T2DM. However, census data 
confirms a largely (>96%) white population, and so any effect from this is likely 
to be moderate at best (Census 2011 (National Records of Scotland), 2013). 
Maternal BMI is  considered one of the strongest predictors of infant birthweight 
(independent of maternal glycaemia).  Whilst some pre-pregnancy BMI data 
could be obtained from SCI-Diabetes for women with T1DM or T2DM,  the data 
for the comparator non-diabetes group on SMR02 are less reliable (Assessment of 
maternity data (SMR02) 2008-09 (Information Services Division Scotland), 2010). 
Customised growth centiles are used in England and Wales (adjusted for 
maternal height, weight and ethnicity), whilst the Scottish datasets utilises 
centiles adjusted for gestational age parity and sex  based on a very large 
number (>100,000) of contemporaneous Scottish births. Debate remains about 
which is the best predictor of adverse perinatal outcome.  In one study, partially 
customised centiles applied to the Scottish obstetric populations did not appear 
to show any discriminatory difference in detecting neonatal mortality or 
stillbirth risk. However this study had a caveat that weight and ethnicity data 
were lacking (Iliodromiti et al., 2017).  Recent analysis of CONCEPPT trial data 
showed that in a T1DM population with high LGA rates, customised GROW 
centiles which take into account maternal height, weight and ethnicity showed a 
better association with neonatal hypoglycaemia and need for NICU versus 
population-standardised centiles (Meek et al., 2021).    
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In this study, a number of observed trends were expected. Although diabetes in 
pregnancy remains relatively uncommon (1 in 178 births in my data), the 
prevalence of both T1DM and T2DM complicating pregnancy is increasing with 
time.  Although somewhat speculative, reasons for this increase may reflect 
higher rates of maternal obesity, advancing maternal age and small increases in 
the size of at-risk ethnic groups seen in the general Scottish population (Waugh 
et al., 2011, Census 2011 (National Records of Scotland), 2013). The prevalence 
of diabetes in the general population is also increasing over these years (Scottish 
Diabetes Survey Monitoring Group, 2014). Whilst this group represent a small 
proportion of the overall obstetric population, there are important health 
resource and spending implications from increasing numbers needing seen in 
specialist clinics.  The increase in duration of both T1DM and T2DM is also of 
importance, as this may translate into increased rates of microangiopathy with 
associated risks of placental insufficiency, IUGR, preeclampsia and stillbirth 
(Ekbom et al., 2001). 
Some of the trends found were less expected. Mothers with T1DM and T2DM are 
being delivered increasingly earlier and caesarean section rates are increasing 
but, despite this, adjusted birthweight is on the rise. In contrast, the population 
without diabetes appear to have a stable gestational age at delivery and 
birthweight increases are much smaller over time (<0.1 SD across 15 years).  
Similar to the population with diabetes, rates of elective and emergency CS are 
increasing significantly with time. I would be interested in the clinical reasoning 
for choosing CS, but the datasets lack this level of detail. Similar rising trends in 
elective CS rates across groups suggest that general obstetric practice might be 
changing, but this does not explain the rising emergency CS rates in T2DM. In 
contrast to the Scottish population, it is noticeable that in England and Wales, 
emergency CS rates in women with diabetes are decreasing (37.6% in 2003/2004, 
30% in 2013) (CEMACH, 2005, National Diabetes in Pregnancy Audit Report 2013, 
2014).  This might reflect subtle changes in clinical guidelines where delivery is 
expected to occur sometime between 37+0 and 38+6 weeks of gestation in 
England and Wales, whilst Scottish guidelines recommend counselling otherwise 
well women with diabetes for delivery at or shortly after 38 weeks, and certainly 
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before 40 weeks gestation (Management of Diabetes (Scottish Intercollegiate 
Guidelines Network), 2017, Diabetes in Pregnancy (National Institute of Health 
and Care Excellence), 2015). Alternatively,  the increase in emergency CS may 
reflect a more adverse metabolic phenotype of the Scottish obstetric population 
with associated increased obstetric risk, factors which are not easily measured 
using these routine clinical data.  
Increasing LGA rates in T1DM appear similar to other UK nations (National 
Diabetes in Pregnancy Audit Report 2018, 2019).  Other nations have also 
reported increasing trends. In Sweden, the proportion of LGA babies was 
reported as 23%, 31% and 47% in successive reports of cohorts in their 
populations of 1982–1985, 1991–2003 and 1998–2007 (Metzger et al., 2010, 
Persson et al., 2009, Persson et al., 2011). Interestingly, this was not attributed 
to deteriorating glycaemic control, which was probably becoming tighter. Data 
on glycaemic control in my study were not standardised across the whole time 
period as all laboratories became DCCT-aligned at differing points pre-2006.  
This makes temporal assessment of glycaemic control difficult but anticipate 
that a deterioration would have been unlikely, as this was not observed in the 
previous surveys conducted in 1998/1999 and 2003/2004 (Kernaghan et al., 
2006, Penney et al., 2003). Smoking is also known to cause a reduction in 
birthweight, and thankfully has reduced significantly in pregnancy in our 
population over the time course of the study. Accounting for this may provide a 
very minor contribution to the rise in Z-scores in T1DM, but is clearly not a 
health behaviour to be recommended to pregnant mothers with diabetes. On the 
other hand, social deprivation as measured by the gross SIMD score, did not 
appear to influence birthweight in women with T1DM or T2DM. It is important to 
understand these health and social factors that may influence LGA, since LGA 
carries an increased risk of adverse perinatal outcomes (Persson et al., 2012).   
The main strengths of this study are its large scale and inclusivity of all 
pregnancies in Scotland, thereby avoiding selection bias. These routinely 
collected clinical data used are subject to regular quality assurance checks, and 
proven to be of both high quality and accuracy. Registration of individuals into 
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SCI-Diabetes occurred in the various Scottish health boards between 2003 and 
2006, including an upload of previously held electronic clinical and biochemical 
records on current patients in those years. Women who delivered prior to  2003 
and subsequently left Scotland may not have had their data entered on SCI-
Diabetes and thus may have not been included in this study. This is likely to 
represent very few women.  The data used in this study appear robust when 
compared with previous national paper audits.  Only a slightly higher number of 
deliveries were ascertained in 2003/2004 than from the previous paper audit for 
that time period (172 vs 165 deliveries respectively) (Kernaghan et al., 2006), 
and 96% of deliveries ascertained compared with the 1998/1999 paper audit 
(Penney et al., 2003). It would appear safe to assume that the population of 
women with diabetes is relatively stable, and that ascertainment is successful. 
The development of similar national audits, most notably in England and Wales, 
which included 86% of consultant-led obstetric units in 2013, is welcome as it 
allows meaningful comparisons of outcomes between countries (National 
Diabetes in Pregnancy Audit Report 2013, 2014).  This allows us the opportunity 
to learn from different approaches and models of care.   
Results from the previous Scottish surveys reported a higher Z-score in T1DM 
(1.64 in 2003/2004 in the previous paper survey compared with 1.34 for that 
year in my data). All data are provided in a pseudonymised format with 
restrictions on reporting case numbers where n is less than 5. This is to protect 
patient anonymity and confidentiality but also means I cannot directly compare 
inclusion in the previous surveys case by case. The difference in Z-score between 
the previously published data and mine is likely to reflect the standard used. 
The previous national surveys used reference data on births from a single centre 
in Aberdeen between 1979–1983, whereas the present study used a 
contemporaneous, whole Scottish population standard (Kernaghan et al., 2006).   
Pseudonymised data also limit any retrospective identification and analysis of 
case records, and so any data inclusion is restricted to information electronically 
captured within the SMR02 and SCI-Diabetes datasets. However, it is major 
strength to use these routine clinical records in that it avoids under-reporting of 
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adverse outcomes by individual units, and the reporting of outcomes such as 
weight, delivery method and gestational age is known to be robust. However, it 
does not allow measurement of aspects of care that have previously been 
assessed in paper surveys. Factors such as attendance at prepregnancy clinics 
are not recorded, detailed information on congenital anomalies and important 
perinatal outcomes such as neonatal intensive care admissions are lacking. 
Prenatal glycaemic control has previously been shown to be unchanged between 
1998/1999 and 2002/2003 and is suboptimal, with only 54% of women having 
documented preconceptual HbA1c values, and with average levels 30% above 
normal (Kernaghan et al., 2006). It seems likely that preconceptual preparation 
remained suboptimal in this cohort across the study period.  Data from England 
and Wales suggest only 1 in 8 women with pregestational diabetes have 
optimised diabetes care preconceptually (National Diabetes in Pregnancy Audit 
Report 2018, 2019). Inadequate preparation for pregnancy may lead to higher 
rates of congenital malformation and pregnancy loss. It would also be of interest 
to be able to account for other maternal factors such as gestational weight gain, 
which may impact infant growth and placental function.  Reliable data on 
hypertensive disorders of pregnancy would also be of interest. 
These data have shown that pregnancy for women with diabetes remains high 
risk, and much is still to be understood regarding causes and effective 
interventions for adverse outcomes. As has been shown for other aspects of 
diabetes care (Mcknight et al., 2015), comparison of rates of complications 
across different countries and healthcare systems offers an important 
opportunity to understand the potential for improvement both in Scotland, and 
on a wider international level. This includes understanding ways to improve pre-
pregnancy care, defining and achieving optimal glycaemic control during 
pregnancy and sharing knowledge of good obstetric practice to reduce risk.  
Further exploration of specific risk factors and their contribution to adverse 
pregnancy outcomes in diabetes is warranted before meaningful policy 
development can occur.  
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4 Chapter 4:  Stillbirth and associated risk factors 
in pregnancy complicated by diabetes 
The work within this chapter has been published in Diabetologia, Oct 2019.  
61(10):1938-1947 (Mackin et al., 2019) 
4.1 Introduction 
I have shown in the last chapter, mothers with pregestational diabetes are at 4–
5-fold increased risk of stillbirth, and that rates are not improving with time in 
Scotland (Mackin et al., 2018).  This data compares similarly to some other 
populations where stillbirth rates in diabetes remain static in recent years (Feig 
et al., 2014), but contrasts to the decreasing stillbirth rates seen in the Scottish 
obstetric population without diabetes. Maternal obesity, advanced maternal age 
and smoking are recognised as important modifiable risk factors for stillbirth in 
the general obstetric population (Gardosi et al., 2013, Flenady et al., 2011). 
Fetal growth is also important, with growth-restricted pregnancies having the 
highest risk (Gardosi et al., 2013). This knowledge comes from large studies in 
the general obstetric population but studies specific to risk of stillbirth in 
diabetes are more limited. Suboptimal maternal blood glucose levels even at 
minimal levels, presence of microvascular complications and poor preparation 
for pregnancy are all associated with stillbirth (Lauenborg et al., 2003, Tennant 
et al., 2014, Murphy et al., 2021). Other traditional risk factors seen in the 
general obstetric population are less well documented in the population with 
diabetes. Prevention of stillbirth underpins part of the clinical rationale for 
increased obstetric intervention in diabetes, particularly around timing of 
delivery. However, there is a distinct lack of good predictive models to identify 
impending stillbirth risk, and so obstetricians are often required to assess 
presence of known risk factors to justify earlier delivery in women. In many 
cases, earlier delivery is appropriate but the benefits can be negated by 
increased risks of neonatal morbidity as a result of premature delivery 
(Stutchfield et al., 2005). The aim of this study was to define the maternal and 
fetal characteristics associated with stillbirth in pregnancy complicated by 
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diabetes, including regional variation in outcomes and timing of delivery in such 
pregnancies.  This would allow us a better understanding of the pregnancy 
phenotype at risk and inform discussion around improved health strategies to 
better detect such pregnancies and offer them appropriate intervention.   
4.2  Methods 
Maternal and delivery characteristics in pregnancies complicated by diabetes 
that ended in stillbirth were compared with those who ended in livebirth. 
Similar to chapter 3 methodology, data from maternity records in SMR02 
database were linked to the national diabetes database SCI-Diabetes and is 
described in detail in chapter 2.1.  
Episodes that resulted in the delivery of an infant at or beyond 24 weeks of 
gestation to mothers with pre-existing T1DM or T2DM from 1 April 1998 to 30 
June 2016 were identified. Analysis was restricted to singleton births only. 
4.2.1 Statistical analysis 
Crude stillbirth rates are presented and when analysed for any given gestational 
age they are presented with a denominator of continuing pregnancies at that 
particular gestation.  
Risk factors and pregnancy outcomes are presented according to diabetes 
diagnosis for those in stillbirth and livebirth groups as means and SDs, or 
frequencies, as appropriate. Comparison of risk factors and outcomes between 
groups was assessed using a generalised mixed model with a term for the mother 
incorporated as a random effect.  
Differences in outcomes between health board and hospital unit size were 
analysed using logistic regression or general linear model with additional terms 
for year of delivery, deprivation score, maternal age, smoking and diabetes 
duration as appropriate. Due to low absolute numbers, effect of health board 
area of delivery and unit size on stillbirth rates was calculated from data 
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combining T1DM and T2DM deliveries together but including a term for type of 
diabetes in the model.  
4.3 Results 
There were 5621 pregnancies in mothers with diabetes, of which 229 were 
excluded for reasons including missing gestational age at delivery (n = 7), missing 
sex of infant (n = 3), delivery before 24 weeks of gestation (n = 5), diabetes 
diagnosis other than T1DM or T2DM (n = 145) or twin pregnancy (n = 74). 
Exclusions could have been in more than one category. 
The remaining singleton babies included 3778 infants born to 2582 mothers with 
T1DM and 1614 infants born to 1265 mothers with T2DM.  Unsurprisingly stillbirth 
rates were similar to those in the previous study at 16.1 per 1000 births (95% CI 
12.4, 20.8) in T1DM (n = 61) and 22.9 per 1000 births (95% CI 16.4, 31.8) in T2DM 
(n = 37).  
4.3.1 Type 1 diabetes 
Table 4.1 shows maternal and infant characteristics for pregnancies complicated 
by T1DM according to live and stillbirth outcomes. Mean maternal age, parity, 
maternal smoking rates and deprivation scores were similar in mothers 
regardless of whether the pregnancy ended in stillbirth or livebirth. Mothers who 
experienced a stillbirth had a slightly lower BMI and lower duration of diabetes 







Table 4.1: Maternal and infant characteristics in mothers with T1DM according to vital status 
of infant 
 Type 1 diabetes (n=3778 babies to 2582 mothers) 
 Stillbirth (n=61) Livebirth (n=3717) 
Maternal age at delivery, 
years (SD) 
29.1 (5.3) 29.8 (5.7) 
SIMD score (SD) 25.4 (16.4) 23.5 (17.1) 
Duration of diabetes, years 
(SD) 
11.4 (9.2)* † 14.1 (8.4) 
Nulliparous 55.7% 50.0% 
Maternal Smoking 25.5% 20.4% 
Pre-pregnancy maternal BMI 
(SD) 
24.8 (4.9) * † 26.3 (4.9) 
% Preconception HbA1c 
below 53 mmol/mol (7%) (n)a 
7.9%* (3 of 38) 20.0% (438 of 2236) 
Male fetus 54.1% 49.4% 
Gestational age delivery, 
weeks (SD) 
33.8 (4.1) *** 36.6 (2.2) 
Birth weight Z-score (SD) 1.38 (1.69) 1.37 (1.30) 
Values are presented as % of group, or mean + SD.  
*p<0.05, **p<0.01, ***p<0.001 for stillbirth versus livebirth by, χ² or t-test as appropriate. (a by 
Fishers exact test) 
† p<0.05 in general linear model for stillbirth versus livebirth 
Missing values (n): Parity: 40; Maternal smoking: 294; Pre-pregnancy BMI: 1302; preconception 
HbA1c: 1427; birth weight Z-score: 50. 
 
4.3.1.1 Glycaemia in mothers with type 1 diabetes 
HbA1c measurements in each trimester and the pre-pregnancy stages were 
available in SCI-diabetes for 50-60% of cases.  Stillbirth rates were no different 
in mothers who had a prepregnancy HbA1c measured compared to those without 
a measure (1.6% in both groups, p = 0.9).  This was despite higher deprivation 
scores (25.0+17.6 versus 22.6+16.7, p<0.001) and higher maternal smoking rates 
(26.1% versus 17.0%) in those without a pre-pregnancy HbA1c measure.  
One in five women achieved pre-pregnancy glycaemic targets of <53 mmol/mol.  
Notably, there was a lower number of women achieving this target in the 
stillbirth group compared with the livebirth group (7.9% versus 20.0%, p<0.05). I 
then went on further to examine temporal trends in HbA1c across pregnancy and 
to compare the live and stillbirth groups.  Women who experienced a stillbirth 
had higher mean pre-pregnancy HbA1c (11 mmol/mol higher) than those 
pregnancies resulting in a livebirth (p = 0.0002). Whilst both groups improved 
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their HbA1c across successive trimesters, mothers who had a stillborn infant 
maintained a similar level of hyperglycaemia relative to their liveborn group 




Figure 4.1: Mean HbA1c in mothers with T1DM at each stage of pregnancy according to infant 
vital status at birth 
Mean maternal HbA1c at each stage of pregnancy is demonstrated for the mothers who delivered 
a liveborn infant (blue diamond) and the mothers who delivered a stillborn infant (red diamond).  
Error bars demonstrate the corresponding SD.  
***p<0.001 for stillbirth versus livebirth for that pregnancy stage by t-test  
 
Number of available HbA1c values:  
pre-pregnancy: 2313 (62%) livebirths and 38 (63%) stillbirths; 1st trimester: 2156 (58%) livebirths 
and 30 (49%) stillbirths; 2nd trimester: 2119 (57%) livebirths and 29 (48%) stillbirths; 3rd trimester: 
1933 (52%) livebirths and 27 (44%) stillbirths 
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Mothers who experienced a stillbirth had consistently higher mean HbA1c values 
from pre-pregnancy and spanning each trimester compared to the livebirth 
group.  Importantly, neither group of women managed to achieve a normal 
HbA1c (<48 mmol/mol) and only the livebirth group managed to achieve <53 
mmol/mol during pregnancy (in the second and third trimesters ). 
 
4.3.1.2 Type 1 diabetes and timing of delivery in relation to stillbirth 
In the T1DM group, stillborn infants were born 2.8 weeks earlier than liveborn 
infants (as shown in table 4.1). Timing of delivery of a stillborn infant was used a 
proxy for estimating gestational age at which stillbirth occurred. Stillbirths 
occurred across a wide range of gestations between 24 and 38 weeks.  Almost 
40% of stillbirths were delivered at or beyond 37 weeks as shown in figure 4.2, 
whilst 63% of livebirths were delivered at term.  
When expressed specific to each week of pregnancy, stillbirth rates in T1DM 
peaked in the 37th and 38th weeks at 5.1 (95% CI 2.8, 9.1) and 7.0 (95% CI 3.7, 
12.9) per 1,000 ongoing pregnancies at that gestation respectively.  Figure 4.2 
shows stillbirth rates according to gestational age, with corresponding numbers 
of livebirths for that particular gestation. There were no stillbirths after 
38 weeks, and only 11% of all deliveries occurred beyond this likely reflecting 





Figure 4.2: Stillbirth rate (per 1,000 ongoing pregnancies) and corresponding number of 
liveborn deliveries according to gestational week of delivery in T1DM  
This figure shows the stillbirth rate at each gestational week expressed per 1,000 ongoing 
pregnancies for that particular week of gestation (x-axis) in mothers with T1DM.  The red bars 
show the crude stillbirth rate for that gestational week with the primary y-axis (left) quantifying 
the rate.  The blue line demonstrates the absolute number of liveborn deliveries occurring at 
each gestational week, for which the secondary y axis (right) is used for quantification.  
 
4.3.1.3 Infant birthweight and stillbirth risk in pregnancy complicated by type 
1 diabetes 
As demonstrated in table 4.1, stillborn infants had similar corrected birthweights 
to liveborn infants (birthweight Z-scores 1.38 and 1.37 respectively despite 
earlier gestation at delivery. Table 4.2 categorises infants according to 
birthweight centile categories.  Half of infants (52% combined live and stillborn) 
had birthweights in the LGA category, and of these, the vast majority (78%) were 
above the 95th centile.  
When compared against appropriate for gestational age infants (10-90th centile), 
there was a significant effect of birthweight centile category on stillbirth risk, 
particularly in those born small for gestational age (<10th centile)  who had a 6- 


















































































Table 4.2: Stillbirth prevalence according to birthweight centile category in infants born to 
mothers with T1DM 
 Birthweight centile (total n within category) 
 








6.9% (5) 1.2% (20) 1.7% (34) 1.7% (26) 
% livebirth 
(n) 
93.1% (67) 98.8% (1685) 98.3% (1917) 98.3% (1501) 
Odds ratio 
(95% CI) 
6.3 (2.3-17.3) REF 1.5 (0.9-2.6) 1.5 (0.8-2.6) 
Missing birthweight values: n=50 
 
 
4.3.2 Type 2 diabetes 
Table 4.3 shows maternal and infant characteristics for those pregnancies 
complicated by T2DM.  Overall, the average BMI in mothers with T2DM fell 
within the obese range (>30kg/m2). For mothers in the stillbirth group, mean 
pre-pregnancy BMI was significantly higher than those mothers who delivered 
live infants (38.2+6.4 versus 33.2+5.6 respectively, p=0.01).  The stillborn group 
had lower rates of primiparous mothers compared with liveborn (16.7% versus 
31.3%) but this did not reach statistical significance. There were no significant 
differences in any of the other measured maternal demographics.  
Interestingly, there was a significantly higher rate of male infants in the stillborn 








Table 4.3: Maternal and infant characteristics in mothers with T2DM according to vital status 
of infant 
 Type 2 diabetes (n=1614 babies to 1265 mothers) 
 
 Stillbirth (n=37) Livebirth (n=1577) 
Maternal age at delivery, 
years (SD) 
33.8 (6.0) 33.2 (5.6) 
SIMD score (SD) 28.4 (19.1) 28.0 (18.1) 
Duration of diabetes, years 
(SD) 
4.4 (4.0) 4.2 (4.1) 
Nulliparous 16.7% 31.3% 
Maternal Smoking 30.3% 21.0% 
Pre-pregnancy maternal BMI 
(SD) 
38.2 (6.4)* † 33.9 (7.1) 
% Preconception HbA1c 
below 53 mmol/mol (7%) (n)a 
23.5% (4 of 14) 47.6% (47.6) 
Male fetus 81.1%*** 50.5% 
Gestational age delivery, 
weeks (SD) 
33.7 (4.7) *** 37.2 (2.3) 
Birth weight Z-score (SD) 1.08 (1.8) 0.8 (1.4) 
Values are presented as % of group, or mean + SD.  
*p<0.05, **p<0.01, ***p<0.001 for stillbirth versus livebirth by, χ² or t-test as appropriate. (a by 
Fishers exact test) 
† p<0.05 in general linear model for stillbirth versus livebirth 
Missing values (n): Parity: 13; Maternal smoking: 128; Pre-pregnancy BMI: 776; preconception 
HbA1c: 801; birth weight Z-score: 14. 
 
4.3.2.1 Glycaemia in mothers with type 2 diabetes 
Similar to the population with T2DM, HbA1c measurements were only available 
for a proportion of the population.  Approximately 50% of mothers in the pre-
pregnancy stage and in each trimester had an available HbA1c measure. Again, 
the stillbirth rates were similar regardless of whether women had a pre-
pregnancy HbA1c measure - 2.1% versus 2.5% stillbirth rates for those with and 
without HbA1c (p=0.6). Higher proportions of women with T2DM achieved the 
target pre-pregnancy HbA1c of <53 mmol/mol compared with those with T1DM in 
both the live and stillborn groups.  However, similar to the pattern seen in the 
T1DM population, those who experienced a stillbirth had lower rates of achieving 
this target compared with the livebirth group, albeit, not statistically significant 
(table 4.3).  
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Figure 4.3 shows the mean HbA1c across each stage of pregnancy for those who 
had live and stillborn infants. There was no association between gestational 
glycaemia and stillbirth. In contrast, preconception HbA1c was 12 mmol/mol 
higher in the stillbirth group (p = 0.01). 
 
Figure 4.3: Mean HbA1c in mothers with T2DM at each stage of pregnancy according to infant 
vital status at birth 
Mean maternal HbA1c at each stage of pregnancy is demonstrated for the mothers who delivered 
a liveborn infant (blue diamond) and the mothers who delivered a stillborn infant (red diamond).  
Error bars demonstrate the corresponding SD.  
*p<0.05  for stillbirth versus livebirth for that pregnancy stage by t-test  
Number of available HbA1c values:  
pre-pregnancy: 796 (50%) livebirths and 17 (46%) stillbirths; 1st trimester: 785 (50%) livebirths and 
15 (41%) stillbirths;  2nd trimester: 775 (49%) livebirths and 16 (43%) stillbirths; 782 (50%) livebirths 
and 11 (30%) stillbirths. 
 
 
4.3.2.2 Type 2 diabetes and timing of delivery in relation to stillbirth 
In T2DM stillborn infants were delivered over 3 weeks earlier than liveborn 
infants (p < 0.0001).  Figure 4.4 demonstrates the stillbirth rate and absolute 
number of livebirths according to gestational age at delivery.  Similar to T1DM, 
stillbirths occurred across a wide range of gestations from 24 to 39 weeks. Two 
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thirds (68%) of stillbirths in T2DM occurred preterm (<37 weeks), and occurred at 
low frequency in any given gestational week. This compares to 24% of livebirths 
being delivered before 37 weeks. Stillbirth rates increased towards term, 
particularly from 36 weeks onwards and peaked in the 39th week at 9.3 (95% CI 




Figure 4.4:  Stillbirth rate (per 1,000 ongoing pregnancies) and corresponding number of 
liveborn deliveries according to gestational week of delivery in T2DM 
This figure shows the stillbirth rate at each gestational week expressed per 1,000 ongoing 
pregnancies for that particular week of gestation (x-axis) for mothers with T2DM.  The red bars 
show the crude stillbirth rate for that gestational week with the primary y-axis (left) quantifying 
the rate.  The blue line demonstrates the absolute number of liveborn deliveries occurring at 
each gestational week, for which the secondary y axis (right) is used for quantification.  
 
4.3.2.3 Infant birthweight and stillbirth risk in type 2 diabetes 
Table 4.4 categorises infants according to birthweight centiles.  The majority 
(60%) of infants born to mothers with T2DM had birthweights appropriate for 


















































































Using the 10-90th centile group as a reference, stillbirth risk appeared highest in 
the small for gestational age babies (3-fold higher) but was also increased in 
those infants who had birthweights above the 95th centile (>2-fold increase) 
(p=0.04).  
Table 4.4: Stillbirth prevalence according to birthweight centile category in infants born to 
mothers with T2DM 
 Birthweight centile (total n within category) 
 








4.9% (4) 1.7% (16) 2.8% (16) 3.6% (15) 
% livebirth 
(n) 
95.1% (78) 98.3% (932) 97.2% (554) 96.4% (402) 
Odds ratio 
(95% CI) 
3.0 (1.0-9.2) REF 1.7 (0.8-3.4) 2.2 (1.1-4.4) 
Missing birthweight values: n=16 
 
 
4.3.3 The relationship of glycemia and maternal BMI to birthweight 
and stillbirth 
Given the association with birthweight and stillbirth, data relating to glycemia 
and its effects on birthweight in T1DM and T2DM where analysed.  Higher 
birthweights were associated with higher HbA1c in both populations.  Table 4.5 
reveals the mean birthweight Z-score for infants according to the combined pre-
pregnancy and third trimester HbA1c.  In T1DM, mean birthweight Z-scores were 
0.9 (0.12) SD higher than the reference population in the subgroup of mothers 
with HbA1c in the lowest quartiles for prepregnancy and third trimester HbA1c 
(<52 mmol/mol and <42 mmol/mol respectively).  This increased to a mean 
birthweight Z-score of 1.73 (0.09) for those who had HbA1c values in the highest 
quartiles (>76 mmol/mol pre-pregnancy and >56 mmol/mol in the third 
trimester).  
In T2DM, a similar pattern was observed.  Mothers who had HbA1c values in the 
lowest pre-pregnancy and third trimester quartiles delivered infants 0.39 (0.13) 
SD heavier than the background population, but for those in the highest 
quartiles, this increased to 1.79 (0.26 SD).   
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Table 4.5: Mean birthweight Z-score according to combined pre-pregnancy and third 
trimester HbA1c values in T1DM and T2DM 
  Type 1 diabetes 
 
Type 2 diabetes 
3rd trimester HbA1c quartile 3rd trimester HbA1c quartile 
 











































































Quartiles defined by HbA1c values from both T1DM and T2DM combined. 
Prepregnancy: 
 Quartile 1: <52 mmol/mol, Quartile 2:  >52 mmol/mol and < 63 mmol/mol, Quartile 3: > 63 
mmol/mol and < 76 mmol/mol, Quartile 4: > 76 mmol/mol 
Third trimester:  
Quartile 1: <42 mmol/mol, Quartile 2:  > 42mmol/mol and < 49 mmol/mol, Quartile 3: > 49 
mmol/mol and < 56 mmol/mol, Quartile 4: > 56 mmol/mol 
 
 
Univariate analysis suggested that higher HbA1c pre-pregnancy (OR 1.03 [95% CI 
1.01, 1.04]; p = 0.0003)  and in each trimester (OR 1.04 [95% CI 1.02, 1.05], 1.05 
[95% CI 1.03, 1.07] and 1.06 [95% CI 1.04, 1.08] in first, second and third 
trimesters, respectively; all p < 0.0001) were significantly associated with 
stillbirth. Multivariate analysis adjusted for maternal age, SIMD score and 
diabetes duration, showed that these effects remained for individual timepoints. 
However, when pre-pregnancy and third trimester HbA1c were added to the 
model (n=1382 for all variables), only third trimester HbA1c remained associated 
with stillbirth (OR 1.05 [95% CI 1.02, 1.08]; p=0.0008).  The effect from pre-




In univariate models, weaker effects were also seen from shorter diabetes 
duration (OR 0.96 [95% CI 0.93, 0.99]; p = 0.01) and lower maternal BMI (OR 0.92 
[95% CI 0.86, 0.99]; p = 0.04). 
In T2DM, univariate analysis revealed associations with stillbirth and higher BMI 
(OR 1.07 [95% CI 1.01, 1.14]; p=0,02) and higher pre-pregnancy HbA1c (OR 1.02 
[95% CI 1.00, 1.04]; p=0.016).  In contrast to T1DM, HbA1c at later stages of 
pregnancy did not have significant associations. The effects from BMI and pre-
pregnancy HbA1c remained in multivariate models adjusted for maternal age, 
SIMD score and diabetes duration. BMI appeared to have effects independent of 
the pre-pregnancy HbA1c with an OR 1.09 [95% CI 1.02-1.17],  p=0.01 when both 
terms added to this multivariate model. Pre-pregnancy HbA1c also remained to 
have a significant and independent effect on stillbirth risk (OR 1.03 [95% CI 1.01, 
1.05], p=0.006).  
 
4.3.4 Regional variation in birthweight, timing of delivery and 
stillbirth outcomes in pregnancy complicated by diabetes 
There were no significant differences in stillbirth rates by health board area of 
delivery (p = 0.60) or by delivering hospital unit size (p = 0.39). There were 
however observed regional differences in gestational age at delivery in both 
T1DM (range 33.4 ± 1.6 to 36.9 ± 0.2 weeks across all health boards, p < 0.0001) 
and T2DM (range 36.4 ± 0.3 to 37.8 ± 0.2 weeks across all health boards, 
p = 0.006).  In case of skew, the smaller health boards delivering <5 women with 
diabetes per annum were then excluded as described in chapter 2.1.6 and data 
reanalysed.  The range of gestational ages was more constricted using this 
method, but significant variation remained between health boards for both T1DM 
(range 36.1 ± 0.1 to 36.9 ± 0.2 weeks, p < 0.0001) and T2DM (range 36.5 ± 0.3 to 
37.8 ± 0.2 weeks, p = 0.007).  Figure 4.5 demonstrates gestational age at delivery 
according to anonymised health board regions. There was also an effect of 
hospital unit size on gestational age at delivery in T1DM, with the largest units 
delivering infants on average 4 days earlier than those delivering moderate 
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numbers of women with diabetes (10-19 per annum), p=0.02.  Similar effects 
were not seen in T2DM (figure 4.6). 
There was also significant regional variation across health boards in mean 
birthweight Z-scores in T2DM (range: 0.25 – 1.46, p<0.0001), as shown in figure 
4.7.  No statistically significant differences were seen in the T1DM population. 
Hospital unit size did not appear to have an effect on birthweight in T1DM or 
T2DM (p=0.2 for both in a model that included smoking, maternal age, year of 













Figure 4.5:  Mean gestational age at delivery of infants born to mothers with T1DM (panel A) 
and mothers with T2DM (panel B) according to health board area of delivery 
Panel A shows the mean gestational age at delivery in weeks (y axis) of infants born to mothers 
with T1DM according to the health board in which they delivered in (anonymised A-K on the  x 
axis). The same information relating to pregnancies complicated by T2DM is shown in panel B.  
The coloured diamond displays the mean gestational age, with corresponding error bars 
demonstrating the standard error of the mean. There was small but statistically significant 
variation across health boards in T1DM (36.1 ± 0.1 to 36.9 ± 0.2 weeks, p < 0.0001), with wider 
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Figure 4.6:  Mean gestational age at delivery to mothers with T1DM (panel A) and T2DM 
(panel B) according to the delivering obstetric unit size (expressed as the number of 
deliveries to mothers with diabetes per annum) 
Panel A shows the mean gestational age at delivery in weeks (y axis) of infants born to mothers 
with T1DM according to the size of the delivering obstetric unit.  The size of the delivering 
obstetric unit is expressed in categories according to the average number of deliveries per year 
that occur in women with diabetes at that particular unit (shown on the x axis). Panel B includes 
the same information for women with T2DM. The coloured diamond (blue for T1DM, red for 
T2DM) displays the mean gestational age, with corresponding error bars demonstrating the 
standard error of the mean. In T1DM, women were delivered on average 4 days earlier if 
delivered in the largest unit size (30-50 deliveries per annum) versus those units delivering 10-19 
diabetic pregnancies per annum (p=0.02). There was no statistical difference in average 
































Average number of deliveries per annum of mothers with diabetes 
in delivering obstetric unit
































Average number of deliveries per annum of mothers with diabetes 
in delivering obstetric unit







Figure 4.7:  Mean birthweight Z-score of infants born to mothers with T1DM (panel A) and 
mothers with T2DM (panel B) according to health board area of delivery 
Panel A shows the mean birthweight Z-scores (y axis) of infants born to mothers with T1DM 
according to the health board in which they delivered in (anonymised A-K on the  x axis).  The 
average birthweight was consistently higher than the reference population irrespective of 
health board in which delivery occurred, and statistically showed no difference.  Panel B 
shows the same mean birthweight Z-scores but for mothers with T2DM.  There was more 
regional variability in birthweight detected in the population with T2DM (p <0.0001), which 
may reflect different unmeasured comorbidity in regions, or differences in antenatal care and 
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In this study, I have explored risk factors for stillbirth in a large population of 
mothers with diabetes. The main finding is that maternal blood glucose level is 
the key modifiable risk factor for adverse perinatal outcomes, including 
stillbirth.  This is similar to findings from other smaller studies (Temple et al., 
2006, Tennant et al., 2014, Pedersen and Brandstrup, 1956) and very recent 
data from the England and Wales population that showed HbA1c> 6.5% in later 
pregnancy as a perinatal mortality risk factor in T1DM and T2DM (Murphy et al., 
2021). In T1DM, mothers who had a stillbirth demonstrated higher mean HbA1c 
levels across all stages of pregnancy compared with those who had livebirths, 
despite clear improvements in glycaemia across the course of pregnancy. 
However, there is considerable overlap in HbA1c values between live and 
stillbirth groups, making it difficult to define a level of glycaemia at which 
stillbirth risk critically increases. The pattern of glycaemia in women with T2DM 
in relation to stillbirth appears different.  Interestingly, pre-pregnancy HbA1c 
appeared a more important predictor here, and more unexpectedly with no 
independent association of HbA1c levels in later pregnancy. The number of 
stillbirths in this group is small, however and so these findings should be 
interpreted with caution. However, it highlights the importance of pre-
pregnancy counselling and metabolic optimisation for women with diabetes.  
This may be a particular area for clinical teams to focus on in T2DM, especially 
since  uptake of preconceptual counselling is generally reported as being lower 
than in T1DM (Macintosh et al., 2006). Taken together, strategies to improving 
blood glucose levels before and during pregnancy are clearly pivotal to 
improving outcomes.   
It was interesting that despite apparent better glycaemia, mothers with T2DM 
had higher stillbirth rates than those seen in the T1DM population.  Similar 
increased risk in T2DM has been reported in other populations (Roland et al., 
2005, Clausen et al., 2005). In this study, higher maternal BMI had a significant 
adverse association with stillbirth in T2DM. It is known from previous general 
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obstetric population studies that maternal obesity is an independent risk factor 
for stillbirth, in addition to other adversarial effects in pregnancy including 
preeclampsia, congenital anomalies and fetal overgrowth (Aune et al., 2014, Ray 
et al., 2001). Excessive gestational weight gain has also been linked with 
increased risk (Yang et al., 2017, Yao et al., 2017, Institute of Medicine, 2009).  
I would have been interested to explore this further, but SMR02 lacks 
standardised data relating to pregnancy weight gain. Other social factors have 
also been implicated in stillbirth risk from studies conducted in the general 
obstetric population. These have demonstrated advancing maternal age (Flenady 
et al., 2011), nulliparity, maternal smoking and social deprivation to confer 
additional risk (Flenady et al., 2011, Gardosi et al., 2013).  Data from 2014-2018 
in England and Wales population showed higher deprivation to be associated 
with perinatal mortality (Murphy et al., 2021). These social factors were not 
formally statistically significant in their effects on stillbirth in this study, but it 
would be wrong to conclude absolutely no effect on risk.  Overall, they are likely 
to contribute to wider maternal health and potentially impact access to or use 
of obstetric services, and therefore remain important to consider when 
developing strategies to improve outcomes. 
One of the limitations of this study, is that the exact causes of stillbirth in this 
population are not known. In diabetes, at least some cases will reflect 
underlying congenital anomaly, the risk of which is associated with HbA1c early 
in pregnancy. Current Scottish guidelines recommend women with diabetes 
achieve an HbA1c <53 mmol/mol three months before pregnancy, in order to 
reduce the anomaly risk (Management of Diabetes (Scottish Intercollegiate 
Guidelines Network), 2017).  Overall rates of women achieving target were 
disappointingly low in the Scottish cohort, and even lower for the stillbirth 
groups. However, in keeping with other studies, we would expect that most 
stillbirths were non-anomalous, and instead caused by metabolic effects on fetal 
growth and placental function (Rackham et al., 2009, Edwards et al., 2013). 
Future work linking the attributed cause of death from post-mortem and 
placental pathology with maternal antepartum metabolic markers is planned to 
explore aetiology further.  
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With this in mind, I was interested to know if fetal characteristics could help us 
predict those babies at risk of stillbirth.  General obstetric studies have shown 
that babies at extremes of growth centiles are at increased risk of stillbirth 
(Contag et al., 2016).  IUGR specifically has been identified as one of the 
strongest indicators of stillbirth risk, with risk increased 4.0-fold when IUGR 
detected antenatally, and 8.0-fold if undetected pre-delivery (Gardosi et al., 
2013). My data shows a similar risk profile in the population with diabetes with 
absolute risk of stillbirth highest in SGA infants.  This is most striking in the 
T1DM mothers, albeit numbers of SGA infants in this study were small (<2% of 
T1DM births, 5% T2DM). Babies born very LGA with birthweights above >95th 
centile were also at increased risk in T2DM, which reflects similarly to general 
obstetric population data. (Contag et al., 2016). This was less apparent in the 
T1DM group where a higher proportion (40%) of infants were born in this weight 
category.  Routine obstetric care for women with diabetes recommends regular 
growth scans from 28 weeks of gestation to help identify at-risk pregnancies and 
allow decision-making around earlier delivery where appropriate (Management 
of Diabetes (Scottish Intercollegiate Guidelines Network), 2017). Given this likely 
pattern of obstetric intervention in the Scottish population, similar rates of 
stillbirth seen in higher birthweight infants may represent some success of these 
policies.  It is also noticeable that stillborn babies had similar adjusted 
birthweights to liveborn infants (both T1DM and T2DM).  In the datasets used, 
birthweight was the only available standardised measure of growth.  
Specifically, data from antenatal growth assessment were lacking and as a 
result, using birthweight as an indicator of fetal growth, may have significantly 
underestimated growth in the stillbirth group in which it may have stopped or 
faltered pre-delivery. It is widely accepted that fetal overgrowth relates to 
maternal hyperglycaemia in later pregnancy. However, it is interesting that even 
in the subgroup of women with HbA1c in the lowest quartiles pre-pregnancy 
(<52 mmol/mol) and in the third trimester (<42 mmol/mol), birthweight 
remained considerably higher in pregnancy complicated by diabetes compared to 
the general obstetric population.   
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Optimal timing of delivery in pregestational diabetes is debated and practice 
varies internationally. In Scotland, routine delivery is recommended between 38 
and 40 weeks, while the American College of Obstetricians and Gynaecologists 
suggests delivery in the 39th week (Pregestational Diabetes (American College of 
Obstetricians and Gynaecologists), 2018, Management of Diabetes (Scottish 
Intercollegiate Guidelines Network), 2017).  In England and Wales, the newest 
NICE guidelines suggest earlier delivery during the 37th or 38th week (Diabetes 
in Pregnancy (National Institute for Health and Care Excellence), 2015). All 
guidelines recommend individualised assessment for expedited delivery in those 
with additional complications or obstetric risk. As mentioned previously, part of 
the rationale to earlier delivery involves avoidance of stillbirth in at-risk 
pregnancy. In two prior series from the UK, stillbirth risk in women with diabetes 
compared with the background population was increased across all stages of 
pregnancy, but significantly so to at least fivefold at term (Tennant et al., 2014, 
Holman et al., 2014). In my data, a third of the stillbirths occurred at term, the 
majority of which would be expected to be antepartum rather than intrapartum. 
While it is facile to observe that earlier delivery might have avoided these, 
decisions to expedite delivery have to be balanced against increased risk of 
complications such as neonatal RDS at earlier gestations (Stutchfield et al., 
2005).  Using data from the general obstetric populations, I could speculate that 
routine delivery of this study population at 37 weeks with expectant 
glucocorticoid administration for fetal lung maturation, could have potentially 
prevented 22 stillbirths in T1DM (resulting in stillbirth rate 10.3 per 1,000 births) 
with resultant 142 cases of RDS.  In T2DM, there may have been prevention of 12 
stillbirths (resulting in stillbirth rate 15.5 per 1,000 births) but with 72 cases of 
RDS. For some, this may seem an acceptable balance of risk, however, the risk 
of neonatal morbidity would need to be more formally explored before 
recommendations for optimal timing of delivery could made, especially 
considering the very low representation of mothers with diabetes in current 
studies (Stutchfield et al., 2005).  Furthermore, RDS is up to five times more 
common in pregnancy complicated by diabetes and surfactant production is 
impaired with hyperglycaemia (Robert et al., 1976, Yildiz Atar et al., 2021).  It 
may also be that mothers with diabetes who are able to achieve near 
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normoglycemia have a different balance of risk compared to those who have 
greater glucose excursions. Whilst further research in this area is warranted, it is 
also important to note that the majority of stillbirths in diabetes are occurring 
preterm.  In these cases, routine earlier delivery would cause harm and be less 
likely to prevent neonatal morbidity, at least until more accurate methods of 
predicting risk become available. 
Studies in other UK nations have suggested significant regional variation in 
delivery of care to women with diabetes in pregnancy (Murphy et al., 2017). In 
Scotland, almost all care is organised in multidisciplinary clinics based in 
secondary (hospital) care. While units are of differing sizes, stillbirth rates do 
not appear significantly different. This is reassuring, although the study is 
underpowered to detect this in a meaningful and robust way.  There was notable 
variation in other important obstetric outcome measures, namely gestational 
age at delivery and birthweight.  Some of this may reflect migration of complex 
cases to larger centres for delivery, but may also indicate regional variation in 
obstetric antenatal care and delivery policies.  
Finally, it was unexpected that stillborn infants were significantly more likely to 
be male in the T2DM population.  It has previously been acknowledged in general 
obstetric studies that male foetuses are more vulnerable in utero, but mortality 
risk is only reported as moderately increased by 10 % (Mondal et al., 2014). Yet, 
in this study, the crude stillbirth rates are fourfold higher in male infants than in 
females for T2DM (36.3 per 1000 male births vs 8.8 per 1000 female births). Male 
fetuses have higher metabolic demand in the later stages of pregnancy and have 
smaller placentas than females, which may mean less compensatory reserve 
(Dearden et al., 2018, Eriksson et al., 2010). The cumulative effects of a 
vulnerable placenta at risk of vasculopathy due to diabetes, higher metabolic 
demand of the male infant, coupled with hyperglycaemia-driven fetal 
overgrowth might explain the observed increased risk. There may also be 
detrimental effects on placental function from hyperglycaemia, a mechanism 
which will be explored later in this thesis (chapter 6).  
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There are major strengths from this study. Mainly, it includes whole-population 
data that is largely free from selection bias and has been shown in quality 
assurance to be robust.  However, it is observational data and does have 
inherent shortcomings. The population being investigated will have undergone 
obstetric intervention, such as earlier delivery, which may impact on risk factor 
estimation at specific timepoints.  Data on glycaemia is also only available in 50-
60% of cases, and so interpretation of available data may not be applicable to 
the remaining 40% of the population in whom data was not measured.  Also, 
HbA1c measures after 2006–2008, would have been from DCCT-aligned 
laboratories but prior to these dates may have shown regional laboratory 
variation. This study used HbA1c as measure of glycemia, but it is important to 
acknowledge that it is not routinely recommended to be measured in later 
pregnancy, although many clinicians do. In later pregnancy, it becomes a less 
robust correlate of maternal blood glucose level and can often underestimate 
glycaemia (Management of Diabetes (Scottish Intercollegiate Guidelines 
Network), 2017, Hughes et al., 2016). However, despite its limitations, HbA1c 
remains of some value even in later pregnancy, and the glycaemia results in this 
study complement others (Edwards et al., 2013, Lauenborg et al., 2003, 
Mathiesen et al., 2011, Mathiesen, 2016).  
It would also have been interesting to include information on microvascular 
complications but standardised data relating to these were not readily available 
within the database.  Nephropathy has previously been recognised to increase 
the risk of both IUGR and stillbirth (Lauenborg et al., 2003, Ekbom et al., 2001). 
Methodologies for detecting microvascular renal disease are numerous (e.g., 
urinary albumin creatinine ratio, urine albumin concentration etc) and changed 
over the audit period in our population, limiting the ability to accurately report 
prevalence. Aspects of prepregnancy counselling uptake such as high dose folic 
acid supplementation (to prevent neural tube anomalies) would also have been 
of interest, as would have exposure to potentially teratogenic drugs.   Robust 
prescription information however was not available for most years of the study. 
Finally, preeclampsia is a risk factor for IUGR and stillbirth (Persson et al., 2009, 
Duley, 2009, Dunne et al., 2003). Preeclampsia is known to be underreported in 
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these routine data, and consistent with this it affects 6.1% of our T1DM and 4.5% 
of our T2DM cohorts, which is lower than other population estimates (Roberts et 
al., 2011)[44]. 
In conclusion, maternal glycaemia and BMI are the main modifiable risk factors 
associated with stillbirth in pregnancy complicated by diabetes. However, there 
is significant overlap in values between live and stillborn groups making it 
difficult to predict exactly which pregnancies are at risk. Achievement of near 
normoglycaemia is likely key to minimising risk, and methods of supporting 
women to achieve this in pregnancy are important.  Programmes designed to 
support maternal weight optimisation pre-pregnancy may also help to reduce 
risk but can be challenging to implement successfully. In my opinion, public 
health programmes should focus on cardiometabolic health in women of 
childbearing age, as a potential strategy to improve both pregnancy outcomes 
and longer-term health of mothers and their offspring.  Better prediction 
methods of at-risk pregnancies are crucial to improving outcomes, but until this 
becomes available, earlier delivery may be an attractive option to reduce term 













5 Chapter 5: Maternal vascular function in 
pregnancy complicated by diabetes     
5.1 Introduction 
Given the notable relationship of higher maternal glycaemia with adverse 
pregnancy outcomes in the population with T1DM and T2DM, it seems pertinent 
to explore maternal and placental physiology in pregnancy complicated by 
diabetes.  Numerous studies have explored physiological differences in adverse 
outcome pregnancy, but importantly, few studies involve, or are specific to 
mothers with diabetes.     
In healthy pregnancy, various maternal vascular adaptations occur from early 
gestation to support the development and optimal perfusion of the 
uteroplacental circulation, which in turn supports growth of the developing 
fetus.  Physiological changes in pregnancy are discussed in more detail in 
chapter 1.2 but in summary, these include a large expansion of maternal 
circulatory volume accompanied by significant systemic and even larger uterine 
vasodilation.  This in turn increases cardiac output and maximises uteroplacental 
flow (Boeldt and Bird, 2017, Sanghavi and Rutherford, 2014).  Maternal 
vasodilatation is of particular importance, and is mediated through several 
complex endocrine and neuronal pathways.  There are ongoing controversies in 
exact mechanisms controlling maternal vascular tone during pregnancy, but 
endothelial function appears to play some role (Dørup et al., 1999).  Notably, a 
progressive increase in endothelium-dependent flow-mediated vasodilatation is 
observed in healthy pregnancy compared to non-pregnant women (Dørup et al., 
1999, Lopes Van Balen et al., 2017, Quinton et al., 2007).  FMD brachial artery is 
a non-invasive measure of endothelium-dependent vasodilatation induced by 
intraluminal hyperaemia post-ischaemia in macrovascular beds.  Coronary 
epicardial vasoreactivity to endothelium-dependent agonists infused during 
coronary angiography is the “gold standard” method to assess endothelial 
function but is undesirable due to its invasive nature.  This is particularly true in 
pregnancy where non-invasive tests are preferred.  FMD brachial artery 
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correlates well with coronary epicardial vasoreactivity and is the most widely 
used non-invasive test for endothelial function (Corretti et al., 2002, Flammer et 
al., 2012).  Studies have also utilised a variety of other endothelial measures 
such as digital pulse wave tonometry post-ischaemia and circulating endothelial 
biomarkers.  
Pregnancies with adverse outcomes, such as in preeclampsia and PIH have 
reduced endothelial function compared to healthy pregnancy (Roberts and 
Redman, 1993, Knock and Poston, 1996, Fitzgerald et al., 1987).  The evidence 
base is strong for pregnancies complicated by preeclampsia, but other 
complications of pregnancy have also been studied. Women who develop 
preeclampsia have been shown to have reduced FMD brachial artery in the 
second and third trimesters compared with healthy pregnant controls (De 
Resende Guimarães et al., 2014, Savvidou et al., 2003), and importantly, have 
been shown to have endothelial dysfunction that predates the clinical syndrome 
(Savvidou et al., 2003, Weissgerber et al., 2016).  Women who develop PIH have 
also been shown to a have a smaller rise in urinary metabolites of the 
endothelially derived vasodilator prostacyclin during pregnancy, suggesting a 
role of altered endothelial function in PIH (Fitzgerald et al., 1987).  Growth 
restricted and placental insufficiency pregnancies have been less studied.  One 
group reported increased expression of the endogenous NOS inhibitor, 
asymmetric dimethylarginine in pregnancies that showed ultrasound evidence of 
increased placental vascular resistance (Savvidou et al., 2003), and we know 
from histopathological studies that placental vascular insufficiency is extremely 
common in pregestational diabetes  (Evers et al., 2003).  Another study showed 
reduced maternal vasodilatory capacity (endothelium-dependent and -
independent) in growth restricted pregnancies (Savvidou et al., 2003).   Many 
studies exploring mechanisms of adverse pregnancy outcome exclude women 
with diabetes, due to potential confounding effects on vascular function. Yet, 
we know that women who have diabetes have significantly higher rates of these 
disorders.  Preeclampsia affects approximately 10-20% of pregnancies 
complicated by diabetes, rising to as much as 64% in those with diabetes 
complications such as severe microangiopathy (Ekbom et al., 2001, Weissgerber 
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and Mudd, 2015).  We also learned from the landmark HAPO study that there is a 
linear relationship of maternal glycaemia with risk of preeclampsia, even at 
apparently mild hyperglycaemia levels (Metzger et al., 2008).  Taken together, it 
would seem plausible that hyperglycaemia in pregnancy may assert effects on 
maternal vasculature that increase the risk of cardiovascular complications in 
pregnancy, and has the potential to affect uteroplacental perfusion. 
There is a wealth of evidence showing longstanding diabetes, and specifically 
toxic effects of hyperglycaemia, to be associated with endothelial dysfunction 
and subsequent cardiovascular disease (Avogaro et al., 2011).  Research into the 
effects of diabetes and hyperglycaemia on endothelium during pregnancy is 
scarcer with conflicting results amongst the few that do exist. Ramsay et al 
showed that in pregnancy complicated by T1DM, microvascular vasodilatory 
capacity was diminished in response to endothelium-dependent (acetylcholine) 
and endothelium-independent (sodium nitroprusside) agonists, and importantly 
the difference in acetylcholine response was attenuated when adjusted for 
HbA1c suggesting that glucose had detrimental effects on endothelium (Ramsay 
et al., 2003).  In contrast, another study by Ang et al showed no difference in 
endothelial reactivity of maternal subcutaneous adipose arteries when exposed 
to vasodilating agonists during wire myography experiments (Ang et al., 2002). In 
GDM the studies are similarly conflicting. One small study looking at temporal 
trends of FMD brachial artery across pregnancy complicated by GDM showed 
women with GDM to have similar FMD values to non-diabetic pregnant controls 
(Garg et al., 2017).  This differs to published work by Guimaraes et al which 
demonstrated women with preeclampsia or GDM had significantly lower FMD% 
values than healthy controls, albeit this included a wide range of gestations for 
all groups (23-39 weeks) (De Resende Guimarães et al., 2014).  
We also know that circulating placentally-derived angiogenic factors, such as 
sFlt1, PlGF and TNF-α are disrupted in hypertensive and growth restricted 
pregnancies (Zeisler et al., 2016, Saarelainen et al., 2012, Åsvold et al., 2011).  
Specifically, the balance between pro-angiogenic factors such as PlGF, and anti-
angiogenic peptides such as sFlt-1 appear to be an important determinant of 
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placental vascular health, and subsequent pregnancy outcomes.  Low PlGF 
values (<5th centile measured using Triage™ system) has high sensitivity for 
predicting imminent delivery due to preeclampsia in women presenting with 
suggestive symptoms presenting before 35 weeks gestation, and was also found 
to be associated with very growth restricted pregnancy (Chappell et al., 2013). A 
further landmark preeclampsia study showed sFlt1:PlGF ratio <38, was useful in 
predicting absence of the condition (Zeisler et al., 2016). Again, these studies 
include small numbers of women with diabetes. The UPBEAT research 
consortium specifically explored the explored GDM pregnancy and suggested that 
PlGF may not be as reliable in prediction of preeclampsia in obese GDM women 
versus obese non-GDM (Vieira et al., 2018).  However, PlGF was measured at a 
much earlier time point in pregnancy.  They suggest increased proinflammatory 
markers in diabetic pregnancy as an alternative mechanism of preeclampsia 
development. This work has therefore also included exploration of these 
angiogenic biomarkers and inflammatory cytokines, to determine if they are 
dysregulated in diabetic pregnancy (irrespective of preeclampsia development), 
and any association with altered vascular function in hyperglycaemic pregnancy.  
The primary aim of this study was therefore to establish if maternal endothelial 
dysfunction existed in women with GDM pregnancy and if there was any 
relationship with maternal glycaemia and vascular function in this group. As a 
secondary measure, the association with endothelial function and circulating 
angiogenic factors (sFlt-1, PlGF) and inflammatory cytokines (IL-6, IL-1β, TNF-α) 
in GDM and non-GDM pregnancy were investigated.  
Primary outcome: 
• FMD% brachial artery in GDM versus control groups 





• Maternal serum angiogenic factors (sFlt1, PlGF) in GDM versus control 
groups 
• Maternal serum inflammatory cytokine concentrations (TNFα, IL-6, IL-1β) 
in GDM versus control groups 
5.2 Materials and Methods 
5.2.1 Participant recruitment and study visit schedule 
 
Women were recruited as outlined in chapter 2.2.3.  In summary, there were 
three groups of women.  30 women diagnosed with GDM according to IADPSG 
criteria, 15 women with risk factors for GDM but normal GTT on routine clinical 
testing, and 15 healthy, pregnant controls without risk factors for GDM.  
Women were eligible for inclusion if they were over 18 and had a singleton 
pregnancy.  They were excluded if they had multiple pregnancy, current 
obstetric or placental problems, significant past medical history or medication 
use that would be likely to influence vascular function tests. 
All women attended four antenatal study visits as below. 
• Visit 1: largely occurred 24-30 weeks gestation  (mean: 196 days, range: 
169-212), with one participant outlying with entry to study at 220 days 
gestation.  
• Visit 2 between 32 and 33 weeks gestation (mean: 231 days, range 224-
237 days)  




• Visit 4 a further two weeks later between 36 and 37 weeks of pregnancy 
(mean: 256 days, range 251-264).  
Women attended each study visit during which information pertaining to current 
and past medical history and maternal demographics was obtained.   
At each visit, BP and FMD brachial artery measurements were taken on the UNEX 
EF 38G™ semiautomated machine. FMD protocol is outlined in chapter 2.2.5.  All 
FMD images were manually analysed by the principal researcher Sharon Mackin 
using UNEX EF PC analysis software (UNEX Corporation, Nagoya, Japan),  and 
measurements taken for rest diameter (mm), maximum diameter (mm), % FMD 
and time to maximum dilatation (seconds)  
Fasting blood samples were obtained at the first and fourth visit.  EDTA samples 
were collected for measurement of HbA1c and fasting plasma insulin. SST 
samples were collected for measurement of serum fructosamine, albumin, lipid 
profiles, angiogenic factors (sFlt-1, PlGF) and inflammatory cytokines (IL-6, IL-1β 
and TNF-α). Full details of sample handling, storage and assays can be found in 
chapter 2.2.6. 
5.2.1.1 Statistical analysis  
Statistical analysis was performed using IBM SPSS Statistics v 22.0. GraphPad 
Prism v 8.0 was used to generate standard curves using logistic regression (5-PL 
or 4-PL if ambiguous fit on 5-Pl curve) and corresponding analyte concentrations 
for the Luminex™ biochemical analysis. 
Differences in maternal demographics between groups were compared using one 
way ANOVA for continuous variables, and χ2 for categorical variables. Data 
relating to time trends of BP and FMD measurements were assessed using linear 
mixed models that included diabetes diagnosis and gestational age (in days) as 
fixed effects, with participant ID incorporated as a random effect.  For 
biochemical analysis that was not normally distributed (assessed by Q-Q plots 
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and Shapiro Wilk test), median values are presented and differences between 
groups assessed by non-parametric tests. 
A p-value of <0.05 was considered statistically significant.  
5.3 Results   
5.3.1 Baseline characteristics 
In total, 64 women were recruited, of which 4 declined ongoing participation 
after their first (n=3) or second visit (n=1). 30 women with gestational diabetes, 
15 women with risk factors but normoglycemia (defined by screening OGTT) and 
15 healthy controls continued participation through to delivery achieving 
targeted recruitment numbers. Baseline characteristics of these mothers at 
study entry (24-30 weeks) are shown in table 5.1. 









Mean maternal age, years (SD) 31.9 (4.9) 31.1 (4.3) 32.2 (5.8) 
Mean early pregnancy BMI, kg/m2 
(SD) 
31.7 (7.5)** 30.0 (6.9) 24.6 (3.3) 
Ethnicity, % (n) 
White UK 


























Primiparous, % (n) 40.0% (12)* 60.0% (9) 73.3% (11) 
















Mean BP, mmHg (SD)a 105/63 (16/9)Ɨ 112/71 (17/14) 104/64 (14/10) 
Aspirin use, % (n) 30.0% (9) 26.7% (4) 13.3% (2) 
Low molecular weight heparin 
use, % (n) 
3.3% (1) 0.0% (0) 6.7% 91) 
Multivitamin use, % (n) 76.7% (23)Ɨ 100.0% (15) 93.3% (14) 
*p<0.05, ** p<0.01 versus control group by one way ANOVA or χ2 as appropriate 
Ɨ p<0.05 versus risk factor group by one way ANOVA or χ2 as appropriate. 
a Statistical difference in DBP only 
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Of note, women with GDM were of higher BMI and higher parity than the control 
group (p=0.004 and 0.035 respectively) but similar to those in the risk factor 
group. GDM mothers were also more ethnically diverse, in particular with higher 
numbers of South Asian women represented compared to controls (p=0.02), 
reflecting the higher GDM risk in this ethnic group.   
Aspirin use remained unchanged across the course of the pregnancy, whilst 
multivitamin use decreased (70.3% GDM, 93.3% risk factor, 86.7% control).  
5.3.1.1  Glycaemia and diabetes treatments 
The women diagnosed with GDM were diagnosed at a mean gestational age 25 
weeks and 3 days (178 + 26 days). Mean fasting plasma glucose levels at the time 
of screening OGTT were 5.2 (range 4.1-6.5) mmol/L with mean 2-hour post 75g 
OGTT levels of 7.8 (range 5.0-12.6) mmol/L.  
Of the 30, 13.3% (n=4) were treated with metformin and 3.3% (n=1) with insulin 
at study entry.  At the final study visit (week 36), this had increased to 36.7% 
(n=11) on metformin monotherapy, 3.3% (n=1) on insulin monotherapy and 6.7% 
(n=2) on combined metformin/insulin treatments.  
Biochemical data for glycemia at visit 1 and 4 is shown in table 5.2. At visit 1, 
women with GDM had higher fasting plasma glucose (p=0.02), higher fasting 
insulin levels (p=0.04) and higher insulin resistance as depicted by HOMA-IR 
(p=0.04) compared to risk factor and control groups. Unsurprisingly, women with 
GDM had higher mean HbA1c (5 mmol/mol higher than controls, p<0.001, see 
table 5.2). At visit 4, the fasting glucose remained higher in the GDM group 
(p=0.01) with a trend to higher HbA1c, fasting insulin concentrations and insulin 







Table 5.2: Maternal glycemia parameters at visit 1 and visit 4 
 GDM Risk factor Control 
Visit 1 
Number of samples 31 15 16 
Fasting plasma 
glucose (mmol/L) 
4.6 (0.4)* 4.4 (0.4)  4.3 (0.3) 
Fasting plasma 
insulin (µU/mL) 
13.7 (8.4)* 12.0 (5.2) 8.3 (3.7) 
HOMA-IR 2.9 (2.0)* 2.3 (1.1) 1.6 (0.8) 
Fructosamine 
(µmol/L) 
164 (18)* 170 (16) 178 (18) 
Albumin (g/L) 26 (2) 26 (1) 27 (2) 
HbA1c (mmol/mol) 39 (4)*** 33 (3) 34 (3) 
 
Visit 4 
Number of samples 26 15 15 
Fasting plasma 
glucose (mmol/L) 
4.5 (0.5)** 4.1 (0.4) 4.0 (0.4) 
Fasting plasma 
insulin (µU/mL) 
14.5 (9.7) 12.0 (7.9) 8.8 (3.7) 
HOMA-IR 3.0 (2.7) 2.3 (1.6) 1.6 (0.8) 
Fructosamine 
(µmol/L) 
182 (13) 186 (18) 177 (17) 
Albumin (g/L) 26 (2) 26 (1) 25 (2) 
HbA1c (mmol/mol) 40 (3) 37 (3) 37 (5) 
* p <0.05, **p<0.01, ***p<0.001 for differences between GDM and control groups by one-way 
ANOVA and post-hoc analysis 
††† p<0.001 for difference between GDM and risk factor by one way ANOVA and post-hoc analysis 
 
5.3.2 Blood Pressure 
225 of 240 (94%) planned automated BP readings were recorded in the 60 women 
across the study period.  Reasons for missing data, were preterm delivery (n=1 
at 34 weeks gestation, n=3 at 36 weeks), non-attendance of participant (n=7 at 
32 week visit, 3 at 34 week visit) and 1 case of BP not recorded by researcher 
(34 week).  
Over the course of pregnancy, 3 (5%) participants were diagnosed with PIH, all of 
which were in the risk factor group.  Of these, 2 were treated with Labetalol.  
Another 3 (5%), developed preeclampsia (n=1 control at 37 weeks, 2 GDM 
participants at 34 and 36 weeks gestation), of which 2 were treated with 
Labetalol and Nifedipine at the time of study.  All antihypertensive treatments 
were initiated by independent clinical teams, and started after the final study 
visit for each participant (one participant delivered preterm resulting in final 
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visit at 32 weeks). Mean BP at study entry was higher in women who developed a 
hypertensive disorder of pregnancy compared to those who did not (126/83 
versus 104/63 mmHg, p<0.001). This difference was driven largely by those in 
the preeclampsia group - mean visit 1 BP 139/93 mmHg in the preeclampsia 
group versus 113/69 mmHg in those who developed PIH (p=0.03 and 0.003 for 
SBP and DBP respectively).   
In a linear mixed model, with the mother ID incorporated as a random effect, BP 
did not change significantly with advancing gestational age (p=0.5 for SBP with a 
marginal effect in DBP (effect size 0.04 mmHg, p=0.05)).  BP trends across 
pregnancy were no different between groups (see figure 5.1), and the small 
effect of gestational age on DBP was attenuated when diabetes diagnosis was 
included (p=0.09). There was no effect from fasting glucose or HbA1c when 
added to the model of gestational age and mother ID (p=0.5 for both). 
5.3.2.1  Subgroup BP analysis of GDM participants 
The FBG range at initial OGTT was narrow within the GDM group (4.1-6.5 
mmol/L).  In a mixed model that included gestational age and FBG as fixed 
effects, and participant ID as a random effect, higher FBG was associated with a 
significant increase in SBP.  Every 1 mmol/L increase in FBG was associated with 
a 14 mmHg increase in SBP (p=0.001).  This significance remained when analysis 
was extended to include the fasting glucose measurements taken at visit 1 and 
visit 4. The effect was attenuated by addition of BMI but remained significant 
with 9 mmHg increase per 1 mmol/L increase in FBG (p=0.03). 
In a similar mixed model that incorporated the fasting glucose measurements 
taken at visit 1 and visit 4, gestational age and mother ID, each 1 mmol/L 
increase in glucose was associated with an 8 mmHg increase in DBP (p=0.005). 
There was also no effect of the 2-hour GTT result (range 5.0-12.6 mmol/L) on 











Figure 5.1: Mean SBP and DBP according to diabetes diagnosis across study visits 1-4 
Figure A shows mean SBP at each study visit (visit 1: 24-28 weeks gestation, visit 2 32 weeks 
gestation, visit 3 34 weeks gestation and visit 4 36 weeks gestation) according to diabetes 
diagnosis group (GDM: red, risk factor: blue, control: green). Error bars demonstrate the SEM. 
Figure B shows mean + SEM DBP for the groups.  There was no change in SBP or DBP with 







5.3.3 Flow mediated dilatation (FMD) brachial artery 
206 (85.8%) FMD measurements of a possible 240 were available for analysis from 
the 60 participants.  Reasons for missing data included: 5.8% (n=10 missed visits 
and n=3 patients with preterm delivery completing study early as detailed in 
section 1.3.2) and 8.3% (n=20) FMD scans deemed of insufficient quality for 
analysis.   This resulted in 58 of 60 participants having an adequate number of 
results (>3 readings across the study period or 2 readings including initial study 
visit and one of visit 3 or 4) to be included in further analysis;  94.8% of which 
had data for 3 (39.7%, n=23) or 4 visits (55.2%, n=32). 
5.3.3.1 Baseline diameter and FMD % of brachial artery 
The mean baseline intraluminal diameter of the brachial artery at each time 
point in pregnancy is shown in table 5.3 There was no significant difference in 
diameter between groups at any of the time points.  In a model that included 
participant ID as a random effect, intraluminal brachial artery diameter was 
shown to increase with advancing gestational age (0.003mm for each day 
increase in gestational age, p<0.001). There was no difference in diameter trend 










Table 5.3: Mean baseline intraluminal diameter (mm) of brachial artery according to stage of 
pregnancy and diabetes diagnosis 
 GDM (n=27) Risk factor (n=15) Control (n=15) 
Visit 1  3.51 (0.37) 3.39 (0.38) 3.43 (0.29) 
Visit 2  3.62 (0.56) 3.38 (0.32) 3.52 (0.36) 
Visit 3  3.63 (0.56) 3.54 (0.42) 3.67 (0.41) 
Visit 4  3.57 (0.38) 3.56 (0.37) 3.60 (0.37) 
Data shown are  mean (SD) 
Available data: 
Visit 1: GDM n=27, Risk factor n= 15, Control n=15; Visit 2: GDM n= 25, Risk factor n=11, Control 
n=12; Visit 3: GDM n=23. Risk factor n=13, Control n=14; Visit 4: GDM n=23, Risk n=13, Control 
n=15.  
 
FMD% did not change with advancing gestational age and was similar between 
groups, p=0.12 (figure 5.2), and remained non-significant after adjustment for 
baseline vessel diameter. There was no effect on FMD% from fasting plasma 
glucose (mixed model with mother ID (random effect) with gestational age and 
fasting plasma glucose measurements from visits 1 and 4 (fixed effects), p=0.3. 
There was no significant effect of fructosamine (p=0.8), HbA1c (p=0.7) nor 
HOMA-IR (p=0.3) on FMD% in similar models.  
Similarly, there were no differences between groups in time to reach maximum 
vasodilatation (mean from visit 1-4 measurements: 54.3+2.2s GDM, 47.5+2.8s 
risk factor, 50.6+2.9s controls, p=0.1).  There was no significant effect on time 
to maximum dilatation from fasting plasma glucose measurements (from visits 1 
and 4) (p=0.3 in model including mother ID as random effect, gestational age 
and glucose as fixed effects).  Similarly, no significant effects were seen when 





Figure 5.2: Mean flow mediated dilatation (FMD) % of brachial artery according to diabetes 
diagnosis across study visits 1-4 
The mean flow mediated dilatation (%) of brachial artery for the GDM group (red), risk factor 
group (blue) and control group (green) are shown, with error bars reflecting the standard error 
of the mean. There is no difference evident between the groups across progressive study visits.  
 
5.3.4  Circulating angiogenic markers and lipid profiles 
5.3.4.1 Soluble fms-like tyrosine kinase 1 (sFlt-1) , placental growth factor 
(PlGF) and sFlt-1:PlGF ratio 
The median maternal serum concentrations of sFlt-1, PlGF and the sFlt-1:PlGF 
ratio for each group are shown in table 5.4  The range was wide for each 
parameter across all groups.  The sFlt-1:PlGF ratio was significantly lower in the 
GDM group at visit 1 (p=0.003 by independent sample median test).  The median 
sFlt-1: PlGF ratio was numerically higher in the GDM and risk factor groups at 
visit 4 (p=0.1).  There was no significant effect of these biochemical measures 
on any of SBP, DBP or FMD when tested in individual mixed models that included 
maternal ID, gestational age, the tested biomarker and its interaction with 
gestational age.  
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There was no correlation with PlGF and corresponding fasting plasma glucose 
(Pearson’s r=0.05, p=0.6), fasting insulin (Pearson’s r=-0.2, p=0.9) and HOMA-IR 
(Pearson’s r=-0.1, p=0.2).  sFlt-1 correlated weakly with fasting insulin 
concentrations and HOMA-IR measures (Pearson’s r=0.211 p=0.03, and r=0.226 
p=0.02 respectively).  There was no significant correlation of sFlt-1 and glucose 
concentrations.  
 
Table 5.4:  Median concentrations and interquartile range of soluble fms-like tyrosine kinase 
1 (sFlt-1), placental growth factor (PlGF) and sFlt-1: PlGF ratio in maternal serum according 
to diabetes diagnosis 
 GDM 
 
Risk factor Control 
Visit 1 
 
Median sFlt-1 (IQR) 
(pg/mL) 
 
2040.5           
(1472.0-2636.3) 
2366.9            
(1738.2-3052.6) 
2435.5            
(2079.4-2791.6) 
Median PlGF (IQR) 
(pg/mL) 
 
153.6                
(74.6-358.1) 
112.7                
(23.6-183.1) 
79.8                   
(33.3-141.3) 
Median sFlt-1: PlGF 
ratio (IQR) 
7.1**                    
(4.1-14.3) 
23.7                    
(8.5-124.1) 




Median sFlt-1 (IQR) 
(pg/mL) 
 
3763.2           
(2743.7-4611.8) 
3018.3           
(2263.9-3454.9) 
3448.9           
(2805.4-5308.8) 
Median PlGF (IQR) 
(pg/mL) 
 
67.5                  
(12.3-201.4) 
32.2                  
(13.2-161.3) 
110.0                
(65.5-260.4) 
Median sFlt-1: PlGF 
(IQR)  
85.7                  
(17.9-273.1) 
87.4                  
(15.9-171.1) 
30.1                  
(10.2-48.6) 
 
** p<0.01 via independent-samples median test 
Number of available samples included based on good reproducibility of results (<20% CV  on 
duplicate samples): 
 
Visit 1:  sFlt-1 – GDM 27,  Risk factor 15, Control 16; PlGF: GDM 25, Risk factor 15, Control 14; 
both sFlt-1 and PlGF for ratio: GDM 21, Risk  factor 15, Control 14. 
Visit 4:  sFlt-1 – GDM 24, Risk factor 13, Control 13; PlGF:   GDM 20, Risk factor 12, Control 9;  




5.3.4.2 Tumour necrosis factor alpha (TNF-α), interleukin-6 and interleukin-
1β 
The Luminex™ analysis for these three biomarkers were performed on the same 
samples on the same assay plates.  Review of this data suggested systematic 
errors in the assay and so was not interpreted further.  Standard curves and 
control samples from all three plates run showed a consistent inability to detect 
standard concentrations at and below 80 pg/mL (high CV% and > 30% outwith the 
predicted range for controls).  There was a high proportion of undetectable 
levels of IL-6 (76% samples). In the case of IL-1β, each plate had remarkably 
consistent values for samples measured on that plate suggesting measurement 
error.  For example, plate 1 samples read within range 5.9-7.0pg/mL, plate 2 
had a range from 1.9-3.5pg/mL and plate 3 had largely undetectable values. 
5.3.4.3 Lipid profiles 
Table 5.5 shows the mean cholesterol, HDL-cholesterol and fasting triglyceride 
levels for each group at visit 1 and visit 4.  At visit 1, serum total cholesterol and 
HDL cholesterol concentrations were different between groups, with GDM having 
significantly lower levels of both ((p<0.01 and <0.001 for total cholesterol and 
HDL-cholesterol respectively).  At visit 4, total cholesterol remained lower in the 
GDM group (p=0.046 one way ANOVA, p=0.07 GDM versus control) with a trend to 
lower HDL cholesterol (p=0.1 GDM versus control).  
There was no statistical effect seen from total cholesterol, HDL cholesterol or 
fasting triglycerides on BP or FMD (mixed model with maternal ID, gestational 







Table 5.5:  Circulating serum lipid concentrations according to diabetes diagnosis 
 GDM 
 

































2.76 (0.90) 2.33 (0.69) 5.57 (0.64) 
*p<0.05, ** p<0.01, *** p<0.001 between groups by one way ANOVA 
†† p<0.01, ††† p<0.001 GDM versus control post-hoc t-test 
Available sample numbers: Visit 1: GDM 31, Risk factor 15, Control 16; Visit 4 GDM 26, Risk factor 
15, Control 15. 
 
5.4 Discussion 
5.4.1 FMD Brachial artery 
Macrovascular endothelial function, as measured by FMD brachial artery in the 
third trimester of pregnancy is no different in GDM mothers compared with non-
GDM mothers. Furthermore, there is no relationship of FMD brachial artery 
measures and biochemical markers of glucose control (fasting plasma glucose, 
HbA1c or fructosamine).  However, in the GDM subgroup analysis, higher fasting 
glycaemia has a strong association with both SBP and DBP, suggesting that 
uncontrolled hyperglycaemia still exerts effects on vascular function.  This 
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observation is in keeping with the large, multicentre studies that have shown 
small rises in glycemia to be associated with significant risks of developing 
hypertensive disorder in pregnancy (Metzger et al., 2008, Landon et al., 2009).  
The pathophysiological mechanism for disease remains unclear. 
The FMD results are similar to a recent study by Garg et al, which explored 
trends in FMD across pregnancy, and whilst they found an attenuated decrease in 
FMD between first and third trimester in GDM versus non-GDM mothers, there 
was no difference in third trimester FMD values between groups (Garg et al., 
2017). This contrasts with a slightly older study by Guimares which showed GDM 
mothers to have lower brachial artery FMD in the third trimester than non-GDM 
mothers (De Resende Guimarães et al., 2014). However, this study included only 
a single time point measurement of FMD in the third trimester, and included a 
wide range of gestations from 25-38 weeks so may not be directly comparable.  
The latter Garg study had a more comparable study design that restricted third 
trimester measurement to a more constricted gestational period.  Furthermore, 
the Garg study included women with a similar severity of GDM as in my study 
(mean fasting levels 5.3 mmol/L and 2-hour post-75g GTT of 6.3 mmol/L), whilst 
the range of glycaemia included in the Guimares study was less clear.  My study 
findings show no relationship of FMD to glycaemia, but this may not be true if 
women with a more severe hyperglycaemic phenotype were examined. To my 
knowledge, my study is the first to explore serial FMD measurements across the 
third trimester, and specifically the time period post-GDM diagnosis where 
glucose excursions would be expected to be greatest.   
Whilst there was no difference in brachial artery FMD, nor the time to reach 
peak dilatation between groups, it would be premature to translate this as 
meaning no effects of glycaemia on maternal endothelial function.  Using 
different methodologies, others have demonstrated maternal microvascular 
endothelial dysfunction in pregnancy complicated by diabetes (Knock and 
Poston, 1996, Ramsay et al., 2003), and importantly, the presence of normal 
microvascular function when diabetes is well controlled (Ang et al., 2002). There 
is a wealth of evidence that glycaemia impairs endothelial function outwith 
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pregnancy (Avogaro et al., 2011).  Based on OGTT results, the women in this 
study entered with GDM that was largely on the milder scale of hyperglycaemia, 
albeit 40% progressed to requiring pharmacotherapy suggesting higher excursions 
as pregnancy progressed. Pharmacotherapy was initiated by the clinical team, 
and decisions made independent of study involvement.  Treatments included 
insulin and metformin therapy, both of which could have had effects on 
endothelial function and confounded results. Metformin treatment has been 
shown to have positive effects on endothelial function through various pathways 
which act to increase NO availability and reduce inflammatory leucocyte 
adhesion (Nafisa et al., 2018).  Euglycaemic clamp studies in non-pregnant 
volunteers have also shown that short term exposure to modest hyperinsulinemia 
has detrimental effects on large vessel endothelial function (Arcaro et al., 2002, 
Campia et al., 2004).  This is likely as result of increased oxidative stress.  
We know from landmark studies that microvascular beds are particularly 
susceptible to adverse clinical sequelae of hyperglycaemia (UKPDS 33, 1998).  
Perhaps due to their larger intraluminal diameter, macrovasculature requires a 
bigger insult before clinical or physiological effects from endothelial dysfunction 
become apparent.  FMD has clear advantages as a test of being non-invasive and 
safe for mother and baby, and is accepted as standard test of endothelial 
function (Corretti et al., 2002). However, it has not been validated in 
pregnancy. There are also known susceptibilities to inter- and intra-user 
variability.  The initial study design had hoped to improve upon this variability 
by using novel semi-automated technology, but myself and colleagues have since 
shown in our separate non-pregnancy study (Dobbie et al., 2020), that manual 
assessment of images provides better reproducibility.  Furthermore, in this 
current study all primary image ascertainment and secondary analysis was 
performed only by me, and after several months of training so variability is likely 
to be minimised.  Alternatively, FMD brachial artery may not be the optimal test 
of endothelial function in the vasodilated late stages of pregnancy. It is notable 
that our data suggests that women may be nearing peak vasodilatory state (in 
brachial artery) in these later stages of pregnancy.  Additional measures of 
endothelial function would have been of interest. For example, peripheral 
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arterial tonometry (EndoPAT™) to assess microvascular beds and quantifying 
circulating biomarkers of oxidative stress.   
5.4.2 Angiogenic and inflammatory biomarkers 
The sFlt-1:PlGF ratio was lower in GDM at 24-28 week visit, with no difference 
seen between groups at 36 weeks.  The difference in ratio seen at the first visit 
appears to be affected by higher, albeit not statistically significant, PlGF levels 
in the GDM group.  This reflects similar to previous work which has shown PlGF 
levels to be higher in early pregnancies that are either affected by pre-existing 
non-insulin requiring T2DM or who go on to develop GDM (Ong et al., 2000). This 
is of interest, as it is the opposite to what is seen in women who present with 
suspected preeclampsia.  Lower levels of PlGF, and higher sFlt1:PlGF are 
associated with placental vascular maladaptation and subsequent preeclampsia 
development (Kleinrouweler et al., 2012).  Recent landmark trials in the use of 
PlGF and the sFlt1: PLGF based assays, have enabled more widespread use of 
these biomarkers to help rule out current or impending preeclampsia in women 
with suspected symptoms in clinical guidelines (Chappell et al., 2013, Duhig et 
al., 2019, PlGF-based testing to help diagnose preeclampsia (National Institute 
for Health and Care Excellence), 2016), but low specificity for longer term (>14 
days) or asymptomatic prediction of preeclampsia has prevented more 
widespread adoption (Kleinrouweler et al., 2012).  These large trials included 
women with pregestational and gestational diabetes, but these women 
comprised the minority of the study populations, as would be expected in the 
general obstetric population.  Given the differences demonstrated in this study 
and in others around PlGF in diabetes, it would seem pertinent to explore 
whether these PlGF based tests hold the same predictive value in the population 
with diabetes.    
In the same study by Ong et al, similar results of higher  PlGF were not evident 
in the subgroup with insulin-requiring diabetes suggesting that PlGF effects in 
diabetic pregnancy are not mediated predominantly by hyperglycaemia (Ong et 
al., 2000).  Our data support this with no correlation seen between glucose and 
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PlGF.  Ong et al hypothesised that insulin resistance may be the 
pathophysiological mechanism driving higher PlGF, but there was no significant 
correlation with PlGF and HOMA-IR or insulin concentration values in my study.  
The results are interesting as it seems to suggest differences in placental 
development and function across the spectrum of diabetes phenotypes. 
Interestingly, research in non-pregnant subjects has shown elevated PlGF to be 
an antecedent risk factor for development of future incident T2DM and is also 
independent of the traditional markers of glycaemia (HbA1c) and insulin 
resistance.  
Inflammatory cytokine pathways are upregulated in metabolic disease and 
thought to contribute to preeclampsia risk (Rusterholz et al., 2007, B et al., 
2011, Lau et al., 2013).  The original methods of this study, therefore also 
included measurement of some of the most commonly implicated inflammatory 
cytokines (TNF-α, IL-6, IL-1β) to try identify any association with these 
biomarkers and maternal endothelial function in GDM.  However, concerns 
regarding the assay results and limited laboratory time for repetition of 
experiments meant that this aspect of my study was excluded from ongoing 
analysis. 
In conclusion, endothelium-dependent macrovascular vasodilatation is similar in 
women with GDM compared to pregnant women without diabetes. Macrovascular 
endothelial dysfunction is unlikely to be a major contributory mechanism to the 
increased risk of adverse outcomes seen in GDM pregnancy. Higher glycaemia is 
however significantly associated with higher maternal BP suggesting vascular 
dysfunction independent of endothelial function occurs. Further work into 
microvascular endothelial function and non-endothelial vascular pathways is 
warranted to better understand pathophysiology in such pregnancies.  An 
unexpected secondary outcome of this work was of lower sFlt-1:PlGF and higher 
PlGF in GDM pregnancy, raising suspicions that current PlGF cut-offs used in 
preeclampsia diagnosis may not hold relevance to the obstetric population with 
diabetes.  Ongoing work exploring their accuracy in this population will be 
important given the widespread use of such assays in clinical practice.  
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6 Chapter 6: Placental vascular function in 
gestational diabetes versus non-diabetic controls 
6.1 Introduction 
My data, and data from others have shown that pregnancies complicated by 
diabetes have significantly increased risk of adverse outcomes, with up to 6-fold 
higher rates of preterm delivery and 5-fold higher rates of stillbirth than the 
background obstetric population (Mackin et al., 2019, Murphy et al., 2021).  
Many preterm deliveries will occur due to concerns of preeclampsia or stillbirth.  
As I have already discussed, diabetes increases preeclampsia risk, particularly in 
pregestational diabetes where rates are 4-fold higher (Duley, 2009), but it also 
occurs with higher frequency in gestational diabetes (GDM) (Weissgerber and 
Mudd, 2015).  The pathophysiology of preeclampsia has not been fully 
elucidated, but is recognised to be placental in origin with high resistance 
uteroplacental circulation and vascular dysfunction.  The details of this are 
discussed more in chapter 1.2.2 (Raymond and Peterson, 2011).  Fetal growth 
may be compromised because of reduced placental perfusion, and in some cases 
can be severe enough to cause intrauterine death. In diabetes, there appears to 
be a dynamic relationship between maternal glycaemic status and preeclampsia 
risk, even in the later stages of pregnancy, beyond the stages of placental 
vascular development (Metzger et al., 2008). Third trimester maternal HbA1c in 
pregestational diabetes is associated with risk of preeclampsia over and above 
first trimester HbA1c and the risk associated with coexisting diabetes 
complications (Holmes et al., 2011). In gestational diabetes (GDM) reduction of 
glucose reduces risk of preeclampsia despite this intervention only starting after 
24-28 weeks and reflecting a much milder biochemical abnormality than in 
pregestational diabetes (Landon et al., 2009, Crowther et al., 2005).  Taken 
together, this suggests that glycaemia is an important modifiable risk factor for 
preeclampsia and importantly appears to have effects that occur beyond first 
trimester placental development. However, the placenta remains central to 
preeclampsia pathogenesis in diabetes, with the only recognised curative 
treatment being delivery of the placenta. It is also of interest that even in the 
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absence of preeclampsia women with diabetes have a high prevalence of 
subclinical placental vascular insufficiency detected on histopathological 
examination of placentae (Daskalakis et al., 2008). This leads us onto the 
hypothesis that placental vascular function is adversely affected by diabetes, 
and may be important in the pathophysiology of adverse outcomes seen in such 
pregnancies. 
Alterations in placental vascular function have been reported in patients with 
adverse outcome pregnancy.  Chorionic plate vessels are those vessels which 
control oxygen and nutrient delivery from placenta to the fetus and are 
important to regulate fetal growth.  Chorionic plate veins deliver nutrients to 
the fetus, whilst the chorionic plate arteries (CPAs) return deoxygenated blood 
and toxins to the placenta.  CPAs appear to be integral in regulating placental 
vascular resistance.  Wire myography studies have shown reduced 
vasoconstrictive and vasodilatory responses of the chorionic plate arteries in 
preeclamptic pregnancy compared with uncomplicated pregnancy (Ong et al., 
2002). Similar changes are also seen in placental vessels of growth restricted 
pregnancies suggesting compromise of fetal-placental perfusion as a cause for 
adverse neonatal outcomes (Mills et al., 2005). However, most mechanistic 
studies of the chorionic plate actively exclude women with diabetes, leaving a 
paucity of data in this high-risk group. I explored whether fetoplacental vascular 
function is altered in GDM, and generate further hypothesis about how this may 
relate to adverse pregnancy outcomes. 
6.2 Methods 
Placentas were collected prospectively from the same cohort recruited as part 
of the wider study described in earlier chapters, and split into GDM and non-GDM 
groups.  
Following alert from the clinical team, the principal investigator (Dr Sharon 
Mackin) collected placentas immediately following delivery and transported 
them to the lab where wire myography experiments were conducted on CPAs. 
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Experimental conditions are described in detail in chapter 2.3.  In brief, CPAs 
were mounted on wire myographs and normalised to 0.9L5.1kPa whilst bubbled 
with 5%02/5%CO2/N2.   
Vessel viability was confirmed by measuring contractile response to 62.5 mmol 
K+ containing salt solution (KPSS).  Cumulative dose response curves were then 
assessed to 1x10-10-3x10-5M U46619 to assess contractility.  Vasodilatory response 
was then assessed to either: 
• Bradykinin (1x10-10 mol – 3x10-5 mol) – endothelium-dependent 
vasodilator 
• Sodium Nitroprusside (SNP) (1x10-10 mol -3x10-4mol) – endothelium-
independent vasodilator 
• Calcitonin-gene related peptide (CGRP) (1x10-10mol -3x10-4 mol) – 
endothelium-dependent and -independent vasodilator actions 
• Calcitonin-gene related peptide (CGRP) (1x10-10 mol -3x10-4 mol) + 20-
minute incubation with the 100 µmol of nitric oxide synthase (NOS) 
inhibitor, N(ω)-nitro-L-arginine methyl ester (L- NAME) to determine if 
acting in endothelium-dependent or -independent manner in CPAs 
Maximal vasoconstrictive responses are expressed as % vasoconstriction relative 
to maximum tension reached following 62.5 mmol KPSS. Vasodilatory responses 
are expressed as % vasodilation relative to the maximum tension reached 
following preconstriction with 3x10-7 mol U46619.   
 
6.2.1 Statistical analysis 
Statistical analysis was performed using IBM SPSS™ statistics v 22.0 and  
Graphpad Prism™ v 8.0 (GraphPad Software Inc™, USA). Raw vessel tension data 
was analysed using LabChart Reader™ software v 8.1.13 (AD Instruments™, UK).   
202 
 
Maternal and fetal demographics between groups were compared using one way 
ANOVA or χ2 as appropriate. For each CCRC, comparison of curves between 
groups was compared using extra sum of squares F test. Differences in mean 
Emax and mean EC50 for each agonist were compared between groups using one-
way ANOVA.   Statistical significance was assumed if p<0.05.  
6.3 Results 
In total, 32 placentas from the original cohort of 60 were women obtained.  This 
included 16 women with GDM, 9 women from the risk factor group and 7 women 
from the control group.  The remainder (n=28) were not obtained due to variable 
reasons of: researcher unable to collect immediately or researcher not 
contacted by clinical team (n=22), home birth (n=1), researcher unavailable to 
perform myography (n=2), non-viable vessels for experimentation (n=2) and a 
clinical need for immediate transfer of placenta to NHS pathology services (n=1). 
6.3.1 Maternal and delivery characteristics of study population  
Maternal and delivery characteristics of those women who had placentas 
included in myography studies is detailed in table 6.1.  The key differences 
between groups are similar to those seen in the larger cohort, with GDM mothers 
having higher BMI than control women but similar to the risk factor group and 
GDM mothers delivering at earlier gestation.  There was no statistical difference 
in mode of delivery between groups, but numbers are too small to detect this 








Table 6.1:  Maternal and delivery characteristics of woman with placentas included in 
myography studies (n=32) 
 GDM (n=16) Risk factor (n=9) Control (n=7) 
 
Mean maternal age, 
years (SD) 
 
32.0 (5.6) 31.3 (5.0) 32.7 (6.5) 
Booking BMI 
 
32.6 (6.9)** 31.3 (7.0)* 24.1 (3.7) 





105 (14) 110 (20) 99 (16) 





66 (11) 72 (16) 64 (8) 
Mean gestational age 
at delivery, weeks 
(SD) 
 
38.4 (1.0)ƗƗƗ 40.4 (1.2)* 39.3 (0.6) 
Male infant (%) 
 
44% (n=7) 44% (n=4) 0 
Mean birthweight, g 
(SD) 
 
3426.6 (643.1) 3387.1 (492.1) 3426.1 (179.3) 
Mean GROW™ 
birthweight centile   
(SD) 
59.0 (29.3) 48.4 (34.2) 60.9 (33.5) 
Mean placental 
weight, g (SD) 
 
504.6 (148.3) 473.9 (119.7) 499.0 (91.2) 




56% (n=9) 44% (n=4) 71% (n=5) 
Elective caesarean 
 
31% (n=5) 44% (n=4) 29% (n=2) 
Emergency 
caesarean  
13% (n=2) 12% (n=1) 0 
 
*p<0.05, ** p<0.01 versus controls by one way ANOVA or χ2 as appropriate 
ƗƗƗ p<0.001 versus risk group by one way ANOVA or χ2 as appropriate 




6.3.2 Vasocontraction to U46619 (thromboxane A2 mimetic)  
In total, 144 viable vessels from 32 placentas were examined.  This included 71 
vessels from 16 GDM placentas, 29 vessels from 9 risk factor placentas and 19 
vessels from 7 control placentas.   
Mean vessel diameter were 310 (69), 278 (49) and 382 (112) μm for GDM, risk 
factor and control vessels respectively (p=0.2).  
The maximum response to 62.5 mmol KPSS max (absolute tension) was similar at 
2.6 mN GDM, 2.0 mN risk factor and 2.4 mN in the control group. There were no 
differences in vessel contractility to U46619 across groups (Figure 6.1A). Mean 
Emax was similar across groups (167.1% control, 161.1% risk factor and 149.9 
GDM), as was logEC50 (-7.04 mol control, -7.01 mol risk factor and -7.08 mol 
GDM). Individual data points are shown in figures 6.1B and 6.1C). 
6.3.3 Vasodilatation to bradykinin (endothelium-dependent) 
19 viable CPAs from 6 placentas (5 risk factor, 1 GDM) were pre-constricted with 
3x10-7 mol U46619, followed by exposure to cumulative concentrations of 
bradykinin (1x10-10 mol – 3x10-5 mol).  There was no significant vasodilatory 
response of CPAs to bradykinin (figure 6.2).  Bradykinin was removed from the 






































































































































Figure 6.1: Vasoconstrictive response of CPAs to U46619 from women with GDM, risk factors 
for GDM but normoglycaemia and healthy controls  
There was no difference in contractility of CPAs taken from placentas from women with GDM, 
risk factors for GDM or healthy controls (A).  There was no difference in the maximal contractile 
response to U46619 (B), nor in the log EC50 between groups (C).  GDM groups are shown in red, 
risk factor group in blue and control group in green. 
The cumulative concentration response curve shows mean + SEM, and was compared using the 
extra sum of squares F test. The scatter plot diagrams show mean Emax and EC50 for individual 
subjects, with a group mean demonstrated by the line.  Where more than one vessel was used 
for a subject, the average of the readings across the vessels for that subject was used. The mean 
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Figure 6.2: Vasodilatory response of CPAs to increasing concentrations of Bradykinin 
There was no demonstrable vasodilatation of CPAs to bradykinin after pre-constriction with  
3x10-7M U46619.  This analysis included 19 vessels from 6 subjects.  Each dot represents the 
mean % vasodilatation at each log[bradykinin] whilst the error bars show SEM.  
 
6.3.4 Vasodilatation to CGRP  
Following preconstriction with 3x10-7 mol U46619, CGRP vasodilatory CCRC was 
conducted for 43 CPAs from 23 placentas.  This included 25 vessels from 14 GDM 
placentas, 5 vessels from 3 risk factor group placentas and 13 vessels from 6 
control placentas.  Due to the low number of subjects included in the risk factor 
group, analysis of this CCRC was restricted to GDM versus non-GDM groups. 
Vessels were of similar mean diameter at 315+66μm and 300+99μm in GDM and 
non-GDM groups respectively. There was no difference in CPA vasodilatory 
response to CGRP between GDM and non-GDM pregnancy (p=0.6, figure 6.3A).  
LogEC50 (-7.9 mol both groups) and Emax (35.2+23.8% GDM, 30.8+16.3% non-GDM) 
were similar between groups.  Individual data points for both are shown in 
































































































































Figure 6.3: Vasodilatory response of CPAs to CGRP from women with and without GDM  
Following preconstriction with 3x10-7M U46619, there was no difference in vasodilatation 
response of CPAs to CGRP in placentas from women with GDM and those without GDM (A).  There 
was no difference in the mean maximal vasodilatory response to U46619 (B), nor in the log EC50 
between groups (C).  GDM groups are shown in red and non-GDM group in blue. 
The cumulative concentration response curve shows mean + SEM, and was compared using the 
extra sum of squares F test. The scatter plot diagrams show mean Emax and EC50 for individual 
subjects, with a group mean demonstrated by the line.  Where more than one vessel was used 
for a subject, the average of the readings across the vessels for that subject was used. The mean 
Emax and EC50 between groups was compared using student t-test (p n.s. for all).  
A 
B C 
•  GDM              •  Non-GDM 
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6.3.4.1 Vasodilatory response of CPAs to CGRP in presence of NOS inhibition 
There were 7 placentas (from entire cohort) with sufficient viable vessels to 
allow simultaneous CGRP CCRCs to be conducted – one cohort as described 
above, and others following the same protocol but after a 20-minute incubation 
with 100µM L-NAME.  Figure 6.4 shows that there was no difference in 
vasodilatory response of CPAs to CGRP in the presence of NOS inhibition, 
suggesting that CGRP effects on CPAs occur predominantly  via endothelium-






























































Figure 6.4: Vasodilatory response of CPAs with and without NOS inhibition 
There was no difference in vasodilatory response of preconstricted CPAs to CGRP (1x10-10M to 
3x10-4 mol) following incubation with the NOS inhibitor L-NAME (100 µM) compared to non-
incubated vessels.  This suggests that CGRP effects on CPA vasodilatation occur mainly through 
endothelium-independent pathways.  
Those vessels incubated with L-NAME (12 vessels from 7 placentas) are shown in red, whilst those 
without prior incubation (10 vessels from 7 placentas) are shown in blue. The best fit cumulative 






6.3.5 Vasodilatation to SNP (endothelium-independent) 
Endothelium-independent vasodilatation response were assessed with increasing 
concentrations of SNP (1x10-10 mol -3x10-4 mol).  This cohort included 15 vessels 
from 9 GDM placentas, 13 vessels from 6 risk factor placentas and 11 vessels 
from 6 control placentas.   
Mean vessel diameters were similar across groups at 341+120µm for GDM, 
298+103µm for risk factor group and 364+145µm for control group (p=0.4).  
Vessels from GDM placentas had a significantly attenuated vasodilatory response 
to cumulative doses of SNP, compared with vessels from the risk factor and 
control cohorts (p<0.0001 for maximum vasodilatation using best fit curve 
analysis, see figure 6.5A).  There appeared to be greater variation amongst 
mean Emax in individual subjects in the GDM group (see figure 6.5B).   Mean Emax 
was 49.5+11.0%, 73.9+11.0% and 74.0+12.0%  in GDM, risk-factor and control 






































































Figure 6.5:    Vasodilatory response of CPAs to SNP from women with GDM, risk factors for 
GDM but normoglycemia and healthy controls 
Following pre-constriction with 3x10-7M U46619, CPAs from women with GDM had attenuated 
vasodilatation to increasing concentrations of SNP (1x10-10-3x10-4mol).  Best fit cumulative 
concentration curves were fitted and compared using extra sum of squares F test, as shown in 
figure A (p<0.001 for maximal response different across groups). Dots represent the mean 
response whilst error bars show SEM. 
CCRCs were then fitted for each subject, and mean Emax and EC50 data for each individual 
subject are shown in figure B and C accordingly.  Mean Emax was 49.5+11.0% in GDM compared 

































































6.3.5.1 Effect of fasting glucose and insulin on SNP vasodilatation 
There was a significant inverse correlation of fasting plasma glucose measured at 
visit 4 with Emax  to SNP ( Pearson’s r -0.526, p=0.01, figure 6.6).  The effect of 
glucose on Emax remained significant when tested in a general linear model that 
included diabetes diagnosis, fasting glucose and their interaction (p=0.03).  
Insulin resistance, as measured by HOMA-IR was also negatively correlated with 
Emax to SNP (Pearson’s r -0.521, p=0.02, figure 6.7).  When this was tested in a 
model that included diagnosis, HOMA-IR and its interaction, the effect of HOMA-
IR on was attenuated (p=0.08).   
 
 
Figure 6.6  Scatterplot diagram showing relationship of fasting plasma glucose at end of 
pregnancy to Emax of SNP for CPAs 
This scatterplot shows a moderate negative correlation with fasting plasma glucose (x axis) 
measured at visit 4 (approximately 36 weeks gestation) and the maximal vasodilatory response of 





Figure 6.7:  Scatterplot diagram showing relationship of insulin resistance scores (HOMA-IR) 
at end of pregnancy to Emax of SNP for CPAs 
This scatterplot shows a similar negative correlation with insulin resistance, as measured by 
calculated HOMA-IR  (x axis) from fasting bloods taken at visit 4 (approximately 36 weeks 
gestation) and the maximal vasodilatory response of CPAs to the endothelium independent 
vasodilator, SNP (y axis) (Pearson’s r -0.521, p=0.02).   
 
 
6.3.5.2 Effect of circulating maternal angiogenic factors on SNP vasodilatation 
There was no correlation between Emax to SNP and concentrations of sFlt-1, 
PlGF nor the sFlt-s:PlGF ratio found in maternal blood. Numbers available for 
analysis were small (n=15 for sFlt-1, 13 for PlGF and 8 for sFlt-1:PlGF), the 
reasons for which are detailed in chapter 5.2. 
6.3.5.3 Effect of delivery method on SNP vasodilatation 
Although not statistically significant, there were observed differences in the 
number of women undergoing caesarean and vaginal delivery between groups. 
Subgroup analysis is limited by small numbers and so to assess whether these 
methods of delivery had statistical impact on the mean SNP Emax observed 
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between groups, a general linear model that incorporated both diagnosis, 
delivery method (vaginal versus caesarean delivery) and the interaction between 
the two was utilised. Only diagnosis had a significant effect on SNP Emax (p=0.07 
for diagnosis) whilst delivery method and interaction between the two remained 
non-significant (p=0.11 and 0.9 respectively).  
Similarly, the effects of drugs used during delivery such as prostin and 
syntocinon were analysed to see if significant effect on vasodilatory response to 
SNP.  In total, 7 of the 21 women received prostin for labour induction (1 risk 
factor, 6 GDM women), and all women received syntocinon whether that be for 
induction/augmentation of labour or routine use in the third stage of labour.  
In a generalised linear model that incorporated terms for diagnosis, prostin use 
and the interaction between the two, prostin use did not have a significant 
effect on Emax (p=0.4), although effect of diagnosis was augmented (p=0.1). 
Syntometrine was used to manage the third stage of labour in 5 women (3 GDM, 
1 risk factor and 1 control subject) and in a similar model, did not significantly 
alter Emax (p=0.3). Syntocinon effect was not analysed as it was used in all 
women. 
6.3.5.4 SNP CCRC and relationship to birthweight centile 
For those women who had vessels included in SNP CCRC analysis, birthweight 
data are shown in table 6.2.  Absolute birthweight (grams) and birthweight 
GROW centile were similar across groups.  In a generalised linear model that 
included SNP Emax and diagnosis, birthweight centile was not significantly 







Table 6.2:  Mean birthweight (g) and birthweight GROW centile according to diabetes 
diagnosis for women included in SNP CCRC analysis 





3467 (312) 61.1 (19.3) 
Risk factor (n=6) 
 
3646 (710) 54.6 (38.00 
Control (n=6) 
 
3363 (487) 57.1 (34.9) 
No statistical difference between groups using ANOVA. 
 
6.3.6 Discussion 
In this study, CPAs from GDM pregnancies have reduced endothelium-
independent vasodilatory capacity, suggesting a pro-contractile phenotype of 
placental vasculature.  These differences have been demonstrated in the fetal 
side of the placental circulation, which could have direct and detrimental 
effects on fetal growth and development (Mills et al., 2005). Importantly, 
differences were not seen in the group of mothers with risk factors for diabetes 
but normal glucose tolerance, suggesting that these effects are specifically 
diabetes, and not obesity related. This is further corroborated by our data 
showing an association with higher maternal glucose and lower vasodilatory 
response to SNP.  
To my knowledge, this is the first study to explore fetoplacental vascular 
function in GDM pregnancy, and there is a paucity of placental studies in pre-
existing diabetes.  A study using dual-perfused placental cotyledon methodology 
showed attenuated endothelium-independent vasodilatory response to glyceryl 
trinitrate in T1DM compared to non-diabetes controls (Kossenjans et al., 2000). 
This study also showed diminished responses in preeclamptic pregnancies. 
Similar to SNP, glyceryl trinitrate has similar pharmacological properties 
whereby it acts through NO donation to vessels to cause vasodilation.  
Diminished vasodilatory capacity of fetoplacental vessels to SNP has also been 
associated with preeclampsia (Ong et al., 2002). CPAs have a key contribution to 
maintain placental vascular resistance.   Taking this together with our findings, 
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we hypothesise further that there is higher vascular resistance in the 
fetoplacental unit in GDM pregnancy, which could compromise fetal nutrient 
transfer and perfusion.  Although speculative, this may be an important 
mechanism for increased adverse fetal outcomes.  In preeclampsia increased 
placental vascular resistance is also thought to contribute to dysregulated 
production of placental growth factors and inflammatory markers which when 
released into maternal circulation, cause widespread endothelial dysfunction 
and the clinical syndrome of preeclampsia (Tomimatsu et al., 2017).  Reduced 
capacity to vasodilate in GDM could contribute to increased resistance on the 
fetal side of the placental circulation, which could lead to fetal hypoxia and 
stimulation of angiogenic and inflammatory cytokine production similar to what 
is seen in preeclampsia.  The measured angiogenic markers (sFlt-1 and PlGF) did 
not correlate with maximum vasodilatory response in my study, but were limited 
by small numbers of placentas examined and furthermore by lack of reliable 
sFlt-1/PlGF results across the group.  There are also several inflammatory and 
anti-angiogenic mediators implicated in preeclampsia pathophysiology that are 
unmeasured in this study. 
Interestingly, there was no difference in vasodilation of CPAs to CGRP between 
groups.  CGRP receptors are expressed abundantly in placental endothelial, 
VSMCs and trophoblast cells (Dong et al., 2003, Dong et al., 2004).   Both CGRP 
receptor expression and concentrations of CGRP in maternal and cord blood are 
reduced in pregnancies complicated by preeclampsia (Dong et al., 2005, Dong et 
al., 2006).  More interestingly, others have shown CGRP concentrations in fetal 
and cord blood correlate with fetal growth (Parida et al., 1998).  This is 
suggesting an important role of CGRP in maintaining placental vascular flow to 
support fetal growth.   CGRP also bears close homology to other proteins 
(adrenomedullin, amylin) that have physiological effects on glycaemic control.  
These hormones in addition to CGRP have been shown to be dysregulated in 
diabetes and insulin resistance, and can contribute to oxidative stress (Brain and 
Grant, 2004, Shimosawa et al., 2003).  These features made CGRP a novel 
agonist to explore further in GDM pregnancy. 
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The present studies showed that CGRP exerted vasodilatory effects 
predominantly through endothelium-independent mechanisms in placental 
vessels.  The endothelium-independent pathways through which CGRP affects 
VSMCs are different to those through which SNP acts. Briefly, CGRP acts via G-
protein coupled receptors to activate cAMP and intracellular calcium pathways 
within VSMCs, whilst SNP donates NO to activate cGMP pathways (see figure  
6.8).  Since there is significant difference between groups in SNP induced 
vasodilation but not CGRP, we can conclude that placentas from GDM pregnancy 
have direct or indirect dysregulation of VSMC cGMP pathways.  
There was no significant vasodilatory response to the endothelium-dependent 
agonist, bradykinin.  This has been demonstrated by others also (Mccarthy et al., 
1994, Ong et al., 2002).  This is despite presence of appropriate receptors for 
agonists present in these tissues (Valdés et al., 2016). Potential reasons for such 
findings include high levels of peptidases in placental tissue that could 
metabolise peptide agonists, or reduced intraluminal contact with agonists 
during wire myography experiments may not be sufficient to mimic in vivo 
conditions. Hayward et al showed that addition of high dose Bradykinin to pre-
constricted CPAs reduced perfusion pressure in these vessels, but not in the 
same measurable way used in standard myography techniques where there is 
progressive vasodilation with increasing agonist concentration.  Instead, there 
was reduced amplitude and frequency of vasomotor oscillations (Hayward et al., 
2013). In constricted CPAs, vasomotion is slow and can occur as little as once 
every 15 minutes (Hayward et al, 2013), or may not be induced in some vessels 
at all as I learned through my experience in the specialist unit at the University 
of Manchester.  Vasomotion is observed in many vascular beds and may serve a 
role in optimising fetoplacental flow, but this role is less clearly defined. 
Furthermore, others have shown marked vasodilation in response to bradykinin 
in pressure myography studies (Gray et al., 2015). Taken together with previous 
evidence that flow-induced NO release is present in fetoplacental circulation 
and histopathological evidence of bradykinin receptors in these tissues, it seems 
likely that endothelial induced vasodilation is an important mechanism in 
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regulating fetoplacental flow but that wire myography methodologies are very 




Figure 6.8: Endothelial and vascular smooth muscle pathways involved in vasodilatation and 
the effects of CGRP and SNP 
This figure shows the endothelial cell in blue and VSMC in orange.  Within the endothelial cell, 
nitric oxide (NO) is produced from the oxidisation of L-Arginine by the catalyst endothelial Nitric 
Oxide Synthase (eNOS).  eNOS can be stimulated through pathways which increase intracellular 
calcium production within the endothelial cell, or via calcium independent pathways that 
increase cAMP and phosphorylation of protein kinases (PKA and Akt).  Following synthesis, NO 
diffuses across the endothelium into the VSMC where it acts to increase levels of the second 
messenger, cGMP.  cGMP pathways cause vasodilatation through several mechanisms. These 
include 1) reduction in intracellular calcium stores by inhibiting release from the endoplasmic 
reticulum 2) activation of voltage gated K channels which cause a K influx and repolarisation of 
the VSMC and 3) activation of protein kinase G which activates myosin phosphatase resulting in 
dephosphorylation of myosin light chains and inhibiting vasoconstriction (Gewaltig and Kojda, 
2002). cGMP is deactivated by Phosphodiesterase 5 (PDE5). 
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VSMC have NO independent mechanisms for vasodilatation.  When cAMP pathways are activated 
by agonists, they cause phosphorylation and activation of protein kinase A.  This in turn leads to 
activation of potassium gated channels on the cell membrane, activated myosin phosphatase 
with reduced calcium sensitivity of contractile apparatus and increased calcium uptake by the 
endoplasmic reticulum. All of this results in vasodilatation (Consigny, 1991). cAMP is broken 
down by Phosphodiesterase 3.  
In this study, NO donation via SNP was used and would activate cGMP pathways.  CGRP activates 
cAMP within both the endothelial and VSMC cell, with subsequent phosphorylation of protein 
kinases as described.   
 
The mechanisms by which GDM may alter cGMP pathways in placental VSMCs 
needs further exploration.  One hypothesis is that expression of 
phosphodiesterases (PDE), is upregulated in hyperglycaemic pregnancy.  PDEs 
hydrolyse cGMP and cAMP and inactivate it causing smooth muscle contraction. 
PDE5 is cGMP specific and expressed in placental vasculature (Larré et al., 
2017). Plasma PDE5 and PDE activity within the placenta has been found to be 
increased in women with preeclampsia compared to healthy controls (Pinheiro 
Da Costa et al., 2006, Sohlberg et al., 2014).   Hyperglycaemia has also been 
shown to increase PDE5 expression in neurovascular tissues in non-pregnant 
mouse models (Wang et al., 2011).     It seems plausible that similar altered 
expression may occur in the placenta of diabetic pregnancy as an effect of 
hyperglycaemia.  However, further studies are needed, initially exploring the 
expression of cGMP and PDE5 in these placentas before definitive conclusions 
can be drawn.  
It is also likely that increased oxidative stress from reactive oxygen species 
(ROS) plays a role in the altered vascular smooth muscle function seen here.  
Superoxide (O2-) is the most abundant ROS in humans and reacts with NO to 
produce the cytotoxic peroxynitrite (ONOO-).  ROS dysregulation has been 
implicated in many vascular diseases, and in health is kept in check by ROS 
scavenger enzymes, such as Superoxide Dismutase (SOD) (Cervantes Gracia et 
al., 2017).  In animal models, it has been demonstrated that VSMCs have 
attenuated cGMP production in the presence of O2- (Wu et al., 2000).  O2- also 
increases PDE5 expression in human VSMCs (Muzaffar et al., 2008). Both 
mechanisms combined lead to reduced bioavailability of cGMP, which in turn can 
lead to reduced vasodilatory effects in vasculature. Enhanced ROS activity can 
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also contribute to other detrimental effects on cells from DNA damage, impaired 
autophagy, mitochondrial damage and dysregulated inflammatory pathways 
(Taniyama and Griendling, 2003), all of which could lead to cellular dysfunction. 
Studies have demonstrated enhanced O2- production from endothelial cells in the 
presence of hyperglycaemia, and more so that this occurs within the 
mitochondria and enhanced effects of NADPH oxidase (Dymkowska et al., 2014, 
Nishikawa et al., 2000).  Higher concentrations of O2- are also seen in placentas 
from mothers with preeclampsia particularly in early-onset disease (Poston et 
al., 1995, Sikkema et al., 2001).  Nitrotyrosine residues, a proxy measure of 
ONOO- activity in tissue have also been shown to be increased in placentae from 
T1DM (Lyall et al., 1998).  Taken in combination with the impaired endothelium-
independent vasodilation shown in my work, this suggests a common pathway for 
vascular dysfunction in the GDM placenta.  In order to differentiate the 
mechanisms further, further work exploring the expression of  ONOO-, cGMP and 
PDE5 in placental tissue and cord blood will be of interest.  
The findings in this study are interesting, but it is important to acknowledge the 
weaknesses of this study.  Firstly, it includes a small cohort, recruited 
prospectively as part of a wider trial.  As a result, I have been unable to control 
for method of delivery and treatment options.  Reassuringly, there were no 
differences in vascular reactivity of CPAs according to method of delivery, a 
finding which is replicated by others  (Mills et al., 2007), nor in treatments used 
to manage their labour. Due to the prospective enrolment of women (n=60), 
placental collection was significantly limited by  external factors, resulting in  
just over 50% being available for inclusion.      
In conclusion, this novel study demonstrates that arteries on the fetal side of 
placental circulation have reduced vasodilatory capacity in GDM pregnancy.  The 
effects seem largely to be mediated by alterations in cGMP pathways in vascular 
smooth muscle, and is negatively associated with hyperglycaemia.  This may be 
an important mechanism to better understand placental health and mechanisms 
of adverse neonatal outcome in pregnancy complicated by diabetes.  I would like 
to hypothesise that hyperglycaemia results in increased oxidative stress within 
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the fetoplacental unit, and further mechanistic studies into markers of oxidative 

















7 Discussion and Summary 
7.1 Summary of main findings 
The key aim of this thesis was to investigate the role of vascular function as a 
potential pathophysiological mechanism for adverse outcomes in hyperglycaemic 
pregnancy.  I have examined outcomes of pregnancy women with diabetes and 
further examined in a detailed case control study vascular function on women 
with GDM.  Since many placentally-derived illnesses such as pre-eclampsia and 
stillbirth occur with higher frequency in pregnancies complicated by diabetes, it 
was hypothesised that placental vascular function would be altered in 
pregnancies complicated by GDM. It was also hypothesised that maternal 
systemic endothelial function would be reduced in such pregnancies.  Extensive 
evidence in systemic vascular beds shows altered endothelial function in those 
with longstanding diabetes.  Preeclampsia the pregnancy unique condition 
associated with widespread endothelial dysfunction is also increased in diabetes, 
but risk can be significantly reduced by treatment of hyperglycaemia.  I firstly 
set out to quantify the prevalence of adverse outcomes in pregnancy 
complicated by pregestational diabetes using our national data. Following the 
results of this study, I then investigated in the same population the key risk 
factors associated with stillbirth, an important but poorly understood 
complication that was up to 5-fold higher in diabetes.  Simultaneously, I 
designed, led and implemented a mechanistic cohort study exploring temporal 
trends in systemic endothelial function in women with GDM compared to control 
groups, and after delivery examined vascular reactivity of the fetoplacental 
resistance arteries in the chorionic plate to determine if vascular function 







The main findings from my studies are: 
1) Pregnancies complicated by T1DM and T2DM have significantly higher 
rates of adverse outcomes compared to non-diabetic controls, and this 
is not improving over time 
As detailed in chapter 3, epidemiological data from Scottish births 
between 1998-2013 showed higher rates of operative delivery (2-3 fold), 
preterm delivery (3-6 fold), infant overgrowth (4-5 fold) and stillbirths (4-
5 fold) in pregnancies complicated by T1DM and T2DM compared to 
pregnancies without diabetes.  Mothers with T1DM had the highest rates 
of operative and preterm delivery and birthed larger infants, whilst 
mothers with T2DM had the highest rates of stillbirth.  In clinical practice, 
T1DM can be more challenging to optimise glycaemia than in T2DM leading 
to fetal hyperinsulinaemia and may be an explanation for the highest 
adverse outcomes seen in our T1DM population.  Despite anecdotal 
suggestion that T2DM is often a more easily controlled state of 
hyperglycaemia, they had the highest rates of stillbirth suggesting that 
coexisting vascular and metabolic risk factors associated with the T2DM 
phenotype  may be contributing to risk, in addition to glycaemia. 
2) In T1DM and T2DM, higher levels of glycaemia are seen in pregnancies 
that end in stillbirth compared to livebirth, and although glycaemia 
during pregnancy (as measured by HbA1c) is better in T2DM than 
T1DM, rates of stillbirth are higher in T2DM. 
Chapter 4 demonstrates that in pregnancies complicated by T1DM and 
T2DM, the main modifiable risk factors associated with stillbirth were 
hyperglycaemia (as measured by HbA1c) and higher maternal BMI in T2DM. 
Importantly, these effects on stillbirth risk were independent of each 
other. Strongest glycaemic associations were seen in later pregnancy in 
the case of T1DM although the association was present in all trimesters, 
whilst in T2DM the glycaemic association was restricted to the 
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preconception period.  This suggests that hyperglycaemia in pregnancy 
contributes to stillbirth risk.  From work by others, we know that in many 
cases of stillbirth in diabetes, the exact cause of fetal demise is not 
known.  However, a high proportion of women will have subclinical 
evidence of vascular defects on histopathological examination of 
placentas in diabetes, regardless of pregnancy outcome.  The association 
with higher glycaemia and stillbirth risk in T2DM especially suggests 
detrimental effects around the time of implantation which could lead to 
impaired invasion and placental vascular development. Taken together, 
higher glycaemia is associated with stillbirth, a complication of placental 
vascular insufficiency and supports the hypothesis that glycaemia may 
contribute to altered placental vascular function in these pregnancies. 
Other important risk factors identified in this study included birthweights 
at the extremes of centiles (<10th and >95th centile) and delivery beyond 
38 weeks gestation.  Low birthweight may be a sign of placental failure, 
whilst larger and older babies may place more demand on the placental 
circulation.   
3) Maternal systemic endothelial-dependent vasodilatory function (as 
measured by FMD brachial artery) is not different in pregnancies 
complicated by diabetes compared to non-diabetic pregnancies. 
Studies in chapter five demonstrated similar endothelial-dependent 
vasodilatation in women with diabetes and controls.  Similarly, there was 
no effect of fasting plasma glucose, insulin resistance measurements or 
HbA1c on endothelial-dependent vasodilatation.  Only three women in 
this study developed preeclampsia and so it would be wrong to make 
inferences on shared pathology between preeclampsia and GDM, but my 
data show that hyperglycaemia in pregnancy itself is not associated with 
clinically meaningful macrovascular systemic endothelial dysfunction that 
results in altered vasodilatory capacity.  This study examined only one 
aspect of endothelial function.  Retrospectively, it would have been 
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interesting to quantify multiple markers of endothelial function.  
Biochemical measures of NO metabolism may have been useful to 
measure although are confounded by NO production from other sources 
including dietary consumption.  There may also be alterations in the non-
vasodilatory endothelial pathways such as procoagulant factors and 
cellular adhesion molecules.  Microvascular endothelial function was also 
not assessed and would be of interest given the strong relationship of 
hyperglycaemia and microangiopathy.   
4) In GDM pregnancy, higher fasting plasma glucose is strongly associated 
with higher SBP and DBP suggesting adverse effects of glucose on 
vascular function that are non-NO mediated. 
In chapter 5, subgroup analysis of the GDM group revealed a strong 
association with fasting plasma glucose and higher BP.  Whilst endothelial-
dependent vasorelaxation did not appear to be impaired in these women, 
this effect suggests that hyperglycaemia is associated with a pro-
contractile phenotype but via alternative pathways to endothelial NO 
release.  Research into other vascular pathways including ROS generation 
and VSMC function may reveal a common vascular pathophysiological 
mechanism to GDM and complications such as preeclampsia.    
5) Fetoplacental arteries from GDM subjects show diminished cGMP-
mediated vasodilation of VSMCs compared with controls.  This effect is 
negatively associated with higher fasting plasma glucose suggesting a 
pathophysiological mechanism for GDM and complication associated 
with placental vascular insufficiency such as preeclampsia and 
stillbirth.   
There is a paucity of data in human studies of vascular reactivity in 
hyperglycaemic pregnancy (GDM or pregestational DM).  Chapter 6 
demonstrates that vasodilatory response to endothelial-independent 
agonist, SNP, is reduced in pregnancies complicated by GDM suggesting a 
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pro-contractile phenotype of the fetoplacental resistance vessels.  Higher 
resistance in the fetoplacental vasculature is associated with impaired 
fetoplacental perfusion and may be a mechanism for placentally-derived 
disease in GDM.  These vascular effects seem to be mediated mainly 
through glucose effects on cGMP pathways.  Further work to establish if 
these are due to altered cGMP expression, breakdown by PDEs, or ROS 
generation is warranted. It is well recognised in non-pregnant subjects with 
longstanding diabetes that chronic hyperglycaemia alters these pathways.  
Temporary hyperglycaemia may have similar effects and contribute to 
placental disease in GDM.  
7.2 Challenges 
1) Limitations of clinical databases 
My work benefited from the data infrastructure within NHS Scotland. The 
clinical databases used nationally are used universally, validated for key 
aspects of data capture and are well integrated into pathways that make 
them accessible for epidemiological research. However, all databases 
have their limitations.  Clinical databases are susceptible to misreporting 
of information which may be for a variety of reasons such as missing 
information, different historical diagnostic criteria and miscoding.  For 
many of the variables I was interested in, the data was validated.  
However, preeclampsia diagnosis, an important outcome that was central 
to the thesis was not validated in the SMR02.  Discussions with senior 
authors who have previously published using the SMR02 preeclampsia 
coding and who have extensive knowledge of the database for other 
obstetric studies, suggest that preeclampsia  is underreported in SMR02.  
In a multinational study, Scotland reported preeclampsia rates 1.5-2.5% in 
the obstetric population, compared to almost double that in the other 
Westernised populations (Roberts et al., 2011).  Importantly, in this 
publication Scotland was the only database where preeclampsia coding 
had not been validated, nor was it possible to identify how preeclampsia 
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diagnosis had been reached. For this reason, preeclampsia was not 
included as a reliably reported outcome in these studies but clearly was 
of interest. The risk factor associations study in chapter 4 therefore 
focused solely on stillbirth, as a condition significantly associated with 
vascular pathology in diabetes.  
Furthermore, within the SCI diabetes database very few were diagnosed 
as GDM when one would anticipate that approximately 5% of the obstetric 
population would be diagnosed.  This supports the anecdotal evidence I 
see in clinical practice that GDM is not routinely entered into SCI 
Diabetes.  These studies therefore excluded women with GDM, despite 
being the most common metabolic disorder seen in pregnancy and a 
significant burden on population health.    
2) Association or causation 
All of my studies, whether epidemiological or mechanistic, have 
demonstrated that hyperglycaemia is associated with adverse outcome 
pregnancy or altered vascular function.  Whilst my analysis is supportive 
across all chapters of glycaemia being a critical factor in development of 
these outcomes, they do not definitively prove that hyperglycaemia either 
causes or predicts placental dysfunction, preeclampsia or stillbirth.  In a 
human model, this would be challenging since metabolic and 
cardiovascular pathways are often interlinked, human populations and 
disease are heterogenous and pregnancy is an adapting physiological 
state. There are a host of unmeasured factors such as genetics and there 
will  be unknown biological variables that are unaccounted for.  In a small 
study such as this, important confounders need to be accounted for, but 
to explore multiple confounders in tandem would require much larger 




3) Placental myography – unique aspects 
The Institute of Cardiovascular and Medical Sciences at the University of 
Glasgow have a unique and expert laboratory for vascular myography 
studies.  They are well published in myography, and it is a proud feature 
of the Centre of Excellence for cardiovascular research.  However, my 
study was the first to use placental chorionic plate arteries which are 
more delicate to handle, less contractile and respond to different agonists 
compared to systemic vessels.  I was lucky that I was able to liaise and 
visit the specialist placental research centre at the University of 
Manchester and work with Dr Mark Wareing. Dr Wareing and his team had 
accumulated a wealth of data over years and already optimised placental 
artery myography protocols.  I was able to use these protocols for my 
study.  However, the practical aspects of myography such as dissection 
and mounting and maintaining viability in these delicate vessels was a 
large challenge that required months of ongoing practice before I felt 
comfortable.  
Furthermore, the experiments were of 8+ hours duration and should be 
performed on fresh vessels to ensure viability. A novel aspect of my study 
was to demonstrate hyperglycaemic effects on maternal and placental 
vasculature in the same cohort. The nature of pregnancy, delivery and 
need for immediate placental collection meant that I had to be always 
available to go to the lab and be ready for these long experiments.  For 
the 18-month period during which my participants delivered their babies, 
I received telephone calls to let me know of imminent delivery at all 
times of day.  A significant proportion would deliver overnight.  Extreme 
flexibility in work and sleep pattern was required on my part to fulfil this 
aspect of the study.  This was the most challenging aspect of this study 
but also the most satisfying personally. For the most part, I achieved this.  
The only absolute times I knew in advance I could not collect samples 
where when I was on shift for clinical duties and during the period when I 
was out of the country presenting my research.  All participants were 
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aware on entry to the study that due to the sporadic nature of delivery, 
there was a risk that some placental collections may be missed.   
I was on target to achieve collection in two thirds of my cohort, but 
sustained an injury in the final months that significantly restricted my 
mobility.  For a 5-week period, during which six participants delivered, I 
was not safe to transport samples nor work in the laboratory safely.  The 
final number of placentas included (32 out of 60) was still a good number 
to include in a myography study but as result, I had to condense some of 
my analysis into two groups (GDM versus non-GDM).  
4) Prospective recruitment in pregnancy and placental studies 
Pregnancy is a dynamic situation and clinical staff will make clinical 
decisions throughout the duration of pregnancy.  Recruitment strategies 
were designed to limit effects of concurrent morbidity and medication use 
at entry of study, but it does not negate clinical decisions taken 
throughout pregnancy. None of my population were prescribed 
definitively vasoactive medication (other than Aspirin) throughout the 
pregnancy period that required FMD measurement, but some were taking 
iron supplementation, laxatives and antacids to treat common pregnancy 
complaints at various points.  Whilst none of these are expected to alter 
vascular function, effects have not been formally tested. Temporal trend 
observational studies in pregnancy are at risk of bias. This was evident in 
my placental studies. My study was novel in that it investigated maternal 
and placental vascular function in the same pregnant cohorts.  The 
advantage of this approach was that I could demonstrate vascular 
dysfunction within the placenta, despite similar vascular function 
systemically.  However, I could not control for various factors across 
pregnancy such as method of delivery nor medications used during it. 
Whilst my, and others analysis, have demonstrated that neither method of 
delivery, nor medications used peri-partum had significant effect on the 
vascular reactivity results, it does not completely negate any effect.  A 
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cleaner experiment would have involved including recruiting both cohorts 
separately, and only including women undergoing elective caesarean 
section without need for peri-partum medications in the placental study. 
5) Recruitment 
There are two tertiary obstetric centres within NHS Greater Glasgow and 
Clyde, the Princess Royal Maternity covering North-East Glasgow and the 
Queen Elizabeth University Hospital covering South-West.  These hospitals 
serve regions with different population demographics.  For example, the 
Princess Royal Maternity serves some of the more materially deprived areas 
in Scotland, whilst the Queen Elizabeth University Hospital serves some 
regions with higher ethnic diversity.  I was keen to recruit from both, but 
all study visits had to be conducted at the Queen Elizabeth University 
Hospital.  The reasons for this are that the FMD technology was based at 
the Queen Elizabeth University Hospital Clinical Research Facility.  
Attempts were made to recruit from both hospitals, but despite the 
coverage of travel expenses, women who stayed in areas served by the 
Princess Royal Maternity were more reluctant to enter the study with travel 
being cited as a common reason.  The overall demographic of the study 
population is mixed, and I do not think recruitment bias impacts on the 
study results. However, we should be aiming to overcome obstacles that 
prevent participants from entering studies from a wide variety of 
backgrounds, particularly if their demographics are key risk factors in the 
conditions that we are investigating.   
7.3 Future work 
There are multiple facets of additional studies that I think are needed to 
progress understanding in pathophysiology and prevention of obstetric 
complications in diabetes, and mechanisms for altered placental vascular 
function.  I have summarised further work that I think is important to improving 
outcomes in these pregnancies, or enhance our understanding of vascular 
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mechanisms of disease in these pregnancies.  Some of this I have already 
initiated as part of my clinical lectureship.  
7.3.1 Epidemiological studies 
1) Validation of preeclampsia in national databases 
It is important for us to be able to quantify the impact that preeclampsia 
has on public health nationally.  However, previous extracts of the linked 
databases are limited in allowing us to do this, although we have not 
defined the extent of underreporting in these databases.  A study 
exploring random samples of women (with and without diabetes) from 
each maternity centre in Scotland and comparing coded diagnosis in 
SMR02 against clinical records would be useful.  From this we could 
provide an estimate of how many are incorrectly coded as preeclampsia, 
but also how many who met diagnostic criteria were not coded.  This 
would afford us better estimates of prevalence nationally.  This would 
require a large, multicentre study with unblinding of individual level data 
so would need to be performed as part of a multi-centre audit with 
individual clinical teams collecting data.  
2) Cause of stillbirth – national audit 
This work has demonstrated that higher glycaemia in pregnancy is 
associated with stillbirth. However, does not define the causes of 
stillbirth. From audits performed in other nations, we surmise that 
upwards of 50% will have no clear identifiable cause of stillbirth, but a 
majority will show evidence of placental vasculopathy. I am currently 
leading on a national paper audit of stillbirths in diabetes, in 
collaboration with the individual regional representatives on the Scottish 
Diabetes Group Pregnancy Subgroup to better define this in the Scottish 
population.  Each regional representative has agreed to review their 
clinical notes from 2010-2018 of women with diabetes who experienced 
stillbirth. From this, they will collect information on: pre-pregnancy 
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preparation, glycaemic control during pregnancy, medication use, 
microvascular complications, comorbid illness, maternal obstetric 
complications, suggested cause of stillbirth and importantly available 
post-mortem and placental pathology results.  Data will then be collated 
in anonymised format and allow us to identify if achieving obstetric care 
targets in these women, identify specific causes of stillbirth and decide if 
alterations in care pathways are needed to improve upon this stubbornly 
high poor outcome.  
3) Reanalysis of outcomes following nationally funded strategies to 
improve pregnancy outcomes 
The results from chapter 3 and 4 have helped inform the Scottish Diabetes 
Improvement Plan strategies in 2021-2026. This, alongside the landmark 
CONCEPTT trial from Prof Helen Murphy, has helped secure £5million in 
national funding in Scotland, part of which will help to improve access to 
CGM in pregnancy for all mothers with T1DM.  In future years, it would be 
important to reanalyse our obstetric outcome data for improvement in 
obstetric outcomes in this group following widespread use of this 
technology.  Mothers with T2DM and other types of diabetes will however 
not be automatically afforded access to CGM during pregnancy due to lack 
of studies in these cohorts.  For this group, optimisation of pre-pregnancy 
weight and metabolic health is likely to be key. The Scottish Diabetes 
Prevention Programme has been developed and includes £40 million 
funding over 5 years to impede the rising prevalence of diabetes and 
obesity related complications in Scotland.  Improved and equitable access 
to evidence-based weight management programmes for at risk individuals 
is a key component of the prevention programme.  GDM and T2DM are 
identified within these cohorts. Currently, access to weight management 
service has been agreed post-GDM diagnosis and will occur post-
pregnancy, so is unlikely to have an immediate effect on pregnancy 
outcomes, but with time, an improvement in the health of women of 
reproductive age will hopefully lead to a reduction in adverse outcomes in 
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such pregnancies.  Furthermore, awareness campaigns and empowering 
the public with the knowledge of their diabetes risk may trigger some to 
adopt changes in lifestyle and seek support for their weight.  Metabolic 
pre-conceptual clinical services also need to be better developed in many 
areas to afford women the best chance of entering pregnancy with 
optimal chances of a good outcome.  Reanalysis of obstetric outcomes 
following implementation of these strategies will be important in future 
years.  
4) Optimal timing of delivery to prevent stillbirth and neonatal morbidity 
in pregnancies complicated by diabetes 
My work has shown that stillbirth rates per 1,000 ongoing pregnancies at 
that particular gestation peak at 38-39 weeks in T1DM and T2DM.  Current 
national guidance suggests that women are counselled for delivery from 
38 weeks onwards.   The question is therefore raised if stillbirths could be 
prevented by lowering that recommendation to 37 weeks.  However, 
there are already high numbers of these women experiencing pre-term 
delivery and the risk of neonatal morbidity at delivery at 37 weeks 
compared to 38 weeks needs to be quantified.  In chapter 4.4, I 
simplistically estimate that stillbirth rates could be reduced by 6 per 
1,000 births (1-2 stillbirths per year) with an estimated additional 12 
cases per year of RDS caused as result.  At this gestation, many of these 
are likely to be of milder severity. However, this estimate is based on 
prevalence rates in the general obstetric population and assumes delivery 
of prenatal steroids for lung maturation. In diabetes, fetal lung 
maturation can be delayed and so this may be a gross underestimate.  
Numerous studies are required before recommendations can be made to 
lower recommended gestational age at delivery.  
In the first instance, an observational study using national neonatal 
clinical databases (SMR01, SMR02 and BadgerNet™) to quantify neonatal 
mortality and serious morbidity according to week of delivery in the 
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population with diabetes would be useful.  Identification of a time point 
where neonatal mortality exceeds severe morbidity rates would help 
identify optimal timing of delivery in diabetes. The best methodology for 
determining optimal timing of delivery in this population would be a very 
large, multi-national trial that randomised women with diabetes to 
delivery at 37 or 38 weeks in otherwise healthy pregnancies.  However, 
any such trial would be challenging to conduct logistically, would require 
robust evidence of morbidity at each gestational age, and would be 
fraught with multiple ethical dilemmas making it less appealing to 
researchers and participants.  As such, most of our evidence in this area is 
likely to continue to come from observational data.  
7.3.2 Vascular mechanistic studies 
My research has suggested altered vascular function in the fetoplacental unit in 
hyperglycaemic pregnancy.  Further mechanistic studies would help consolidate 
these findings, and simultaneously advance knowledge in mechanisms of 
placental disease in these pregnancies.  Some future studies that I think would 
be important to complete are: 
1) Understanding biochemical pathways leading to altered VSMC function 
in placentae from hyperglycaemic pregnancy 
I have demonstrated impaired NO-independent vasodilatation in 
fetoplacental arteries in GDM, with a negative association between higher 
maternal glycaemia and vasodilatory capacity.  This implies effects on 
vascular smooth muscle pathways that control vascular tone, specifically 
relating to cGMP pathways.  Based on my findings, it would be important 
to explore how key components of these cGMP-mediated vasodilatation 
are different in GDM pregnancy.  As discussed in chapter 6.3.6, these 
effects could result from reduced bioavailability of cGMP either directly 
due to reduced cGMP levels  via enhanced degradation by increased 
phosphodiesterase activity. From my studies, I have fresh frozen samples 
of placental tissue and cord blood.  I would be interested to explore this 
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further.  To investigate reduced cGMP levels, I would be interested in 
performing a number of other experiments.  Firstly, quantifying cGMP 
levels via immunoassay in placenta and cord blood to determine if there is 
any difference in levels between GDM and non-GDM pregnancy.  
Mechanisms of reduced cGMP availability could result from enhanced 
oxidative stress, and scavenging of NO by reactive oxide species. 
Measuring expression of both superoxide (NO scavenger) and peroxynitrite 
(superoxide+NO) in these samples could determine if NO scavenger 
activity is increased in these samples, leading to reduced cGMP 
production.  Furthermore, measurement of other highly toxic reactive 
ROS such as hydrogen peroxide would be useful to determine if ROS being 
produced is having a deleterious effect on tissue.  
Another potential mechanism for altered cGMP function is through 
enhanced degradation  by PDE enzymes.  As discussed in chapter 6, 
diabetes is known to increase PDE and PDE5 is found in abundance in the 
placenta.  PDE5 quantification in placental tissue and cord blood would 
allow us to establish if upregulation of PDE5 due to hyperglycaemia is a 
potential mechanism of placental vascular disease.  
2) miRNA expression in placental tissue as key regulators of vascular 
homeostasis 
miRNAs are small, non-coding RNAs that have important regulatory 
functions in various aspects of vascular and endothelial homeostasis. 
miRNAs have been found to be dysregulated in a number of cardiovascular 
diseases including preeclampsia (Sheikh et al., 2016).  As part of my 
lectureship, I plan to perform miRNA sequencing on placental tissue from 
my cohort to identify if there is differential expression of these regulatory 
miRNAs in GDM placentas, and if so, what gene pathways they regulate.  
This could provide further insight into placental vascular function, and 




3) Maternal systemic vascular function 
The studies of maternal systemic vascular function contained in this thesis 
focused primarily on endothelial function, which we know is dysregulated 
in other obstetric conditions of interest such as preeclampsia.  There was 
no demonstrable difference in this.  However, my studies did not include 
any other vascular phenotyping studies and in hindsight, I think this would 
be important to look at.  An example of an interesting experiment to 
answer whether non-endothelial dependent vascular function was altered 
in these pregnancies would be to perform wire myography experiments 
using systemic maternal vessels.  This could use arteries contained within 
subcutaneous fat from samples taken at the time of caesarean section and 
measuring contractile or vasodilatory responses to incremental increases in 
endothelial- dependent and independent vasoactive agonists.  Other 
generic, non-invasive measures of vascular function such as measuring 
vascular stiffness may also have broadened knowledge of how vasculature 
behaves in these pregnancies.  
7.4 Summary 
In summary, this thesis has demonstrated that adverse obstetric outcome is 
common in pregnancies complicated by diabetes, and there appears to be a 
dynamic relationship between higher levels of maternal glycaemia and these 
outcomes.  Some of these effects are very well understood and occur as a result 
of fetal overgrowth due to stimulated fetal hyperinsulinaemia. However, other 
effects such as stillbirth and preeclampsia are less understood and thought to 
relate to adverse placental function in such pregnancies.  Based on the 
experiments contained within this thesis, fetoplacental vessels have diminished 
vasodilatory capacity and may contribute to high vascular resistance within the 
fetoplacental circulation.  These effects appear to be related to cGMP mediated 
vascular smooth muscle function, but exact mechanisms for alterations in these 
pathways need to be explored further.  This may be an important mechanism of 
disease in these pregnancies.  
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In the same cohort, maternal vascular endothelial function was assessed and 
there was no difference in endothelial NO-dependent vasodilation.  However, 
subgroup analysis of the GDM suggested that higher maternal glycaemia was 
associated with higher BP suggesting that maternal vascular function is altered 
in these pregnancies.  The mechanisms for this are unlikely to be endothelial in 










































Appendix 1:  Case report form 
 




Group:  Gestational Diabetes (GDM)    
   
   Risk factors for GDM     
 







Gestational date at screening:  
 
Inclusion Criteria:   Is patient >18 years old?   
 
     Is this a singleton pregnancy?  
 
     For women undergoing oral  
glucose tolerance test, is this  
being done prior to 32 weeks  
gestation? 
    
     Has the woman had a confirmed  
normal 20-week anomaly  
scan? 
 
Exclusion criteria:   Diagnosis of diabetes prior to  
pregnancy (previous  
gestational diabetes accepted  
for gestational diabetes and  
risk factor groups)  
 
     Diagnosis of hypertension prior  
to pregnancy 
 
Diagnosis of pre-existing medical  





Is the patient on any medications  
other than Aspirin, pregnancy  
vitamins, folic acid or thyroxine 
(DISCUSS WITH CI) 
Details……………………………………. 
 
Known placental or obstetric 
complications this pregnancy 
 
Does the participant lack capacity  
to give written informed consent 
 
Is the participant unable to understand 
written English language 
 
 
Results of oral glucose tolerance test (if applicable): 
 
 Fasting 0 hour glucose  …….. 
 2-hour glucose   …….. 
 
 HbA1c (if available)   …….. 
 

































Written informed consent complete  
 
Participant Age (whole years)  ………… 
 
Gestational age (weeks + days) ………… Parity  ………. 
 
 
Past medical history   ………………………………………………………… 
     
     ………………………………………………………… 
 
Medications:    ……………………………………………………….. 
 
     ……………………………………………………….. 
Smoking status   ………………………………………………………. 
 
Any new placental/obstetric  Y/N if Y details …………………………………. 
complications since screening 
 
 
Booking height (m)  ………..  Booking weight (kg) ……… 
 
Current weight (m)  ……….. 
 
BP (mmHg)   ……….. 
 




Bloods   Fasting glucose                  Insulin 
 
    Fructosamine                     HDL 
 
                                      IL6     IL8 
 
    TNF alpha   sFlt1 
 











Gestational age (weeks + days) ………… 
 




Medications:    ……………………………………………………………….. 
 
 
Any new placental/obstetric  Y/N if Y details …………………………………………. 
complications since last study  
visit? 
 
BP (mmHg) …………… 
 









Gestational age (weeks + days) ………… 
 




Medications:    ……………………………………………………………….. 
 
Any new placental/obstetric  Y/N if Y details …………………………………………. 
complications since last study  
visit? 
 
BP (mmHg) …………… 
 












Gestational age (weeks + days) ………… 
 




Medications:    ……………………………………………………………….. 
 
     ……………………………………………………………….. 
 
Any new placental/obstetric  Y/N if Y details …………………………………………. 
complications since last study  
visit? 
 
Weight (m) ………….. 
 
BP (mmHg) …………… 
 
FMD (%)      …………….    Attach FMD print out 
 
Bloods   Fasting glucose                  Insulin 
 
    Fructosamine                     HDL 
 
                                      IL6     IL8 
 
    TNF alpha   sFlt1 
 
    PlGF 
 
 














Study ID  
 
Date of delivery     
 
Gestational age at delivery (weeks + days)    ………….. 
 
Infant sex                                                      ………….. 
 
 
Medical induction     Y/N 
 
Prostin      Y/N 
 
Syntocin      Y/N 
 
Syntometrine      Y/N 
 
 
Mode of delivery     vaginal (incl instrumental)   
(select all that apply)    
Elective caesarean section 
 
      Emergency caesarean section 
 
Fetal distress documented?   Y/N 
 
Hypertension documented antenatally?  Y/N 
 
Pre-eclampsia?     Y/N 
 
 
New medications since study visit 4?  Y/N, If yes, please list 
 
Placental weight (grammes):    
 
Vital status of infant:    
 
 
Placental biopsy taken     
 
 




Appendix 2:  Biochemical assay properties 
 
Manufacturer reported properties of assays used in these studies 








































2 g/L <2.2% 






































Appendix 3: Milliplex™ assay procedures  
 
PlGF assay using Human Cardiovascular Disease Magnetic Bead Panel 1 
(HCVD1MAG-67K) assay 
 
Serum samples were  prepared as in chapter 2.2.6.  Samples were removed from 
the freezer on day of experiment and allowed to thaw.  
 
ANTIBODY-IMMOBILISED BEAD PREPARATION 
1. Antibody-immobilised beads (specific to PlGF) were sonicated for 30 
seconds then vortexed for 60 seconds. 
2. 150µL of immobilised-bead solution was combined with bead diluent to 
achieve a total volume of 3mL and then vortexed for 30 seconds. 
 
QUALITY CONTROL SAMPLE PREPARATION 
1. Two quality control samples were provided by manufacturer.  Low 
concentration (range 24-51pg/mL) and high concentration (171-
355pg/mL).  250µL of deionised water was added to each of these, with 
vials then inverted, vortexed and allowed to settle for 10 minutes 
afterwards. 
 
WASH BUFFER PREPARATION 
1. Manufacturer provided wash buffer was brought to room temperature 
before 60mL was diluted with 540mL of deionised water.  
 
SERUM MATRIX PREPARATION 
1. 1mL of deionised water was added to manufacturer provided lyophilised 
serum matrix and allowed to reconstitute completely over 10 minutes, 
and then mixed by inverting.  
 
STANDARD PREPARATION 
1. 250µL of deionised water was added to vial containing manufacturer 
provided standard solution.  It was then mixed by inverting vial and 
vortexing for 10 seconds. This was standard 7. 
2. Serial dilutions were performed with 250µL assay buffer being added to 
125µL of the previously prepared standard (e.g. standard 6 was produced 
by adding 125µL of  standard 7 to 250µL buffer), and mixing well. The 
table below details standard preparation and resultant PlGF 
concentration. 





Standard number Volume of diluent Volume of standard PlGF concentration 
(pg/mL) 
#7 250µL deionised 
water 
0 2000  
#6 250µL assay buffer 125µL standard #7 666.7  
#5 250µL assay buffer 125µL standard #6 222.2   
#4 250µL assay buffer 125µL standard #5 74.1  
#3 250µL assay buffer 125µL standard #4 24.7  
#2 250µL assay buffer 125µL standard #3 8.2 
#1 250µL assay buffer 125µL standard #2 2.7 
#0 250µL assay buffer 0 0 
 
ASSAY PROCEDURE 
1. All standards, controls and sample analysis were performed in duplicate. 
2. 100µL assay buffer was added to each well of 96-well plate. The plate was 
sealed and mixed on a plate shaker at room temperature. 
3. The plate seal was then removed, and the assay buffer removed by 
inverting the plate and tapping sharply to remove as much assay buffer as 
possible. 
4. 25µL serum matrix was added to each standard (0-7) and control well.  
5. 25µL assay buffer was added to each sample well. 
6. 25µL of standard (0-7) and controls was added to the appropriate wells, 
and 25µL sample to the sample wells.  
7. The mixing antibody bead bottle was vortexed for 30 seconds to ensure 
mixed, and 25µL was added to each well.   
8. The plate was then sealed, covered with foil and placed on gentle 
agitation on a plate shaker for 18 hours overnight in a refrigerated room 
(40C). 
9. The well was then placed and secured on a handheld magnetic plate. The 
plate was allowed to rest for 1 minute to allow the magnetic beads to be 
attracted firmly to the surface of the well. The plate seal was then 
removed, and the plate inverted with a light tap to decant the fluid 
contents of the well.  The magnetic antibody beads should remain 
attached to the well.  
10. The plate was then removed from the magnet, wells washed with 200µL 
of wash buffer, placing on a plate shaker for 30 seconds before being 
reattached to the magnet and decanting contents as above.  
11. This wash step was repeated three times.  
12. 50µL detection antibodies (manufacturer provided) were then added to 
each well before being resealed, covered with foil and agitated on a plate 
shaker at room temperature for 1 hour.  
13. 50µL of Streptavidin-Phycoerythrin (manufacturer provided) into each 
well before being resealed, covered with foil and agitated on plate shaker 
at room temperature for 30 minutes.  
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14. The plate was then removed from the shaker and washed three times as 
per steps 9-11.  
15. 100µL of sheath fluid (manufacturer provided) was added to all wells and 
the beads resuspended by agitation on plate shaker for 5 minutes.  
16. The plates were then run on MAGPIX™ analyser with xPONENT software to 
analyse 50µL from each well.  A Median Fluorescence Intensity was 
reported from the software and results analysed manually as described in 






































sFlt-1 assay using Human Angiogenesis Magnetic Bead Panel 2 (HANG2MAG-
12K) assay 
 
PREPARATION OF SERUM SAMPLES 
1.  Serum samples were removed from the freezer on day of experiment and 
allowed to thaw.  
2. 20µL serum was combined with 80µL assay buffer to produce a 1 in 5 
dilution.  
 
ANTIBODY-IMMOBILISED BEAD PREPARATION 
1. Antibody-immobilised beads (specific to PlGF) were sonicated for 30 
seconds then vortexed for 60 seconds. 
2. 150µL of immobilised-bead solution was combined with bead diluent to 
achieve a total volume of 3mL and then vortexed for 30 seconds. 
 
QUALITY CONTROL SAMPLE PREPARATION 
1. Two quality control samples were provided by manufacturer.  Low 
concentration (range 112-233pg/mL) and high concentration (956-
1985pg/mL).  250µL of deionised water was added to each of these, with 
vials then inverted, vortexed and allowed to settle for 10 minutes 
afterwards. 
 
WASH BUFFER PREPARATION 
1. Manufacturer provided wash buffer was brought to room temperature 
before 60mL was diluted with 540mL of deionised water.  
 
SERUM MATRIX PREPARATION 
1. 1mL of deionised water was added to manufacturer provided lyophilised 
serum matrix and allowed to reconstitute completely over 10 minutes, 
and then mixed by inverting.  
 
STANDARD PREPARATION 
1. 250µL of deionised water was added to vial containing manufacturer 
provided standard solution.  It was then mixed by inverting vial and 
vortexing for 10 seconds. This was standard 7. 
2. Serial dilutions were performed with 250µL assay buffer being added to 
125µL of the previously prepared standard (e.g., standard 6 was produced 
by adding 125µL of  standard 7 to 250µL buffer), and mixing well. The 
table below details standard preparation and resultant sFlt-1 
concentration. 




Standard number Volume of diluent Volume of standard sFlt-1 concentration 
(pg/mL) 
#7 250µL deionised 
water 
0 10000 
#6 200µL assay buffer 100µL standard #7 3333 
#5 200µL assay buffer 100µL standard #6 1111   
#4 200µL assay buffer 100µL standard #5 370  
#3 200µL assay buffer 100µL standard #4 123  
#2 200µL assay buffer 100µL standard #3 41 
#1 200µL assay buffer 100µL standard #2 14 
#0 200µL assay buffer 0 0 
 
ASSAY PROCEDURE 
1. All standards, controls and sample analysis were performed in duplicate. 
2. 200µL assay buffer was added to each well of 96-well plate. The plate was 
sealed and mixed on a plate shaker at room temperature. 
3. The plate seal was then removed, and the assay buffer removed by 
inverting the plate and tapping sharply to remove as much assay buffer as 
possible. 
4. 25µL of standard (0-7) and controls was added to the appropriate wells, 
and 25µL of assay buffer to the sample wells.  
5. 25µL serum matrix was added to each standard (0-7) and control well.  
6. 25µL of the pre-diluted (1:5) sample was added to the sample wells.  
7. The mixing antibody bead bottle was vortexed for 30 seconds to ensure 
mixed, and 25µL was added to each well.   
8. The plate was then sealed, covered with foil and placed on gentle 
agitation on a plate shaker for 18 hours overnight in a refrigerated room 
(40C). 
9. The well was then placed and secured on a handheld magnetic plate. The 
plate was allowed to rest for 1 minute to allow the magnetic beads to be 
attracted firmly to the surface of the well. The plate seal was then 
removed, and the plate inverted with a light tap to decant the fluid 
contents of the well.  The magnetic antibody beads should remain 
attached to the well.  
10. The plate was then removed from the magnet, wells washed with 200µL 
of wash buffer, placing on a plate shaker for 30 seconds before being 
reattached to the magnet and decanting contents as above.  
11. This wash step was repeated three times.  
12. 25µL detection antibodies (manufacturer provided) were then added to 
each well before being resealed, covered with foil and agitated on a plate 
shaker at room temperature for 1 hour.  
13. 25µL of Streptavidin-Phycoerythrin (manufacturer provided) into each 
well before being resealed, covered with foil and agitated on plate shaker 
at room temperature for 30 minutes.  
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14. The plate was then removed from the shaker and washed three times as 
per steps 10-12.  
15. 100µL of sheath fluid (manufacturer provided) was added to all wells and 
the beads resuspended by agitation on plate shaker for 5 minutes.  
16. The plates were then run on MAGPIX™ analyser with xPONENT software to 
analyse 50µL from each well.  A Median Fluorescence Intensity was 
reported from the software and concentration results analysed manually 
as described in the main methods chapter.  Final concentrations were 




































IL-1β, IL-6 and TNF-α assay using Human Cytokine Magnetic Bead Panel  
(HCYTOMAG-60K) assay 
 
PREPARATION OF SERUM SAMPLES 
1. Serum samples were removed from the freezer on day of experiment 
and allowed to thaw.  
 
ANTIBODY-IMMOBILISED BEAD PREPARATION 
1. Antibody-immobilised beads (specific to PlGF) were sonicated for 30 
seconds then vortexed for 60 seconds. 
2. 60µL of immobilised-bead solution was combined with bead diluent to 
achieve a total volume of 3mL and then vortexed for 30 seconds. 
 
QUALITY CONTROL SAMPLE PREPARATION 
1. Two quality control samples were provided by manufacturer.  Low 
concentration (range 109-227pg/mL for IL-6, 100-207pg/mL for IL-1β 
and 110-228pg/mL for TNF-α) and high concentration (518-1076pg/mL 
for IL-6, 485-1008 pg/mL for IL-1β and 532-1106pg/mL for TNF-α).  
250µL of deionised water was added to each of these, with vials then 
inverted, vortexed and allowed to settle for 10 minutes afterwards. 
 
WASH BUFFER PREPARATION 
1. Manufacturer provided wash buffer was brought to room temperature 
before 60mL was diluted with 540mL of deionised water.  
 
SERUM MATRIX PREPARATION 
1. 1mL of deionised water was added to manufacturer provided 
lyophilised serum matrix and allowed to reconstitute completely over 
10 minutes, and then mixed by inverting.  
 
STANDARD PREPARATION 
1. 250µL of deionised water was added to vial containing manufacturer 
provided standard solution.  It was then mixed by inverting vial and 
vortexing for 10 seconds. This was standard 7. 
2. Serial dilutions were performed with 250µL assay buffer being added to 
125µL of the previously prepared standard (e.g., standard 6 was produced 
by adding 125µL of  standard 7 to 250µL buffer), and mixing well. The 
table below details standard preparation and resultant sFlt-1 
concentration. 





Standard number Volume of diluent Volume of standard Concentration of all 
analytes (pg/mL) 
#6 250µL deionised 
water 
0 10000 
#5 200µL assay buffer 50µL standard #6 2000 
#4 200µL assay buffer 50µL standard #5 400   
#3 200µL assay buffer 50µL standard #4 80  
#2 200µL assay buffer 50µL standard #3 16  
#1 200µL assay buffer 50µL standard #2 3.2 
#0 200µL assay buffer 0 0 
 
ASSAY PROCEDURE 
1. All standards, controls and sample analysis were performed in duplicate. 
2. 200µL assay buffer was added to each well of 96-well plate. The plate was 
sealed and mixed on a plate shaker at room temperature. 
3. The plate seal was then removed, and the assay buffer removed by 
inverting the plate and tapping sharply to remove as much assay buffer as 
possible. 
4. 25µL of standard (0-7) and controls was added to the appropriate wells, 
and 25µL of assay buffer to the sample wells.  
5. 25µL serum matrix was added to each standard (0-7) and control well.  
6. 25µL of sample was added to the sample wells.  
7. The mixing antibody bead bottle was vortexed for 30 seconds to ensure 
mixed, and 25µL was added to each well.   
8. The plate was then sealed, covered with foil and placed on gentle 
agitation on a plate shaker for 18 hours overnight in a refrigerated room 
(40C). 
9. The well was then placed and secured on a handheld magnetic plate. The 
plate was allowed to rest for 1 minute to allow the magnetic beads to be 
attracted firmly to the surface of the well. The plate seal was then 
removed, and the plate inverted with a light tap to decant the fluid 
contents of the well.  The magnetic antibody beads should remain 
attached to the well.  
10. The plate was then removed from the magnet, wells washed with 200µL 
of wash buffer, placing on a plate shaker for 30 seconds before being 
reattached to the magnet and decanting contents as above.  
11. This wash step was performed twice.  
12. 25µL detection antibodies (manufacturer provided) were then added to 
each well before being resealed, covered with foil and agitated on a plate 
shaker at room temperature for 1 hour.  
13. 25µL of Streptavidin-Phycoerythrin (manufacturer provided) into each 
well before being resealed, covered with foil and agitated on plate shaker 
at room temperature for 30 minutes.  
14. The plate was then removed from the shaker and washed three times as 
per steps 9-11.  
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15. 150µL of sheath fluid (manufacturer provided) was added to all wells and 
the beads resuspended by agitation on plate shaker for 5 minutes.  
16. The plates were then run on MAGPIX™ analyser with xPONENT software to 
analyse 100µL from each well.  A Median Fluorescence Intensity was 
reported from the software and concentration results analysed manually 












































Appendix 4: Myography experiment solutions  
 
Preparation of Physiological Salt Solution (PSS) and 62.5 mmol 
potassium-containing physiological salt solution (KPSS) 
 
1. First step is to produce Stock Solution A (regular and high-potassium 
variants) and Stock Solution B 
 
STOCK SOLUTION A (REGULAR) 
1. Fill a 1L beaker two thirds full with deionised water 
2.  Weigh out 278.2g NaCl and add to the beaker 
3.  Weigh out 14.0g KCl salt and add to the beaker 
4. Weigh out and add 11.84g MgSO4.7H20 to the beaker 
5. Stir beaker on a magnetic stirrer to allow complete dissolution of all 
salts  
6. Decant all of the solution into a 2L volumetric flask and fill to the 2L 
line with deionised water  
7. Gently, invert the capped flask a few times to mix the solution 
8. Store in a fridge (40C) for maximum 3 months. 
  
HIGH K+ STOCK SOLUTION A 
1. Fill a 1L beaker two thirds full with deionised water 
2. Add 91.34g KCl salt to the beaker 
3. Weight and add 5.92g MgSO4.7H2O 
4. As above, stir on a magnetic stirrer until all salts dissolved and then 
decant into 1L volumetric flask 
5. Top the flask up to 1L with demonised water before capping and 
inverting to mix the solution.  
6. Store the solution in the fridge (40C) for up to 3 months 
 
STOCK SOLUTION B 
1. Fill a 2L beaker two thirds full with deionised water 
2. Weigh and add 84g of NaHCO3 salt to the beaker 
3. Weigh and add 6.4g KH2PO4 to the beaker and sir on a magnetic beaker 
until complete dissolution of all salts 
4. Decant the solution into a 2L volumetric flask and fill with demonised 
water to the 2L volume mark. 
5. Cap and gently invert the flask to mix solutions, and then store in a 
fridge at 40C for up to three months. 
 
PREPARATION OF PHYSIOGICAL SALT SOLUTION (PSS) 
1. Add 100mL of regular stock solution A to a 2L volumetric flask 
2. Measure out 100mL stock solution B and add to the same flask 
254 
 
3. Fill the flask approximately two thirds full with demonised water 
4. Weigh out and add 4g of anhydrous glucose to the flask before capping 
and inverting flask gently to mix the solutions 
5. Bubble the mixture gently with 95%O2/5%CO2 gas for 10 minutes 
6. Add 5mL 1 mmol Calcium Chloride to the flask and bubble again with 
the above gas for a further 10 minutes.  
7. Top up the flask to the 2L mark with demonised water.   
8. Cap and invert the flask gently several times to mix the solution 
9. Store in the fridge at 40C for up to 1 week 
 
PREPARATION OF 62.5 mmol KPSS 
1. Add 50mL of the K+ containing stock solution A to a 1L flask 
2. Add 50mL stock solution B to the same flask 
3. Add 2g of anhydrous glucose to the flask before capping and gently 
inverting to mix the solutions 
4. Gently bubble the solution with 95%O2/5%CO2 for ten minutes 
5. Then add 2.5mL 1M Calcium Chloride to the solution before bubbling 
again with the same gas for 10 minutes. 
6. Fill the flask to the 1L mark with deionised water before capping and 
invert gently to mix.  
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